VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 5 (1-12 marzo/2026)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

India's Dengue Vaccine Candidate Advancing to Approval

Mar 1. The mosquito-transmitted dengue virus remains a significant public health challenge in tropical regions around the world. In India alone, over one million dengue cases and at least 1,500 deaths have been recorded since 2021.

"DengiAll dengue vaccine is conducting Phase III clinical trials."

To address this public health challenge, India's Panacea Biotec Limited has made substantial progress with its vaccine candidate, DengiAll®.

As of March 1, 2026, the company is conducting Phase III clinical trials for DengiAll, a single-dose vaccine designed to provide balanced protection against all four dengue virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. This represents a crucial step toward potentially introducing India's first domestically developed dengue vaccine, which would offer an accessible preventive option in areas where dengue is endemic.

"We will try to get this vaccine out there as soon as possible," said Syed Khalid Ali, Chief Scientific Officer at Panacea Biotec, in a media statement on February 26, 2026.

DengiAll is a live-attenuated, recombinant, lyophilized tetravalent vaccine based on attenuated strains licensed from the U.S. National Institutes of Health, which Panacea Biotec has further developed since 2006. Early clinical data from Phase I/II trials in healthy Indian adults showed that a single dose generated strong immunogenicity against all four serotypes, while maintaining a favorable safety profile.

If successful, DengiAll could become a widely available single-dose dengue vaccine, following recent approvals of similar single-shot candidates in other countries, such as Brazil.

Currently, several dengue vaccines are approved in various countries, though availability remains limited globally, with no dengue vaccine licensed for public use in India yet.

Dengvaxia®: The first approved dengue vaccine, a live-attenuated tetravalent chimeric vaccine requiring three doses and pre-vaccination screening for prior dengue infection. It is approved in the U.S. (Puerto Rico). However, production is being discontinued in 2026.

Qdenga®: A live-attenuated tetravalent vaccine administered in two doses, approved without requiring prior dengue testing in most indications. It is authorized in over 40 countries, and over 18 million doses have been distributed.

Butantan-DV: The world's first single-dose tetravalent live-attenuated dengue vaccine, approved by Brazil's Anvisa in November 2025. It is being launched in Brazil, with millions of doses planned for distribution.

Panacea Biotec's initiatives align with global efforts to combat dengue through vaccination, particularly in high-burden regions. Positive outcomes from Phase III trials may lead to regulatory review and potential introduction as soon as next year, depending on favorable data.

While the U.S. Centers for Disease Control and Prevention does not highlight dengue as a health risk when visiting India, as of March 2026, it has recently identified measles and rabies as concerns.

Fuente: VAX BEFORE TRAVEL. Disponible en https://n9.cl/r2fo8h

Burnet Institute and WEHI unveil immune blueprint for next generation malaria vaccines

Mar 2. New research co-led by Burnet Institute and WEHI has uncovered how the human immune system fights *Plasmodium vivax*, paving the way for the first effective vaccine against the most widespread form of malaria.

Published in *Immunity*, the study provides critical evidence of how protective immunity to *P. vivax* works, identifying specific targets on the parasite and explaining how antibodies function to prevent and clear infection.

Burnet Senior Research Fellow Dr Herbert Opi said progress in global malaria control efforts has stalled despite decades of progress.

“While two malaria vaccines have been rolled out in parts of Africa, both target *Plasmodium falciparum* and offer no protection against *P. vivax*, which dominates in Asia and the Pacific,” he said.

A major obstacle to developing a *P. vivax* vaccine has been limited understanding of what protective immunity actually looks like.

Professor James Beeson, Head of Malaria Immunity and Vaccines at Burnet, said the findings provide critical evidence to guide vaccine design.

“These exciting findings open new avenues for developing *P. vivax* vaccines to combat the malaria burden globally and support a path to elimination,” Professor Beeson said.

WEHI Laboratory Head Dr Rhea Longley said global malaria research and vaccine investment has overwhelmingly focused on *P. falciparum*, leaving major knowledge gaps for *P. vivax*.

“Unlike *P. falciparum*, *P. vivax* has unique biological features including a dormant liver stage that causes relapses, making it more difficult to eliminate,” she said.

“Strategies that work for one species do not translate to the other.”

Using blood samples from children in Papua New Guinea – a region heavily affected by *P. vivax* – researchers examined how antibodies interact with the immune system to prevent disease.

The findings show that protection from *P. vivax* is not driven by the presence of antibodies, but by how those antibodies function and which parasite proteins they target.

Researchers identified antibody responses that recruit immune cells and activate immune pathways to attack the parasite. The immune system response was significantly stronger when it targeted multiple proteins at once.

Targeting the right combination of proteins was crucial and could reduce malaria risk by more than 75% – a finding that provides a clear strategy for future vaccine development.

The study involved a collaborative partnership between Burnet, WEHI, PNG Institute of Medical Research, and Ehime University Japan.

Fuente: BioMelbourne Network. Disponible en https://n9.cl/jdit7

Burnet Institute and WEHI unveil immune blueprint for next generation malaria vaccines

Mar 2. China-based WuXi XDC Cayman Inc. (WuXi XDC), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.

Earendil Labs is an AI-powered biotech company focused on researching and developing next-generation innovative biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs.

This collaboration marks the establishment of a robust strategic partnership aimed at accelerating the development of next-generation ADCs by synergistically combining WuXi XDC's globally leading ADC technology platform with Earendil Labs' cutting-edge AI-driven antibody discovery and development capabilities to address significant unmet medical needs.

Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 payload-linker technology for use against multiple specific targets. Earendil Labs will utilise this technology to conjugate antibodies and bispecific antibodies discovered through its AI platform and to advance the development of the ADC candidates against these specific targets.

The total potential deal value could reach up to approximately $885 million, comprising an upfront payment, and certain development, regulatory, and sales milestone payments. Additionally, WuXi XDC will be eligible to receive tiered royalties on net sales upon commercialization of any resulting ADC products.

Fuente: BioSpectrum. Disponible en https://n9.cl/e4fp5

Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

Mar 3. The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition. The update highlights two key developments: the continued spread of A (H3N2) subclade K and the growing circulation of new B/Victoria lineage strains. In rapid response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched a comprehensive panel of antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains[1] to accelerate influenza vaccine development.

Decoding the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

Since its indentification in August 2025, H3N2 subclade K (J.2.4.1) has become the dominant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO's selection of A/Darwin/1454/2025 (egg-based, cell-based) as the new H3N2 reference viruses. The H1N1 component has been updated to A/Missouri/11/2025 (egg-based, cell-based).

Alongside H3N2, influenza B activity is rising sharply. In regions such as Hong Kong and the U.S., the proportion of B/Victoria lineage viruses recently increased from 6% to over 20%. These trends led WHO to recommendations B/Tokyo/EIS13-175/2025 (egg-based) and B/Pennsylvania/14/2025 (cell-based) strains for the upcoming season.

Sino Biological's Comprehensive Reagents for 2026-2027 Influenza Vaccine Research

To support global influenza vaccine research and development, Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains[2] , spanning key viral antigens including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP). These include:

- ⇒ H1N1 Reagents: A/Missouri/11/2025 (H1N1) HA Trimer (HEK293 cell-expressed, purity ≥90% verified by SEC-MALS, activity validated by ELISA), NA, and NP antigens are available now.
- ⇒ H3N2 Subclade K Proteins: Recombinant HA, NA, NP aligned with A/Darwin/1454/2025—available now.
- ⇒ Influenza B Reagents: In development for B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025.
- ⇒ Stable HA Trimers: High-purity, SEC-MALS–validated trimeric HA maintaining native conformation for accurate immune characterization.

"Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness," said Dr. Rob Burgess, Chief

Business Officer at Sino Biological US. "Sino Biological remains committed to delivering reliable reagents that advance global influenza preparedness and vaccine innovation."

About Sino Biological

Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.

Fuente: BioSpace. Disponible en https://n9.cl/yhosbo

Moderna recibe la opinión positiva del CHMP de la EMA para mCOMBRIAX, su vacuna combinada de ARNm frente a la gripe y la COVID-19

Mar 3. Moderna ha anunciado que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado una opinión positiva recomendando la autorización de comercialización en la Unión Europea de mCOMBRIAX (mRNA-1083), la vacuna combinada de Moderna indicada para la inmunización activa frente a la gripe y la COVID-19 causada por el SARS-CoV-2 en personas de 50 años o más.

“La opinión positiva del CHMP representa un hito importante para la vacunación frente a los virus respiratorios y para Moderna, con la introducción de la primera vacuna combinada frente a la gripe y la COVID-19 del mundo. De aprobarse, sería el cuarto medicamento comercializado de Moderna en Europa”, ha señalado Stéphane Bancel, director ejecutivo de Moderna. “Los vacunas combinadas tienen el potencial de simplificar la vacunación y contribuir a mejorar los resultados en salud. Agradecemos la rigurosa revisión científica llevada a cabo por la EMA”, ha añadido.

mCOMBRIAX se basa en los avances de mNEXSPIKE, la vacuna frente a la COVID-19 de Moderna, y en mRNA-1010, la vacuna estacional en investigación frente a la gripe de Moderna, cuya solicitud ha sido aceptada para revisión en Estados Unidos, la Unión Europea, Canadá y Australia.

La opinión del CHMP está respaldada por los resultados del ensayo clínico pivotal de fase 3, un estudio aleatorizado, ciego y con control activo, que evaluó la seguridad, la reactogenicidad y la inmunogenicidad de mRNA-1083 en dos grupos de edad de aproximadamente 4.000 adultos cada uno.

Un grupo incluyó a adultos de 65 años o más y comparó mRNA-1083 con la coadministración de Fluzone HD (autorizada en la Unión Europea como Efluelda), una vacuna antigripal de alta dosis, y Spikevax®, la vacuna frente a la COVID-19 autorizada de Moderna. El segundo grupo incluyó a adultos de entre 50 y 64 años y comparó mRNA-1083 con la coadministración de Fluarix, una vacuna antigripal de dosis estándar, y Spikevax.

En el ensayo clínico se cumplieron todos los criterios de valoración principales que demostraban la no inferioridad de las respuestas inmunitarias. Tras una única dosis, mRNA-1083 indujo respuestas inmunitarias significativamente superiores frente a tres cepas del virus de la gripe (A/H1N1, A/H3N2 y B/Victoria) y frente al SARS-CoV-2 en ambos grupos de edad. La cepa B/Yamagata, que ya no se recomienda para su inclusión en las vacunas antigripales estacionales, fue la única cepa para la que no se observó una respuesta inmunitaria significativamente superior en adultos de 65 años o más en comparación con las vacunas comparables autorizadas administradas conjuntamente.

mRNA-1083 mostró un perfil de seguridad y tolerabilidad aceptable. Las reacciones adversas más frecuentes fueron de grado 1 o 2 en cuanto a intensidad y similares a las observadas en las vacunas autorizadas utilizadas en el ensayo.

Tras la opinión positiva del CHMP, la Comisión Europea estudiará la recomendación y se espera que adopte una decisión final sobre la autorización de comercialización. Una vez que la Comisión Europea aprueba un medicamento, la autorización de comercialización es válida en todos los Estados miembros de la UE, así como en los países del Espacio Económico Europeo (EEE), que incluyen a Islandia, Liechtenstein y Noruega. Tras la aprobación por parte de la Comisión Europea, Moderna colaborará con las autoridades regulatorias y sanitarias nacionales para apoyar el acceso y la implementación a nivel local.

Fuente: pmfarma. Disponible en https://n9.cl/af0ygq

Aprobada en España la financiación de V116, vacuna que previene la enfermedad neumocócica en el adulto

5 mar. La Sanidad española ha aprobado la financiación de V116, la vacuna diseñada específicamente para la prevención de la enfermedad neumocócica en el adulto, uno de los grupos más vulnerables frente al neumococo teniendo en cuenta que la tasa general de hospitalización y letalidad asociada a esta patología aumenta con la edad.

"El nuevo suero vacunal ofrece protección frente a los serotipos que causan el 75,9% de los casos de esta patología invasiva (ENI) en personas de 65 años o más edad."

"En MSD llevamos más de 100 años dedicados a la investigación y a la prevención de enfermedades a lo largo de toda la vida. Fuimos pioneros en el desarrollo de la primera vacuna contra el neumococo hace más de cuatro décadas y, desde entonces, hemos seguido innovando para ampliar la protección frente a esta afección. Las infecciones causadas por neumococo continúan representando una importante causa de morbimortalidad, especialmente entre los adultos de alto riesgo y las personas de edad avanzada, lo que nos impulsa a continuar reforzando la prevención en este grupo poblacional", explica el Dr. Joaquín Mateos, director médico de MSD en España.

Protección frente a una larga lista de serotipos

V116 ofrece cobertura frente a los serotipos que causan el 75,9% de los casos de enfermedad neumocócica invasiva (ENI) en personas de 65 años o más edad en territorio español. En 2025, la Comisión Europea autorizó su uso para la inmunización activa para la prevención de la enfermedad invasiva y la neumonía causadas por los serotipos de *Streptococcus pneumoniae* 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F y 35B en individuos de 18 años o más. Esta aprobación se basa en un robusto programa clínico.

"Este avance en la prevención de la enfermedad neumocócica en adultos es el resultado de nuestro esfuerzo continuo en investigación. Además, contribuye directamente a la Estrategia de Salud Pública del Ministerio de Sanidad, que subraya la necesidad de mejorar las coberturas de vacunación en la adolescencia y la edad adulta, las cuales aún están por debajo de los objetivos establecidos. Por ello, es fundamental avanzar conjuntamente en estrategias que refuercen la protección en este grupo de edad, no solo ofreciendo vacunas específicas, sino también promoviendo el valor de la vacunación", destaca Mateos.

Las infecciones causadas por neumococo o *Streptococcus pneumoniae*, principalmente la enfermedad neumocócica invasiva (ENI) y la neumonía neumocócica, siguen siendo un importante problema de salud pública a nivel mundial. En adultos, esta bacteria es la causa más común de neumonía adquirida en comunidad a nivel mundial, suponiendo el 30-50% de los episodios microbiológicamente documentados en España.

"Vacunar a los mayores y a los grupos de riesgo es una inversión coste-efectiva" El neumococo sigue siendo una causa importante de morbilidad y mortalidad a nivel mundial, especialmente entre adultos mayores y personas con condiciones médicas subyacentes. En 2024, España registró 462 muertes por enfermedad neumocócica invasiva. De ellas, el 75 % de las defunciones en los hombres se produjeron en el grupo de 65 y más años (206 fallecimientos), mientras que en las mujeres este grupo de edad concentró el 82 % de las muertes (155).

En España la población cada vez está más envejecida y el porcentaje de personas mayores de 65 años supone el 20,4 % de la población. "En este contexto, vacunar a los adultos mayores y a los grupos de riesgo es una inversión coste-efectiva, ya que ayuda a reducir la carga de enfermedad", afirma el Dr. José Antonio Navarro, consultor honorario del Área de Vacunas del Ministerio de Sanidad y miembro de la Real Academia de Medicina y Cirugía de la Región de Murcia.

"La vigilancia epidemiológica desempeña un papel crucial en la identificación continua de los serotipos más prevalentes y aquellos que causan formas invasivas de la enfermedad neumocócica, las cuales presentan una mayor letalidad. Este seguimiento es fundamental para evaluar el efecto de las estrategias de vacunación y la posible sustitución de serotipos. Además, permite conocer los patrones de resistencia antibiótica, lo que facilita la adaptación de las estrategias de vacunación, mejorando así la protección contra las formas graves de la patología", concluye.

Menos tasas de inmunización en comparación con la vacuna antigripal

Las coberturas de la inmunización antineumocócica en adultos son inferiores a las de otras vacunas recomendadas, como la antigripal. Según los datos del Sistema de Información de Vacunaciones del Ministerio de Sanidad (SIVAMIN), en 2024, solo el 34,19 % de los mayores de 65 años habían recibido una vacuna conjugada contra el neumococo, frente al 58,47 % que se había vacunado frente a la gripe.

"Es importante destacar la estrategia de esta nueva vía preventiva, diseñada específicamente para proteger a adultos mayores de 65 años frente al neumococo. La selección de serotipos es especialmente relevante, ya que incluye una selección de los más prevalentes en este grupo de edad. No obstante, resulta crucial reforzar la concienciación de la población para mejorar las coberturas de inmunización frente al neumococo", señala la Dra. María Fernández Prada, facultativa del Área de Gestión Clínica de Medicina Preventiva y Salud Pública del Hospital Vital Álvarez Buylla

en Mieres, Asturias. V116 está indicada para la inmunización activa para la prevención de la enfermedad invasiva y neumonía causadas por *Streptococcus pneumoniae* en personas a partir de 18 años de edad.

Fuente: FARMACOSALUD. Disponible en https://n9.cl/p1son

India to Launch First Dedicated Rs.1,000 Crore Medtech Investment Fund

Mar 7. India's medical technology (medtech) sector is set to receive a major boost with the launch of its first dedicated investment fund aimed at supporting innovation and manufacturing. A group of investors and industry veterans, led by Ganesh Sabat, former CEO of Sahajanand Medical Technologies (SMT), has launched a ₹1,000 crore growth-stage fund to strengthen the country's medtech ecosystem and align with the government's Make in India initiative.

MedArtha Capital Receives Regulatory Approval

The new fund, named MedArtha Capital, recently secured approval from the Securities and Exchange Board of India (SEBI). The fund plans to deploy capital over the next two to three years and will focus on investing in 10 to 12 high-growth medtech companies across India.

According to Sabat, the fund will primarily support small but promising companies that require capital and operational expertise to scale their manufacturing capabilities and expand their market presence.

Government May Contribute Through RDI Scheme

In a significant development, the government may also invest approximately ₹500 crore in the fund through its Research Development and Innovation (RDI) scheme.

MedArtha Capital has already submitted an application under the scheme, which allows eligible entities to receive investment support of up to 50% of the total fund size. The RDI initiative,

announced last year with a ₹1 lakh crore corpus, aims to accelerate investments in research, development, and innovation across key sectors.

Focus on Scaling Growth-Stage Medtech Companies

Unlike early-stage venture funds, MedArtha Capital will operate as a scale-up platform. The fund intends to invest in companies with annual revenues between ₹30 crore and ₹80 crore, helping them expand manufacturing capacity and strengthen their technological capabilities.

Through this strategy, the fund aims to support companies that already have proven products but require financial and operational backing to grow further and compete globally.

Reducing India's Dependence on Imported Medical Devices

As reported by TOI, the fund will focus on critical medtech segments where India remains heavily dependent on imports. These include MRI machines, CT scanners, cathlab devices, and neurovascular devices used in the treatment of stroke and heart failure.

By supporting domestic manufacturing in these areas, the fund aims to reduce reliance on imported medical equipment while strengthening India's healthcare infrastructure.

Building Contract Manufacturing Capabilities

In addition to supporting product development, the fund also plans to build contract development and manufacturing capabilities within the medtech sector. Currently, such specialised manufacturing ecosystems remain largely absent in India.

Therefore, MedArtha Capital intends to fill this gap by encouraging companies to develop scalable manufacturing platforms that can support both domestic demand and global exports.

Overall, the initiative marks an important step toward strengthening India's medtech industry, encouraging innovation, and advancing the country's ambition to become a global hub for medical device manufacturing.

Fuente: The Indian Practitioner. Disponible en https://n9.cl/axtrqx

Future pandemics may be fought faster with mRNA and advanced vaccine platforms

Mar 9. The world's experience with COVID-19 reshaped expectations for how quickly vaccines can be developed during a global health emergency. Advances in genetic sequencing, biotechnology, and international collaboration enabled vaccines to be designed and deployed within months. These developments have raised new questions about whether similar technologies could improve preparedness for other major pandemic threats.

In a paper titled "mRNA and Next-Generation Vaccine Platforms for Pandemic Influenza Preparedness," published in Vaccines, researcher Rick A. Bright evaluates how lessons from COVID-19 vaccine development and advances in mRNA technology could help global health systems respond more effectively to future influenza pandemics.

Why pandemic influenza still poses a global threat

Unlike seasonal influenza, which circulates predictably each year, pandemic influenza arises when a novel virus emerges from animal reservoirs and spreads efficiently among humans.

These viruses evolve rapidly, often mutating or reassorting their genetic material in ways that make them difficult to predict and control.

Modern global conditions amplify these risks. Rapid international travel enables infectious diseases to spread across continents within days. Human populations are increasingly exposed to animal hosts through agriculture, wildlife trade, and environmental changes. At the same time, influenza viruses remain highly adaptable pathogens capable of rapid genetic shifts.

Despite sustained investments in influenza surveillance and vaccination programs, current vaccine systems remain poorly suited to respond to a pandemic. Most licensed influenza vaccines rely on manufacturing processes that require months of preparation. Producers must select viral strains early in the production cycle, often before scientists fully understand which variants will dominate the outbreak.

This early decision-making introduces a major risk: the vaccine may not match the circulating virus by the time production is completed. If a virus mutates after manufacturing begins, there is little opportunity to adjust vaccine composition. As a result, the protective effect of the vaccine can be reduced.

These structural limitations highlight the need for more adaptable vaccine technologies capable of responding to rapidly evolving pathogens.

How mRNA platforms could transform pandemic response

The study argues that messenger RNA vaccine platforms represent one of the most promising tools for improving pandemic preparedness. Unlike traditional vaccines, which rely on growing viruses in eggs or cell cultures, mRNA vaccines use genetic instructions that teach human cells to produce specific viral proteins. This approach allows scientists to design vaccine candidates quickly using only the genetic sequence of the virus.

The COVID-19 pandemic demonstrated the power of this technology. Once the SARS-CoV-2 genome was identified, researchers were able to design mRNA vaccine candidates within weeks. Large-scale manufacturing and clinical trials followed soon afterward, leading to vaccine deployment in record time.

This experience fundamentally changed expectations for vaccine development timelines. Historically, vaccines could take years to develop and produce. The success of mRNA technology showed that safe and effective vaccines could be developed much faster when supported by strong regulatory frameworks, manufacturing infrastructure, and coordinated global investment.

For influenza preparedness, the advantages of mRNA platforms extend beyond speed. Influenza viruses evolve constantly through processes such as antigenic drift, meaning the viral surface proteins targeted by vaccines can change rapidly. Traditional vaccine production requires fixed strain selection months before the vaccine becomes available.

On the other hand, mRNA platforms allow scientists to update vaccine antigen sequences without redesigning the entire manufacturing process. If new viral data emerges during an outbreak, vaccine formulations could potentially be revised quickly.

This flexibility could significantly reduce the consequences of vaccine mismatch, a common problem in seasonal influenza vaccination campaigns. Severe influenza seasons dominated by rapidly evolving strains illustrate how traditional vaccines sometimes struggle to keep pace with viral evolution.

Recent clinical trials also support the feasibility of mRNA vaccines for influenza. Phase III studies of seasonal influenza mRNA vaccines have demonstrated strong immune responses and favorable safety profiles, particularly among older adults who face the highest risk of severe influenza complications.

These findings suggest that mRNA platforms could play a critical role in pandemic response by enabling faster vaccine development and more adaptable manufacturing systems.

Another global initiative shaping pandemic preparedness is the "100 Days Mission," which aims to develop and deploy vaccines for emerging threats within approximately one hundred days of identifying a new pathogen. Achieving this goal will require technologies capable of rapid design, large -scale production, and flexible adaptation as outbreaks evolve.

Building a diverse and resilient vaccine ecosystem

While mRNA technology offers significant advantages, the study emphasizes that pandemic preparedness should not rely on a single vaccine platform. Traditional influenza vaccines remain a vital component of global health systems and continue to provide large-scale production capacity.

Conventional vaccine approaches include egg-based vaccines, cell-culture vaccines, recombinant protein vaccines, and live attenuated influenza vaccines. These technologies benefit from decades of regulatory experience and established manufacturing infrastructure.

Egg-based vaccines, for example, still account for the majority of global influenza vaccine production. However, these systems depend on large supplies of fertilized eggs and require extended production timelines. During a pandemic, these limitations can delay vaccine availability.

Cell-based and recombinant vaccines offer greater flexibility and avoid some of the constraints associated with egg-based production. However, they still involve manufacturing processes that may not adapt quickly enough during rapidly evolving outbreaks.

Emerging vaccine technologies aim to expand the range of tools available for pandemic response. Nanoparticle-based vaccines are being explored to enhance immune responses by presenting viral proteins in optimized structures. Self-amplifying RNA vaccines represent another promising approach that could reduce the amount of vaccine material required per dose, potentially expanding supply during emergencies.

Researchers are also investigating advanced protein expression systems using microbial, plant-based, or cell-free technologies to accelerate vaccine manufacturing and reduce costs.

The study suggests that combining multiple vaccine technologies could create a more resilient preparedness system. If one platform encounters manufacturing or regulatory obstacles, alternative approaches could still provide protection.

Manufacturing capacity and supply chain resilience remain critical challenges in global pandemic response. Vaccine production relies on complex networks of raw materials, specialized equipment, and skilled personnel. Even highly adaptable platforms require operational facilities capable of scaling production quickly.

To address this issue, global health organizations are promoting the concept of "warm-base" manufacturing. This approach involves maintaining vaccine production infrastructure and trained workforces even during periods without active pandemics. By keeping facilities operational, manufacturers can rapidly expand production when a new threat emerges.

Expanding regional manufacturing capacity is another important priority. Many low- and middle-income countries currently depend on vaccine imports from a small number of manufacturing hubs. During pandemics, these supply chains can become strained, leading to unequal access to life-saving vaccines.

Programs such as the World Health Organization's mRNA technology transfer initiative aim to help countries develop their own vaccine production capabilities. These efforts focus on building technical expertise, regulatory capacity, and supply networks that can support local manufacturing.

Scientific challenges also remain. Influenza viruses interact with the immune system in complex ways that complicate vaccine development. Previous exposure to influenza strains can influence how the immune system responds to new vaccines, a phenomenon known as immune imprinting.

Researchers are also working to identify more reliable indicators of vaccine protection beyond traditional antibody measurements. Advances in immunology and systems biology may help scientists design vaccines that provide broader and longer-lasting protection.

Artificial intelligence and computational biology are emerging as powerful tools in this effort. Machine learning algorithms can analyze large datasets of viral genetic sequences to predict how influenza viruses may evolve. These insights can guide vaccine design and help scientists target viral regions less likely to mutate.

New vaccine delivery technologies may also play a role in improving pandemic response. Microneedle patches, for example, could allow vaccines to be administered without traditional syringes, simplifying mass vaccination campaigns. Oral vaccine formulations and thermostable vaccines that do not require ultra-cold storage could further improve access in resource-limited regions.

Maintaining public trust will be equally important. Rapid vaccine development must be accompanied by transparent safety monitoring and clear communication about benefits and risks. Large-scale safety monitoring systems implemented during the COVID-19 pandemic demonstrated that adverse events can be detected and investigated quickly even during mass vaccination campaigns.

Fuente: Devdiscourse. Disponible en https://n9.cl/0ae5e

Varios países de África sufrirán escasez temporal de vacunas contra rotavirus

9 mar. Kenia, Benín, Chad, Tanzania y Zimbabue experimentarán un desabastecimiento temporal de hasta dos meses en las vacunas contra el rotavirus, después de que tres fabricantes mundiales informasen sobre problemas operativos "inesperados", confirmó la Alianza para las Vacunas, Gavi.

"En 2026, el suministro mundial de la vacuna contra el rotavirus será inferior a la demanda prevista de los países que implementan la iniciativa Gavi en aproximadamente 21 millones de dosis", reza un comunicado compartido por correo por un portavoz de la Alianza.


Vacuna rotavirus en África. Foto: Reuters

La vacuna previene la gastroenteritis grave en bebés, causante de diarrea y vómitos, y se administra por vía oral a los bebés a las seis, a las diez y a las 14 semanas de edad, una profilaxis que es especialmente necesaria en el África subsahariana.

Mientras que dos de los proveedores experimentaron retrasos

relacionados con mejoras "esenciales" en la fabricación y un rendimiento de producción inferior al previsto, otro notificó a principios de 2025 reducciones de suministro por complicaciones en su proceso de mejora de sus instalaciones.

"En conjunto, estos problemas han reducido significativamente la producción total. Como resultado, se prevén desabastecimientos temporales de uno a dos meses en cinco países (Kenia, Benín, Chad, Tanzania y Zimbabue)", añadió el portavoz.

Fuente: NOTICIAS VENEVISIÓN. Disponible en https://n9.cl/27aud

Ainnocence Calls for Global Collaboration to Deploy AI-Driven Antibody and Vaccine Discovery Against the World's Deadliest Infectious Diseases

Mar 9. Ainnocence Inc., a biotechnology company pioneering AI-driven therapeutic antibody design, today announced the publication of its landmark study, "AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains", in Nature Scientific Reports (May 2025). The article demonstrates that artificial intelligence can design antibodies capable of neutralizing viral variants that did not yet exist at the time of design, effectively predicting and pre-empting viral evolution.

"The study demonstrates mutation-resistant antibodies with 269× affinity improvement, a critical proof point for achieving CEPI's 100 Days Mission and closing the therapeutic gap for 2.5 billion people at risk."

What the Study Demonstrated

The published research describes the construction of a "digital twin" for SARS-CoV-2, a computational model that integrates viral genomic data, protein structural modeling, graph neural networks, and protein sequence language modeling to simulate how the virus mutates and how antibodies interact with its spike protein.

Using this digital twin, the Ainnocence team computationally designed neutralizing antibodies against more than 1,300 historical strains of SARS-CoV-2, encompassing 64 distinct mutations in the receptor binding domain (RBD). More than 10^9 antibody mutation candidates were generated and screened in silico before the most promising candidates were selected for experimental validation.

- ⇒ 70 AI-designed antibodies were experimentally validated through binding assays and live viral neutralization assays across multiple SARS-CoV-2 strains.
- ⇒ 14% achieved triple cross-binding reactivity against the RBD of multiple strains in ELISA assays, demonstrating broad-spectrum potential from a single design cycle.
- ⇒ 10 antibodies neutralized the Delta variant with IC50 values below 10 µg/mL, and one antibody neutralized the Omicron variant, a strain that was not present in the original design database, confirming the model's predictive power against future variants.
- ⇒ Sub-nanomolar binding affinity was achieved with a 269× improvement over parental antibody candidates, representing one of the highest affinity gains reported in AI-driven antibody design to date.

"What makes this work significant is not just the binding numbers," said Dr. Lurong Pan, Founder and CEO of Ainnocence. "It is that our AI designed antibodies that worked against viral variants the model had never seen. That is not optimization. That is prediction.

And prediction is what you need when the next pandemic pathogen emerges and you have days, not years, to respond."

The SentinusAI® Methodology: Sequence-First, Structure-Free, Animal Free

Ainnocence's proprietary SentinusAI® platform, built on the AINN-P1 protein foundation model, a 167-million-parameter deep learning model trained on more than 53 million protein sequences.

Unlike conventional antibody discovery, antibody discovery approaches that rely on structural data and animal immunization and months of iterative phage display or hybridoma screening; SentinusAI® operate from sequence alone. The platform requires only the amino acid sequence of a target protein to initiate antibody design, no 3D structure, no prior lead compound, no animal model.

The methodology described in the Nature Scientific Reports publication integrates multiple AI architectures in parallel:

- ⇒ Graph Neural Networks (GNNs) to model antibody-antigen molecular interactions as graph structures, capturing spatial and topological relationships between residues.
- ⇒ Protein Sequence Language Models (transformer and LSTM architectures) to learn the "grammar" of protein sequences, identifying hidden dependencies between amino acids that govern folding, binding, and stability.
- ⇒ De novo generation and virtual screening of up to 10^{10} candidate antibody sequences per target, with simultaneous multi-objective optimization for binding affinity, humanization, developability, and off-target safety.
- ⇒ DevProScore™ manufacturability assessment evaluating thermal stability, aggregation propensity, post-translational modification liabilities, and isoelectric point to ensure candidates are developable before entering the wet lab.

The entire pipeline from target sequence input to fully characterized; developability-scored antibody leads operates in approximately 30 days, compared with 3-6 months for traditional methods. This represents an 80% reduction in both timeline and cost, with hit rates reaching 80% versus approximately 50% for conventional approaches.

Why This Matters for the 100 Days Mission

The Coalition for Epidemic Preparedness Innovations (CEPI) has set what it calls a "moonshot" goal: the 100 Days Mission. The ambition, endorsed by G7 and G20 leaders, is for the world to be able to develop safe, effective vaccines, therapeutics, and diagnostics within 100 days of recognizing a pathogen with pandemic potential. Had this capability existed at the start of the COVID-19 pandemic, modeling by Imperial College London suggests that 8 million excess deaths and $1.4 trillion in productivity losses could have been averted.

The 100 Days Mission is achievable for vaccines, where platform technologies like mRNA have already compressed development timelines. But for therapeutic antibodies, which serve as critical first-line countermeasures before vaccines achieve population-scale immunity, no equivalent acceleration technology existed.

Until now

SentinusAI® is the antibody equivalent of what mRNA platforms achieved for vaccines. When a novel pathogen is identified and its genome sequenced, SentinusAI® can generate therapeutic antibody candidates within 30 days, leaving 70 days within the 100-day window for preclinical validation,

manufacturing scale-up, and regulatory filing.

The published Nature Scientific Reports data proves this is not theoretical: AI-designed antibodies already neutralized variants that emerged after the design phase, demonstrating exactly the kind of rapid, predictive countermeasure development the 100 Days Mission demands.


www.nature.com/scientificreports

scientific reports

OPEN

AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains

Yue Kang, Kevin Jin & Lurong Pan

"The 100 Days Mission cannot be met with conventional antibody discovery," said Dr. Pan. "Traditional methods require 12-18 months from target identification to lead candidate. That timeline does not bend to political will. It bends only to fundamentally different technology. SentinusAI® provides that technology and our published results prove it works."

A Career Built for This Moment

Ainnocence's infectious disease capabilities are rooted in the expertise of founder Dr. Lurong Pan, who holds a PhD in Computational Chemistry (UAB) and an MS in AI (Georgia Tech), with 16+ years at the intersection of computational science, AI, and drug discovery.

In 2020, at the height of the COVID-19 pandemic, Dr. Pan was awarded the Merck Pandemic Preparedness Award by Merck KGaA for her "Digital Twin for COVID-19" project, the foundational research that would become the SentinusAI® platform and the basis for the subsequently published Nature Scientific Reports paper.

A Call for Collaboration: 60+ Disease Targets, Zero Approved Antibody Therapeutics

The need is urgent and the gaps are staggering. More than 2.5 billion people live in regions where the deadliest infectious diseases, Nipah virus (40-75% case fatality), Lassa fever (300,000+ cases annually), Marburg virus (up to 88% mortality), MERS-CoV (35% case fatality) have zero approved monoclonal antibody therapeutics. For diseases like Oropouche fever, which caused explosive outbreaks across Latin America in 2024, there is no therapeutic pipeline of any kind.

Ainnocence has mapped 60+ infectious disease targets across all six continents where SentinusAI® can make an immediate impact. These span WHO Blueprint priority pathogens, neglected tropical diseases, and emerging outbreak threats.

Ainnocence Inc. is inviting collaborations:

- ⇒ Government agencies and multilateral health organizations seeking to accelerate pandemic preparedness programs and stockpile development under the 100 Days Mission framework.
- ⇒ Product development partnerships (PDPs) working on neglected tropical diseases where conventional antibody discovery is too slow and too expensive for the available funding.
- ⇒ Pharmaceutical and biotechnology companies looking to add AI-accelerated antibody

candidates to their infectious disease pipelines or license the SentinusAI® platform for internal discovery.

⇒ Academic and public health research institutions study high-consequence pathogens who need rapid, cost-effective antibody design against novel targets.

Ainnocence offers three engagement models:

1. Fee-for-service (target to leads in 3-4 weeks)
2. Co-development partnerships (discovery through IND with shared milestones)
3. Platform licensing (dedicated SentinusAI® deployment within partner organizations).

Looking Ahead

"COVID-19 taught the world a painful lesson: we cannot discover our way out of a pandemic at the speed of traditional R&D," said Dr. Pan. "Our published data shows that AI can design antibodies that not only bind today's pathogens but anticipate tomorrow's variants. That capability, predictive, rapid, and scalable is exactly what the 100 Days Mission requires. We have the platform and the proof. Now we need partners who share the urgency."

About Ainnocence Inc.

Founded in 2021 and headquartered in Mountain View, California, Ainnocence Inc. is a next-generation biotechnology company uses its proprietary generative AI platform to screen up to 10 billion molecules within hours to accelerate drug discovery across antibodies, small molecules, cell therapies, and synthetic biology. Working directly from sequence data, without 3D structural modeling; the platform has been applied across 60+ therapeutic programs. The company partners with leading pharmaceutical companies, academic institutions, and global health organizations to accelerate the discovery of life-saving biologics. For more information, visit www.ainnocence.com.

Fuente: BioSpace. Disponible en https://n9.cl/gj6kg

Los cofundadores de BioNTech crearán una empresa sobre ARN mensajero

10 mar. Los cofundadores del laboratorio alemán BioNTech anunciaron el martes que dejarán sus cargos directivos para crear una empresa dedicada a las innovaciones en ARN mensajero (ARNm), tecnología que impulsó el éxito de su vacuna contra la COVID-19.

Esta empresa biotecnológica independiente contará con "recursos, operaciones y opciones de financiación separadas de BioNTech y estará dedicada a la investigación y desarrollo de innovaciones de nueva generación basadas en ARNm", indica un comunicado.

Ugur Sahin y Özlem Türeci, un matrimonio de investigadores alemanes de origen turco, dejarán la empresa que fundaron en 2008 y que se convirtió en pionera en la carrera por la vacuna durante la pandemia. De hecho lograron imponerse a sus competidores al obtener, junto con la estadounidense Pfizer, la primera autorización de comercialización para una vacuna contra el coronavirus.

Posteriormente BioNTech registró enormes beneficios y una fuerte expansión.

Hoy, sin embargo, sus ingresos disminuyeron y los costos de desarrollo de tratamientos contra el cáncer y otras enfermedades son elevados. Como resultado el grupo con sede en Maguncia (oeste de Alemania) registró una pérdida de 1.100 millones de euros en 2025.

Ugur Sahin y esposa quieren "volver a ser pioneros en la investigación del ARNm" y ven "oportunidades extraordinarias para liberar la próxima generación de innovaciones transformadoras", señala el comunicado.

Esto podría lograrse "en combinación con la inteligencia artificial", declaró el cofundador de BioNTech al diario económico Handelsblatt.

BioNTech prevé mantener un vínculo con la futura start-up, aportándole derechos de propiedad intelectual y tecnologías de ARNm a cambio de una participación minoritaria, regalías y pagos vinculados al cumplimiento de hitos clave. Todo ello se formalizará mediante un acuerdo vinculante antes de finales de junio, según el comunicado.

Los directivos se incorporarán a la dirección de su nueva empresa antes de finales de 2026.

Fuente: France 24. Disponible en https://n9.cl/tj5w7

Dengue vaccine remains 80.5% effective against severe cases after five years

Mar 11. In a phase 3 clinical trial, the tetravalent dengue vaccine, developed by the Butantan Institute in São Paulo, Brazil, was 80.5% effective against severe dengue cases with warning signs over a five-year period. The results of the trial are published in *Nature Medicine*.

The study was conducted at 16 research centers across Brazil's five regions. From February 2016 to July 2019, 16,235 participants between the ages of 2 and 59 were recruited. Of those, 10,259 received a single dose of the vaccine, while 5,976 received a placebo.

There were no reports of hospitalization in the vaccinated group, compared to eight cases in the placebo group.

Overall, the vaccine was 65% effective in preventing symptomatic dengue (caused by any serotype) during the five years of monitoring.

The vaccine, called Butantan-DV, was approved by the Brazilian Health Regulatory Agency (ANVISA) on November 26, 2025, for use by the Brazilian population aged 12 to 59. Since then, the institute has sent 1.3 million doses to the National Immunization Program (PNI), which distributes them to Brazil's national public health network, the SUS (Sistema Único de Saúde).

In January 2026, the Ministry of Health began a pilot project to immunize 90% of the target population in Nova Lima (Minas Gerais state), Maranguape (Ceará state), and Botucatu (São Paulo state). The vaccination of primary care health professionals began on February 9.

The vaccine protects against different types of the dengue virus because of its tetravalent composition. This means that it contains specific components to combat the four known serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.

The vaccine uses live viruses that have been "weakened" (attenuated) in a laboratory setting so that they cannot cause disease, yet are still able to stimulate an immune response. The strains used are based on technology originally developed by the United States National Institutes of Health (NIH).

For DENV-1, DENV-3, and DENV-4, the vaccine uses nearly complete genomes of the respective viruses. For DENV-2, protection is built using a chimeric virus consisting of DENV-2 surface proteins mounted on the attenuated structure ("skeleton") of the DENV-4 virus.

Once administered, the vaccine generates vaccine viremia, the controlled replication of these attenuated viruses in the body. This process induces the immune system to produce neutralizing antibodies specific to each of the four serotypes. The goal is to create specific immunity to each serotype so that the body recognizes and neutralizes each variant individually.

"This vaccine is establishing itself as a very important tool in the fight against dengue in Brazil, with the potential to contribute to reducing the circulation of the virus, in addition to individual protection," Fernanda Boulos, the institute's medical director of clinical trials, told the Butantan Communications Office.

Fuente: MedicalXpress. Disponible en https://n9.cl/wuvc1

Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study

Mar 12. Pfizer Inc. (PFE) has completed a Phase 2 study called “A Phase 2, Randomized, Partially Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine Administered in Healthy Toddlers 12 Through 15 Months of Age.” The goal is to see how well a new pneumococcal vaccine protects toddlers and how safe and tolerable it is, a key step to defend against serious childhood infections and to extend Pfizer’s vaccine franchise.

The trial tests a new multivalent pneumococcal conjugate vaccine, code-named PG4, and compares it with Pfizer’s marketed 20-valent pneumococcal conjugate vaccine, Prevnar 20 (20vPnC). PG4 is designed to broaden protection against more strains of pneumococcal bacteria, while Prevnar 20 serves as an active control and helps benchmark safety and immune response in a real-world commercial context.

The study is interventional and randomized, meaning toddlers are assigned by chance to one of several groups. It uses a parallel design with a partially blinded setup, so most participants and study staff do not know which vaccine is given, and the main aim is prevention, not treatment, allowing a cleaner read on vaccine safety and immune response.

Children are split into three groups: a PG4 1-dose arm, a PG4 2-dose arm, and a single-dose Prevnar 20 arm. The PG4 groups differ only in how many injections they receive, while the Prevnar 20 group helps Pfizer gauge if PG4 can match or beat the current standard, which is critical for future approval and commercial positioning in the pediatric market.

The study was first submitted on July 23, 2024, marking the formal start of regulatory tracking and signaling the early clinical push for PG4. The latest update was filed on March 9, 2026, and the status now shows as completed, which means data collection is done and investors can start to look ahead to upcoming readouts and possible conference presentations.

While primary and final completion dates are not detailed here, toddlers participated for about 6 to 8 months depending on dose group. This window covered clinic visits, vaccine administration, and blood draws, and it suggests that immune-response and safety data should be robust enough to support

dose and schedule decisions for a potential Phase 3 program.

For investors, the main takeaway is that Pfizer continues to invest in next-generation pneumococcal vaccines, a category that already generates material revenue through Prevnar. A positive Phase 2 outcome for PG4 could extend Pfizer's lead in pediatric vaccines, protect share against rivals like Merck in pneumococcal disease, and underpin long-term, high-margin recurring sales from national immunization programs.

In the near term, sentiment around PFE could benefit from the perception that its vaccine pipeline is deeper than current earnings suggest, especially as COVID vaccine revenue normalizes. The real share-price impact will depend on how PG4's safety and immune profile compares with Prevnar 20, but a completed Phase 2 study in toddlers is a meaningful de-risking step for this asset.

The trial is now listed as completed and has been recently updated, and investors can track future data releases and regulatory steps as they appear on the ClinicalTrials portal.

Fuente: THE GLOBE AND MAIL. Disponible en https://n9.cl/eju8q

Artículos científicos publicados en Medline

Filters activated:

(vaccine[Title/Abstract]) AND (("2026/03/01"[Date - Publication] : "2026/03/12"[Date - Publication]))
747 records

Nirsevimab vs RSVpreF **Vaccine** for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M.JAMA. 2026 Mar 3;335(9):787-798. doi: 10.1001/jama.2025.24082.PMID: 41428474

Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children.
Moline HL, Tannis A, Goldstein L, Englund JA, Staat MA, Boom JA, Selvarangan R, Michaels MG, Weinberg GA, Halasa NB, Toepfer AP, Rutkowski RE, Salthouse A, Sahni LC, Schuster JE, Stewart LS, Williams JV, Payne DC, Klein EJ, Szilagyi PG, Dawood FS; New Vaccine Surveillance Network Collaborators.JAMA Pediatr. 2026 Mar 1;180(3):314-324. doi: 10.1001/jamapediatrics.2025.5778.PMID: 41428480

Antibodies Elicited by the 2025-2026 Influenza **Vaccine**.
Liu J, Li SH, Ye N, Griffiths T, Drapeau EM, Atkinson RK, Collman RG, Hensley SE.NEJM Evid. 2026 Mar 3:EVIDpha2600007. doi: 10.1056/EVIDpha2600007. Online ahead of print.PMID: 41774915

Vaccine development for porcine epidemic diarrhea virus and porcine Deltacoronavirus: Updated progress, challenges, and future perspectives.
Tran MT, Doan TD, Wu HC, Chu CY.Microb Pathog. 2026 Mar;212:108286. doi: 10.1016/j.micpath.2026.108286. Epub 2026 Jan 6.PMID: 41506494 Review.

Vaccinating patients with autoimmune diseases.
Yeo AL, Winthrop KL.Joint Bone Spine. 2026 Mar;93(2):105978. doi: 10.1016/j.jbspin.2025.105978. Epub 2025 Sep 26.PMID: 41016585 Review.

Clinical progress note: Hepatitis A virus.
McCluskey JM 3rd, Bockrath RA, Jhaveri R.J Hosp Med. 2026 Mar;21(3):294-297. doi: 10.1002/jhm.70171. Epub 2025 Sep 11.PMID: 40932297 **Free PMC article.** Review.

Hepatitis B virus vaccination in people with HIV: what's new?
Gispen F, Luetkemeyer AF, Marks KM.Curr Opin HIV AIDS. 2026 Mar 1;21(2):133-139. doi: 10.1097/COH.0000000000001001. Epub 2025 Dec 5.PMID: 41353569 Review.

Immunisation against **vaccine**-preventable diseases in individuals receiving immunosuppressive targeted therapies.

Wang X, Patel C, Sharma K, Giles ML, Burns P, Macartney K, Flanagan KL, Teh BW, Williams PCM.Vaccine. 2026 Mar 3;78:128399. doi: 10.1016/j.vaccine.2026.128399. Online ahead of print.PMID: 41780104 Review.

Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis.
Murthy S, Hagedoorn NN, Faigan S, Rathan MD, Marchello CS, Crump JA.Lancet Infect Dis. 2026 Mar;26(3):270-283. doi: 10.1016/S1473-3099(25)00551-1. Epub 2025 Nov 12.PMID: 41240962

Vaccine confidence and information sources among children and adolescents: A national cross-sectional survey.
Hansen BT, Greve-Isdahl M.Hum Vaccin Immunother. 2026 Dec;22(1):2639798. doi: 10.1080/21645515.2026.2639798. Epub 2026 Mar 5.PMID: 41784535 **Free PMC article.**

Targeting CD27 Boosts **Vaccine**-induced Immune Memory.
[No authors listed]Cancer Discov. 2026 Mar 2;16(3):OF1. doi: 10.1158/2159-8290.CD-NW2026-0004.PMID: 41569091

Herpes Zoster and Frailty in Older Adults: a Systematic Review.
D'Elia MPB, Andrew MK, Pott H.Can Geriatr J. 2026 Mar 4;29(1):50-58. doi: 10.5770/cgj.29.916. eCollection 2026 Mar.PMID: 41743978 **Free PMC article.** Review.

Detection, treatment and prevention of tuberculosis.
Goetzl EJ.Am J Med. 2026 Mar;139(3):283-286. doi: 10.1016/j.amjmed.2025.11.022. Epub 2025 Nov 26.PMID: 41314484 Review.

Mass immunization without public consent.
Su Z, Liu Y, Zhang R, Kaburu FM, Tong C, Bentley BL, McDonnell D, Cheshmehzangi A, da Veiga CP, Xiang YT.Int J Infect Dis. 2026 Mar;164:108329. doi: 10.1016/j.ijid.2025.108329. Epub 2025 Dec 18.PMID: 41421785 **Free article.**

Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients.
Bronder S, Abu-Omar A, Lennartz S, Tschausowsky D, Radun R, Fliser D, Schmidt T, Wilkens H, Schmit D, Sester M.Am J Transplant. 2026 Mar;26(3):499-511. doi: 10.1016/j.ajt.2025.09.023. Epub 2025 Oct 6.PMID: 41062073 **Free article.**

The potential of GPR31 as a target for effective oral vaccination.
Nakanishi K, Yukishima K, Umemoto E.Expert Opin Ther Targets. 2026 Mar 8:1-4. doi: 10.1080/14728222.2026.2641654. Online ahead of print.PMID: 41777183 No abstract available.

A replication-incompetent adenovirus type 55 **vaccine** induces broad and durable protective immunity against pathogenic adenoviruses.

Feng Y, Shu T, Li L, Sun X, Yu C, Liu W, Hong L, Li J, Zhao S, Zeng W, Yang C, Wang C, Zheng X, Ye X, Sun X, Liu Y, Li Z, Chen S, Niu X, Zhou R, Li P, Feng L, Chen L.Mol Ther. 2026 Mar 4;34(3):1597-1615. doi: 10.1016/j.ymthe.2025.12.027. Epub 2025 Dec 11.PMID: 41383016 **Free article.**

Study on the detection method of Brucella differential type PCR.
Luo Y, Qin Y, Zhang H, Zhang Y, Lu J, Liu X, Liu C, Zuo L, Lv Z, Liu H, Xie M, Yu Y, Wang T, Sun Y, Wen H, Wang W.Vet Immunol Immunopathol. 2026 Mar;293:111075. doi: 10.1016/j.vetimm.2026.111075. Epub 2026 Feb 2.PMID: 41643375

Intralesional measles, mumps, and rubella **vaccine** versus vitamin D for treatment of warts: A randomised clinical trial.
Sallam M, Awad A, Hamdy S, State A.Indian J Dermatol Venereol Leprol. 2026 Mar-Apr;92(2):285-291. doi: 10.25259/IJDVL_1669_2024.PMID: 40357930 **Free article.** Clinical Trial.

Protein-glycan engineering in **vaccine** design: merging immune mechanisms with biotechnological innovation.
Kearns M, Li M, Williams AJ.Trends Biotechnol. 2026 Mar;44(3):662-677. doi: 10.1016/j.tibtech.2025.06.022. Epub 2025 Jul 25.PMID: 40713219 Review.

Insights on **vaccine**-derived poliovirus type 2 outbreaks and novel oral polio **vaccine** candidates.
Aboshanab KM, Alshahrani MY, Enshasy HAE, Shabana MR, Majeed ABA.Diagn Microbiol Infect Dis. 2026 Mar;114(3):117221. doi: 10.1016/j.diagmicrobio.2025.117221. Epub 2025 Dec 9.PMID: 41389444 Review.

Modeling **vaccine** failures and behavioral change: Effects on disease transmission dynamics and thresholds.
Pedroza-Meza I, Acuña-Zegarra MA, Velasco-Hernández JX.Math Biosci. 2026 Mar;393:109619. doi: 10.1016/j.mbs.2026.109619. Epub 2026 Jan 7.PMID: 41513119

Filling the Federal Void Through Shared Leadership in **Vaccine** Policy.
Higgins DM.Am J Public Health. 2026 Mar;116(3):292-294. doi: 10.2105/AJPH.2025.308369.PMID: 41671539 No abstract available.

Improved cross-protection and immunity against influenza A virus in mice using a novel mRNA **vaccine** with optimized design of RNA sequence.
Wang T, Han R, Hao Z, Cheng X, Li J, Zhai C, Guo J, Wang D, Deng Y, Zhang L, Tan W.Mol Ther Nucleic Acids. 2025 Dec 3;37(1):102787. doi: 10.1016/j.omtn.2025.102787. eCollection 2026 Mar 12.PMID: 41503581 **Free PMC article.**

Risk of Celiac Disease Before and After Nationwide Infant Rotavirus Vaccination: A Population-Based Study.

Östman M, Stene LC, Tapia G, Kivelä L, Kurppa K, Størdal K; Human Exposomic Determinants of Immune Mediated Diseases (HEDIMED) Investigator Group.J Pediatr. 2026 Mar;290:114938. doi: 10.1016/j.jpeds.2025.114938. Epub 2025 Dec 10.PMID: 41386434 **Free article.**

Maternal immunization and early-life immunity: Mechanisms shaping neonatal protection.
Portet Sulla V, Soussan S, Bizot E, Ridyard A, Fovet CM, Picone O, Seddiki N, Vauloup-Fellous C.Vaccine. 2026 Mar 7;78:128423. doi: 10.1016/j.vaccine.2026.128423. Online ahead of print.PMID: 41797174 Review.

United states nursing home COVID-19 mortality 2020-2022.
Na L, Lan M, Liu R, Steiner V.Geriatr Nurs. 2026 Mar;68:103780. doi: 10.1016/j.gerinurse.2025.103780. Epub 2025 Dec 20.PMID: 41422734

Sex Differences in Response to Viral Vector Vaccines-Implications for Future **Vaccine** Design.
Grewe I, Zoran T, Addo MM.Immunol Rev. 2026 Mar;338(1):e70098. doi: 10.1111/imr.70098.PMID: 41612856 **Free PMC article.** Review.

Breaking the deadlock in antigen discovery for Leishmania vaccines.
Adriaensen W, de Vrij N, Pham TT, Laukens K, Meysman P, Kaye PM.Trends Parasitol. 2026 Mar;42(3):183-191. doi: 10.1016/j.pt.2026.01.005. Epub 2026 Mar 2.PMID: 41771716 Review.

Pathogenicity and **vaccine** protection of circulating pertactin- and filamentous hemagglutinin-deficient Bordetella pertussis strains.
Dai H, Sui X, Che J, Zhang C, Zhao J, Li J, Chen B, Guo L, Yan D, Wang H, Liu X, Xu L, Gao Y, Qin A, Zhu T, Zhang M, Shao Z.Emerg Microbes Infect. 2026 Dec;15(1):2640283. doi: 10.1080/22221751.2026.2640283. Epub 2026 Mar 10.PMID: 41807281 **Free PMC article.**

Impact and **vaccine** effectiveness of the 23-valent pneumococcal polysaccharide **vaccine** in adults aged 65 years or older in the Netherlands.
Niessen FA, Steens A, Knol MJ, Groenwold RHH, Bonten MJM, van Sorge NM, de Melker HE, van Werkhoven CH.Clin Microbiol Infect. 2026 Mar;32(3):440-445. doi: 10.1016/j.cmi.2025.09.027. Epub 2025 Nov 12.PMID: 41237898

mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts.
Moschioni M, Siraji RA, Dissard R, Segafredo G, Mutungi H, Jain A, Thakur R, Maurya N, James I.Hum Vaccin Immunother. 2026 Dec;22(1):2628424. doi: 10.1080/21645515.2026.2628424. Epub 2026 Mar 4.PMID: 41781347 **Free PMC article.** Review.

Combating **Vaccine** Disinformation: The Professional Responsibilities of Pediatric Nurse Practitioners.
Hallas D, Koslap-Petraco M.J Pediatr Health Care. 2026 Mar-Apr;40(2):335-340. doi: 10.1016/j.pedhc.2025.12.018. Epub 2026 Jan 14.PMID: 41532895

Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F **vaccine** against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.
Symes R, Whitaker HJ, Ahmad S, Arnold D, Banerjee S, Evans CM, Gore R, Hart J, Heaney K, Kon OM, Melhuish A, Ortale Zogaib M, Pelosi E, Rahman NM, Woltmann G, McKeever T, Zambon M, Watson CH, Lim WS, Lopez Bernal J; HARISS network collaborators.Lancet Infect Dis. 2026 Mar;26(3):229-238. doi: 10.1016/S1473-3099(25)00546-8. Epub 2025 Oct 27.PMID: 41167207 **Free article.**

High-Dose vs Standard-Dose Influenza **Vaccine** in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.
Nielsen AB, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Claggett BL, Janstrup KH, Bartholdy KV, Bernholm KF, Borchsenius JIH, Davidovski FS, Davodian LW, Dons M, Duus LS, Espersen C, Fussing FH, Jensen AMR, Landler NE, Langhoff ACF, Lassen MCH, Ottosen CI, Sengeløv M, Skaarup KG, Pareek M, Müller-Wieland D, Solomon SD, Landray MJ, Gislason GH, Køber L, Sivapalan P, Martel CJ, Jensen JUS, Biering-Sørensen T.JAMA Intern Med. 2026 Mar 1;186(3):311-320. doi: 10.1001/jamainternmed.2025.7286.PMID: 41525066 **Free PMC article.** Clinical Trial.

Modification and validation of the teen **vaccine** hesitancy scale toward vaccines for adolescents.
Nuzhath T, Yang Y, Couture MC, Callaghan T, Arah OA, Tsui J, Regan AK.Vaccine. 2026 Mar 4;77:128385. doi: 10.1016/j.vaccine.2026.128385. Online ahead of print.PMID: 41785515

Overcoming Challenges in Dengue **Vaccine** Development: Advanced Delivery Approaches.
Sengupta A, Bhattacharyya J.Mol Pharm. 2026 Mar 2;23(3):1319-1336. doi: 10.1021/acs.molpharmaceut.5c00937. Epub 2026 Feb 15.PMID: 41693158 Review.

The Current Landscape and Future Prospects of **Vaccine** Manufacturing in Africa: Challenges, Innovations, and Opportunities: A Narrative Review.
Chandipwisa C, Shimilimo A, Uwishema O, Onyeaka H.Health Sci Rep. 2026 Feb 28;9(3):e71926. doi: 10.1002/hsr2.71926. eCollection 2026 Mar.PMID: 41773217 **Free PMC article.**

Immunoinformatic-driven design of a multi-epitope **vaccine** against Helicobacter pylori.
Rahimi-Farsi N, Bostanian F, Ahmadi K, Zangooie A, Sedighi M, Shahbazi B, Mottaghi-Dastjerdi N.Biochem Biophys Rep. 2026 Feb 18;45:102498. doi: 10.1016/j.bbrep.2026.102498. eCollection 2026 Mar.PMID: 41756012 **Free PMC article.**

Emphasising herd immunity in **vaccine** advocacy: a systematic review and meta-analysis.
Reiter L, Voracek M, Betsch C, Böhm R.Health Psychol Rev. 2026 Mar;20(1):223-254. doi: 10.1080/17437199.2025.2562841. Epub 2025 Sep 24.PMID: 40992381 **Free article.** Review.

Japanese Encephalitis: Understanding Its Impact, Prevention, and the Role of Vaccination.

Shaikh MS, Khan ZZ, Majeed SSA, Iftekhar SS, Imran SJ, Faiyazuddin M, Sharma S, Mohanty A, Sah S, Mehta R, Srivastava S, Alshammari TM, Zambrano L, López-Marín JF, Rodriguez-Morales AJ.Rev Med Virol. 2026 Mar;36(2):e70123. doi: 10.1002/rmv.70123.PMID: 41755551 Review.

Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated **vaccine** (LAV) Ixchiq and the virus like particle (VLP) **vaccine** Vimkunya.
Kling K, Falman A, Branke L, Ramharter M, Rothe C, Schönfeld C, Grünewald T.Vaccine. 2026 Mar 7;75:128251. doi: 10.1016/j.vaccine.2026.128251. Epub 2026 Jan 20.PMID: 41564838 **Free article.** Review.

2024-2025 COVID-19 mRNA **Vaccine** Effectiveness against Severe Disease.
Jayawardena I, Dean NE, Witrick B, Litwin AH, Rennert L.J Infect Dis. 2026 Mar 2:jiag137. doi: 10.1093/infdis/jiag137. Online ahead of print.PMID: 41766610

Global inequities in pandemic **vaccine** allocation: what could academia do?
Gordijn B, Ten Have H.Med Health Care Philos. 2026 Mar;29(1):1-3. doi: 10.1007/s11019-026-10324-8.PMID: 41591718 No abstract available.

Risk Perceptions Regarding Tuberculosis Among Hispanic Adults - United States, 2020-2022.
Caruso E, Mangan JM, Maiuri A, Bouwkamp B, DeLuca N.Am J Health Promot. 2026 Mar;40(3):285-294. doi: 10.1177/08901171251376650. Epub 2025 Sep 4.PMID: 40906515 **Free PMC article.**

Regional variation in maternal RSV **vaccine** access and attitudes across two California cohorts.
Cirillo AA, Zeme M, Morales A, Rahseparian N, Cortez C, Gaw SL, Blauvelt CA.Prev Med Rep. 2026 Feb 11;63:103408. doi: 10.1016/j.pmedr.2026.103408. eCollection 2026 Mar.PMID: 41756026 **Free PMC article.**

High-Risk HPV in Men: A Hidden Threat to Public Health?
Coker KL, Morgan EL.Rev Med Virol. 2026 Mar;36(2):e70115. doi: 10.1002/rmv.70115.PMID: 41689447 **Free PMC article.** Review.

Increasing COVID-19 **vaccine** uptake through motivational interviewing-informed tailored digital intervention: Study protocol.
Ku CP, Christian A, Delacroix E, Trzeciak K, Resnicow K, Bailey S, Israel B, Valbuena F, Williamson S.Contemp Clin Trials. 2026 Mar;162:108221. doi: 10.1016/j.cct.2026.108221. Epub 2026 Jan 17.PMID: 41554332

Genetic and immunologic determinants of BCG disease: from mechanism to prevention.
Chen F, Shen Y, Yan Q, Zheng D, Chen X, Fang L, Sun M, Zhang Y, Chu M, Yang E, Huang XF.Ann Med. 2026 Dec;58(1):2634548. doi: 10.1080/07853890.2026.2634548. Epub 2026 Mar 2.PMID: 41770622 **Free PMC article.** Review.

Langat Virus Biology and Infection.

Klestova Z, Sauter D, Schindler M, Iftner T.Rev Med Virol. 2026 Mar;36(2):e70127. doi: 10.1002/rmv.70127.PMID: 41804201 **Free PMC article.** Review.

Vaccine Policy and Eliminating Nonmedical Exemptions-Read the Room.
Navin MC, Diekema DS.JAMA Pediatr. 2026 Mar 1;180(3):229-230. doi: 10.1001/jamapediatrics.2025.5290.PMID: 41428283

Plant-derived vaccines for veterinary disease management in ruminants and swine.
Shanmugaraj B, Aly ABA, Murugan C, Jayaraj K, Ramalingam S.Biotechnol Lett. 2026 Mar 6;48(2):45. doi: 10.1007/s10529-026-03715-7.PMID: 41792499 Review.

Nanoparticle-stabilized Pickering emulsions as **vaccine** delivery carriers: a review.
Sahoo R, Mandal S, Jana NR.Chem Commun (Camb). 2026 Mar 3;62(17):4947-4962. doi: 10.1039/d5cc06900a.PMID: 41700550 Review.

Characteristics, Motivation, and Challenges of Global Research on Dengue Vaccination.
Klingelhöfer D, Braun M, Kramer IM, Naser CA, Groneberg DA, Brüggmann D.Rev Med Virol. 2026 Mar;36(2):e70122. doi: 10.1002/rmv.70122.PMID: 41766108 **Free PMC article.** Review.

The Burden of HPV35 in African Cervical Pathologies: Prevalence, Contributing Factors, and **Vaccine** Prospects.
Murahwa AT, Dzobo M, Mahenge A, Rantshabeng P, Dube Mandishora RS.Rev Med Virol. 2026 Mar;36(2):e70129. doi: 10.1002/rmv.70129.PMID: 41776984 Review.

Maximizing impact: the power of early HPV vaccination for long-term protection-lessons from a systematic review and meta-regression analysis.
Navarro-Torné A, Aris E, Callegaro A, Benninghoff B, Yun H, Vetter V.J Public Health (Oxf). 2026 Mar 6;48(1):216-227. doi: 10.1093/pubmed/fdag002.PMID: 41612578 Review.

Antigen anisotropy: The overlooked geometric determinant of **vaccine** immunogenicity and fidelity.
Santiago D.Hum Vaccin Immunother. 2026 Dec 31;22(1):2638640. doi: 10.1080/21645515.2026.2638640. Epub 2026 Mar 4.PMID: 41782397 **Free PMC article.** Review.

Update on the efficacy of vaccination on host immunity to influenza virus infection.
Mortaz E, Abdolmohammadi-Vahid S, K Dezfuli N, Hojjati F, Jamaati H, Varahram M, Tabarsi P, Adcock IM.Int Arch Allergy Immunol. 2026 Mar 5:1-16. doi: 10.1159/000551286. Online ahead of print.PMID: 41785195 **Free article.** Review.

Genomic and antigenic analysis of G1P[8] rotavirus strains in Ningxia, China.
Cao M, Zhang W, Yuan F, Wu Z, Ma J, Ma X.Int J Infect Dis. 2026 Mar;164:108372. doi: 10.1016/j.ijid.2026.108372. Epub 2026 Jan 8.PMID: 41519377 **Free article.**

Research progress on immunoprotective mechanisms of enteric fever and **vaccine** development.

Chen Y, Chen L, Lin Y, Cong Y.J Adv Res. 2026 Mar;81:583-592. doi: 10.1016/j.jare.2025.05.054. Epub 2025 May 26.PMID: 40436138 **Free PMC article.** Review.

Time for a New Yellow Fever **Vaccine**.
Bailey AL, Stapleton JT.J Infect Dis. 2026 Mar 9:jiag152. doi: 10.1093/infdis/jiag152. Online ahead of print.PMID: 41802272 No abstract available.

Single-dose mSEB-mi3 nanoparticle **vaccine** elicits robust humoral immunity and protects mice against SEB intoxication and MRSA infection.
Liao Z, Wu M, Chen Y, Zhu Z, Li Y, Mei Q, Huang B, Cheng X, Zhang Y, Zeng H, Ma D, Gu J.Vaccine. 2026 Mar 7;75:128245. doi: 10.1016/j.vaccine.2026.128245. Epub 2026 Jan 29.PMID: 41616648

Design a multi-epitope **vaccine** targeting Chlamydia psittaci plasmid proteins through reverse vaccinology.
Xu L, Liang M, Chen Z, Zhu Y, Wu J, Yuan H, Peng B, Li R, Lu J.Int J Biol Macromol. 2026 Mar;350:150954. doi: 10.1016/j.ijbiomac.2026.150954. Epub 2026 Feb 17.PMID: 41708036

Chandipura Virus: A Neglected Sandfly-Borne Neurotropic Virus in Children - Insights From Seven Decades of Evidence.
Dangi RR, Vageriya V, Sharma A, Dabhi P.Rev Med Virol. 2026 Mar;36(2):e70119. doi: 10.1002/rmv.70119.PMID: 41769747 Review.

Evaluating online vaccination imagery: how misleading photos could impact safety.
Zhang X, Vlasenko D, Hickman J, Buttery J, Davis M.Vaccine. 2026 Mar 4;78:128398. doi: 10.1016/j.vaccine.2026.128398. Online ahead of print.PMID: 41785677 **Free article.**

Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 **vaccine** to address current challenges.
Domachowske JB, Zimet GD, Hanage W, Beck E, Sule P, Wahid R, Vicic N.Expert Rev Vaccines. 2026 Dec;25(1):2632657. doi: 10.1080/14760584.2026.2632657. Epub 2026 Mar 3.PMID: 41744151 **Free article.** Review.

Case Studies of Rapid Community Assessment Implementation to Improve **Vaccine** Confidence and Demand During the COVID-19 **Vaccine** Rollout.
Fraze JL, Asif AF, Zajac J.J Public Health Manag Pract. 2026 Mar-Apr 01;32(2):E98-E104. doi: 10.1097/PHH.0000000000002308. Epub 2025 Dec 8.PMID: 41364471

Controlled human helminth infection models: insights into type 2 immunity and therapeutic development.
Droghini HR, Nutman TB, Loke P.Trends Parasitol. 2026 Mar 7:S1471-4922(26)00045-0. doi: 10.1016/j.pt.2026.02.009. Online ahead of print.PMID: 41795870 Review.

Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.
Govender V, Reddy T, Maenetje P, Beattie T, Adonis T, Nielson T, Moodley J, Mdluli J, Bhoola A, Angelo S, Panchia R, Mngadi K, Innes C, Brumskine W, Mlotshwa M, Nhlangulela L, Ncube I, Moyo-Gwete T, Moore PL, Keeton RS, Burgers W, Kumar K, Garg N, Tripathi A, Sayed S, Matsimela K, Mchunu N, Wallis R, Edward VA, Churchyard GJ; COVID-19 Vaccine Strategies study group.Lancet HIV. 2026 Mar;13(3):e163-e175. doi: 10.1016/S2352-3018(25)00275-9. Epub 2026 Feb 11.PMID: 41690324 Clinical Trial.

Vaccine Candidates Designed to Prevent Enterotoxigenic Escherichia coli Diarrhoea: A Scoping Review of Clinical Trials Evaluating **Vaccine** Candidates in Development.
Nafade V, Sule NO, Zhang Y, Sassi A, Basta NE.Trop Med Int Health. 2026 Mar;31(3):295-306. doi: 10.1111/tmi.70070. Epub 2026 Jan 23.PMID: 41575733 **Free PMC article.** Review.

Pro/con: vaccination and waning immunity - presents contrasting perspectives on the durability of **vaccine**-induced protection and the potential need for booster strategies.
Nguyen LBL, Ghosn J.Curr Opin HIV AIDS. 2026 Mar 1;21(2):125-129. doi: 10.1097/COH.0000000000001013. Epub 2026 Jan 6.PMID: 41496368 Review.

Measles Resurgence: Could a Third **Vaccine** Dose Be the Solution?
Chau HTB, Minh BC, Aziz JMA, Van HBT, Tien BNH, Gad A, Nguyen KD, Gam PH, Hamraa J, Hang LTT, Ngan TTK, Son PT, Huy NT.Rev Med Virol. 2026 Mar;36(2):e70134. doi: 10.1002/rmv.70134.PMID: 41814671 Review.

Co-administration of oral killed whole-cell recombinant cholera toxin B-subunit **vaccine** (WC-rCTB) and live Salmonella Typhi Ty21a **vaccine**: a prospective randomized open-label trial.
Riekkinen M, Terrinoni M, Pakkanen SH, Kaim J, Vahlberg T, Lundgren A, Kantele A.J Travel Med. 2026 Mar 2;33(2):taag008. doi: 10.1093/jtm/taag008.PMID: 41641963 Clinical Trial.

"Toward tuberculosis elimination: an update on tuberculosis vaccines in clinical trials".
Martín C, Gonzalo-Asensio J, Aguiló N, Arbués A.Int J Infect Dis. 2026 Mar 1:108513. doi: 10.1016/j.ijid.2026.108513. Online ahead of print.PMID: 41775317 **Free article.** Review.

Global Interdependence, Just **Vaccine** Allocation, and Compensatory Justice: A New Model.
Fredette KJ.Dev World Bioeth. 2026 Mar;26(1):17-22. doi: 10.1111/dewb.12486. Epub 2025 Jun 8.PMID: 40483724

Exploring COVID-19 pandemic perceptions and **vaccine** uptake among community members and primary healthcare workers in Nigeria: A mixed methods study.
Sogbesan A, Bakare AA, Herzig van Wees S, Salako J, Bakare D, Olojede OE, Akinsola K, Bakare OR, Falade AG, King C.PLoS One. 2026 Mar 11;21(3):e0310437. doi: 10.1371/journal.pone.0310437. eCollection 2026.PMID: 41811854 **Free PMC article.**

Increasing HPV and Cervical Cancer Education Among Native American Communities and Healthcare Providers.
Joe TR, Natonie KM, Charley KR, Lee NR.J Cancer Educ. 2026 Mar;41(1):40-48. doi: 10.1007/s13187-025-02619-w. Epub 2025 Apr 10.PMID: 40208507 **Free PMC article.**

What Should We Believe? The Case of COVID-19 **Vaccine** Mandates.
Kim SJS.J Med Philos. 2026 Mar 5:jhaf034. doi: 10.1093/jmp/jhaf034. Online ahead of print.PMID: 41786674

Adjuvanted-RSVPreF3 **vaccine** uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.
Fonseca MJ, Bratković S, Çolak Y, Helleberg M, Vestbo J, Burns S, Spanggaard M, Løwe Lundgren K, Gkalapi F, Theiss-Nyland K.Expert Rev Vaccines. 2026 Dec;25(1):2641671. doi: 10.1080/14760584.2026.2641671. Epub 2026 Mar 10.PMID: 41782458 **Free article.**

Identification and **vaccine** efficacy evaluation of a canine coronavirus isolated in central China.
Zhang X, Li Y, Liu X, Zhou M, Zhao L.Vet Microbiol. 2026 Mar;314:110879. doi: 10.1016/j.vetmic.2026.110879. Epub 2026 Jan 10.PMID: 41529644

Understanding COVID-19 vaccination choices and development of a toolkit and training for Botswana, 2022-2023.
Mansfield ME, Okui L, Simon S, Hosangadi D, Montebatsi M, Ikgopoleng K, Kuate L, Mothowaeng B, Ryan N, Yee D, Dahlke M, Stafford KA, Ndwapi N, Sebaka A, Greby SM.Vaccine. 2026 Mar 7;75:128274. doi: 10.1016/j.vaccine.2026.128274. Epub 2026 Jan 23.PMID: 41579755 **Free article.**

An age-structured mathematical model to assess the combined effects of **vaccine** and non-**vaccine** interventions on malaria transmission and burden.
Glèlè Kakaï R, Djomatin LC.Infect Dis Model. 2025 Oct 31;11(1):355-376. doi: 10.1016/j.idm.2025.10.007. eCollection 2026 Mar.PMID: 41321682 **Free PMC article.**

Influenza **vaccine** recommendations and coverage (2018-2023): a foundation for pandemic preparedness and response.
Meslé MMI, Jorgensen P, Barakat A, Herring BL, Nogareda F, Contreras M, Velandia-Gonzalez M, Wijesinghe P, Doshi R, Ghiga I, Gibson R, Dumolard L, Brooks DJ, Akande OW, Lambach P, Cozza V, Moen AC, Tempia S, Goldin S.Vaccine. 2026 Mar 10;78:128391. doi: 10.1016/j.vaccine.2026.128391. Online ahead of print.PMID: 41814119

COVID-19 mRNA revaccination is safe and well tolerated in individuals with previous adverse reactions to the **vaccine** and/or long COVID.
Slack IF, O'Shea KM, Freigeh GE, Franco LM, Jaafar S, Schuler CF 4th, Baker JR Jr.J Allergy Clin Immunol Glob. 2025 Nov 29;5(2):100620. doi: 10.1016/j.jacig.2025.100620. eCollection 2026 Mar.PMID: 41550084 **Free PMC article.**

Increasing HPV **vaccine** uptake using a "start at 9"strategy: A pilot program.
Malik S, Gu S, Sisskind J, Blatt S, Suryadevara M.Vaccine. 2026 Mar 4;78:128401. doi: 10.1016/j.vaccine.2026.128401. Online ahead of print.PMID: 41785678 **Free article.**

Evaluation of recombinant SIP, enolase, and GAPDH as subunit **vaccine** candidates against Streptococcus iniae in four-finger threadfin (Eleutheronema tetradactylum): Immunogenicity, protective efficacy, and multivalent potential.
Giovanni A, Shi YZ, Wang PC, Tsai MA, Chen SC.Fish Shellfish Immunol. 2026 Mar;170:111146. doi: 10.1016/j.fsi.2026.111146. Epub 2026 Jan 21.PMID: 41577307

Development and efficacy test of a live, attenuated Mycoplasma hyorhinis **vaccine** candidate strain.
Nagy EZ, Szeredi L, Földi D, Belecz N, Kovács ÁB, Sulyok KM, Grózner D, Wehmann E, Bányai K, Marton S, Tenk M, Kreizinger Z, Gyuranecz M.Vaccine. 2026 Mar 7;75:128278. doi: 10.1016/j.vaccine.2026.128278. Epub 2026 Jan 29.PMID: 41610462 **Free article.**

COVID-19 **vaccine** policy: a response and way forward.
Poland GA, Ratishvili T, Pitts PJ.Vaccine. 2026 Mar 7;75:128292. doi: 10.1016/j.vaccine.2026.128292. Epub 2026 Jan 31.PMID: 41621118 No abstract available.

Multi-epitope **vaccine** against nucleoprotein and envelopment polyprotein of Batai orthobunyavirus using molecular docking and molecular dynamics studies.
Naveed M, Asim M, Ali A, Amjad S, Majeed MN, Sandrine MNY, Al-Hoshani N, Mohamed RAEH, Alwethaynani MS, Almsaud MM.Sci Rep. 2026 Mar 4. doi: 10.1038/s41598-026-41964-8. Online ahead of print.PMID: 41781575 **Free article.**

Environmental and physiological factors influencing the survival of resistant *Salmonella* under infection-related gut conditions.
Prabhu C, Kotian A, Aditya V, Deekshit VK.Clin Microbiol Rev. 2026 Mar 12;39(1):e0019625. doi: 10.1128/cmr.00196-25. Epub 2025 Dec 5.PMID: 41364116 Review.

Improving Vaccination in People With CKD: Report From a National Kidney Foundation Working Group.
Massengill SF, Andreoni KA, Bellovich KA, Courtlandt C, Derebail VK, Feldman DL, Oh GJ, Sleasman JW, Bryant KA; Improving Vaccination in CKD Working Group.Am J Kidney Dis. 2026 Mar;87(3):402-411. doi: 10.1053/j.ajkd.2025.10.014. Epub 2025 Dec 22.PMID: 41443538 **Free article.**

Recent advances in vaccination strategies against acute hepatopancreatic necrosis disease (AHPND) in shrimp for sustainable aquaculture industry: A comprehensive review.
Isa T, Widodo RT, Noor SM, Amdan NAN, Kari ZA, Taufek NM, Zuki FM, Abdullah A, Bhassu S, Sofian ZM, Mustapha S, Haron DEM, Azemi AK, Nordin ML.Fish Shellfish Immunol. 2026 Mar;170:111136. doi: 10.1016/j.fsi.2026.111136. Epub 2026 Jan 17.PMID: 41554323 Review.

Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis.
Săndulescu O, Mantovani S, Roque-Afonso AM, Sahin GÖ, Rajan AK, Altındiş M, Miron VD, Küçükkaya S, Mondelli MU; ESGVH.Clin Microbiol Infect. 2026 Mar;32(3):416-426. doi: 10.1016/j.cmi.2025.11.026. Epub 2025 Nov 28.PMID: 41319806 **Free article.** Review.

Factors affecting pharmacy and medical students knowledge and attitude towards respiratory syncytial virus vaccines.
Hammour KA, El-Dahiyat F, Al-Ashwal FY, Manaseer Q, Hammour WA, Abu-Farha RK.Curr Pharm Teach Learn. 2026 Mar;18(3):102554. doi: 10.1016/j.cptl.2025.102554. Epub 2025 Dec 18.PMID: 41418708

Mpox vaccination uptake and acceptance in the Democratic Republic of Congo: a systematic review and meta-analysis.
Cheuyem FZL, Amani A, Umar AA, Achangwa C, Ajong BN, Dabou S, Goupeyou-Youmsi J, Ndibo GRP, Tchamani R, Ambo EE, Ndungo JH, Nadarajah S.Arch Public Health. 2026 Mar 4. doi: 10.1186/s13690-026-01863-w. Online ahead of print.PMID: 41782060 **Free article.**

A replication-defective bivalent adenovirus-vectored **vaccine** provides robust and durable protection against both canine distemper virus and canine parvovirus.
Hu Y, Han X, Zhu S, Zhang Y, Peng Y, Zhang C, Zhou M, Zhao L.Vet Microbiol. 2026 Mar;314:110933. doi: 10.1016/j.vetmic.2026.110933. Epub 2026 Feb 6.PMID: 41655498

Burden of *Shigella* and enterotoxigenic *Escherichia coli* infections among children under 5 years in Ethiopia, Kenya and Malawi: a systematic review and meta-analysis.
Mwendera CA, Yilma M, Wairimu C, Kering K, Mwinjiwa E, Kariuki JN, Asrat D, Mekasha A, Msefula C, Kariuki S, Cornick J, Clough H, French N, Pitzer V, Jere KC, Hungerford D; GHRG-GI Consortium; GHRG-GI Consortium.BMJ Glob Health. 2026 Mar 2;11(3):e018515. doi: 10.1136/bmjgh-2024-018515.PMID: 41771662 **Free PMC article.**

A community pharmacy vaccination nudge intervention: Final results of a nationwide study.
Hohmeier KC, Brookhart A, Kinney O, Dillon K, Chiu CY, Frederick KD, Hagemann T, Ramachandran S, Gatwood J.Res Social Adm Pharm. 2026 Mar;22(3):443-450. doi: 10.1016/j.sapharm.2025.11.010. Epub 2025 Nov 28.PMID: 41339191

A brief review of chikungunya fever: From molecular virology to countermeasures.
Zhang X, Li X, Jiang T, Fu J.Infect Med (Beijing). 2025 Dec 25;5(1):100231. doi: 10.1016/j.imj.2025.100231. eCollection 2026 Mar.PMID: 41657861 **Free PMC article.** Review.

Exploring regional variations in the provision of influenza vaccination in Italy.
Contarino F, Fiorilla C, Bella F, Orsi A, Mistretta A, Icardi G.Vaccine. 2026 Mar 7;75:128266. doi: 10.1016/j.vaccine.2026.128266. Epub 2026 Jan 22.PMID: 41576703

Neonatal mice immune response to COVID-19 mRNA **vaccine**.
Lotspeich-Cole L, Jha MK, Parvathaneni S, Lee RC, Weissman D, Major M, Akkoyunlu M.Vaccine. 2026 Mar 7;75:128271. doi: 10.1016/j.vaccine.2026.128271. Epub 2026 Jan 28.PMID: 41610463 **Free article.**

Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening.
Palmer TJ, Kavanagh K, Cuschieri K, Cameron RL, Graham C, Wilson A, Roy K.Int J Cancer. 2026 Mar 1;158(5):1348-1360. doi: 10.1002/ijc.70183. Epub 2025 Nov 3.PMID: 41185413 **Free PMC article.**

In situ-generated **vaccine**-like pyroptosome for personalized cancer immunotherapy.
Chen B, Wan F, Xia H, Pan X, Wang L, Wang Y, Yan Y, Liu J, Tang M, Yang Y, Qin M, Ren J, Zhou B, Zhong L, Chen W, Han C, Deng M, Zhang Q, Wang Y.Nat Mater. 2026 Mar 3. doi: 10.1038/s41563-026-02506-9. Online ahead of print.PMID: 41775900

Meningococcal quadrivalent ACYW-TT conjugated **vaccine** at 6-23 months: phase III study (US/Puerto Rico).
Duffy C, Lyabis O, Dhingra MS, Zambrano B, Chaix J, Syrkina O, B'Chir S, Gupta S, Rehm C.Pediatr Res. 2026 Mar 6. doi: 10.1038/s41390-026-04833-8. Online ahead of print.PMID: 41792337

Intention to vaccinate children against measles: findings from a national survey in the United States.
Melchinger H, Kuppalli K, Elharake JA, Omer SB, Malik AA.Lancet Reg Health Am. 2026 Feb 12;55:101393. doi: 10.1016/j.lana.2026.101393. eCollection 2026 Mar.PMID: 41732482 **Free PMC article.**

Impact of pharmacy-based interventions on vaccination coverage among vulnerable and underserved populations: a systematic review and meta-analysis.
Stefania B, Flavia P, Antonio P, Emanuele P, Carole DA, Carlo S.Vaccine. 2026 Mar 7;78:128426. doi: 10.1016/j.vaccine.2026.128426. Online ahead of print.PMID: 41797172 Review.

Vaccination games of boundedly rational parents toward new childhood immunization.
Yin W, Ndeffo-Mbah ML, Oraby T.Infect Dis Model. 2025 Sep 19;11(1):150-164. doi: 10.1016/j.idm.2025.09.004. eCollection 2026 Mar.PMID: 41079257 **Free PMC article.**

Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination.
Tursi NJ, Agostino CJ, Huang J, Kannan T, Laenger N, Londregan J, Lederer K, Helble M, Bedanova N, Livingston C, Gary EN, McCanna M, Medina MT, Habib R, Relaño IR, Maillard I, Patel A, Allman D, Kossenkov A, Escolano A, Kulp DW, Weiner DB.Adv Sci (Weinh). 2026 Mar;13(14):e17556. doi: 10.1002/advs.202517556. Epub 2026 Jan 28.PMID: 41604577 **Free PMC article.**

Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.
Bebia Z, Dieussaert I, Jose L, Kantele A, Välimaa H, Middleton G, Pirela HDE, Reyes O, Sánchez MG, Vigil-De Gracia P, Hua N, Kirabo M, Lese P, Kim JH.Hum Vaccin Immunother. 2026 Dec;22(1):2613565. doi: 10.1080/21645515.2026.2613565. Epub 2026 Mar 1.PMID: 41766205 **Free PMC article.** Clinical Trial.

Assessment of genetic diversity and pathogenicity of porcine rotavirus A, and immunogenicity of a bivalent inactivated **vaccine** in southern China.
Hu G, Zhao Z, Gao L, Geng R, Liu S, Zhang H, Cao Y, Shen H, Xue C.Vet Microbiol. 2026 Mar;314:110893. doi: 10.1016/j.vetmic.2026.110893. Epub 2026 Jan 22.PMID: 41616680

Epitope-Based Multimeric Subunit **Vaccine** (ATOMSSUISpenta) Confers Broad Protection Against Streptococcus suis Infection.
Kim SY, Chen F, Kim WS, Ji HJ, Kim MK, Park HR, Lamien CE, Wijewardana V, Kim KH, Ahn KB, Seo HS.J Infect Dis. 2026 Mar 4:jiag131. doi: 10.1093/infdis/jiag131. Online ahead of print.PMID: 41778368

Lipid Nanoparticles Formulated with a Molecular Hybridization-Derived Ionizable Lipid Enabled OVA-mRNA Delivery for Melanoma Prevention in Mice.
Liu Z, Jiang Q, Li H, Shi Y, Qian X, Sun T, Wang Z, Su Z, Li Y, Wu J.ACS Biomater Sci Eng. 2026 Mar 9;12(3):1592-1602. doi: 10.1021/acsbiomaterials.5c01698. Epub 2026 Feb 19.PMID: 41711595

Recommendation for Human Papillomavirus **Vaccine** after Abnormal Pap Smear in Unvaccinated Active Duty Women.
Stout CE, Poiani LTH, Mcglynn A, Enujioke CDRSC.Mil Med. 2026 Mar 1;191(3-4):e508-e512. doi: 10.1093/milmed/usaf404.PMID: 40802575

Advances in melanoma immunotherapy: harnessing vaccination as a potential novel immunotherapeutic strategy.
Abuelainain DS, Abdel-Aziz AK, Saadeldin MK.Biochem Pharmacol. 2026 Mar;245:117687. doi: 10.1016/j.bcp.2026.117687. Epub 2026 Jan 7.PMID: 41513106 **Free article.** Review.

The Florida **Vaccine** Mandate Elimination and Its Potential Domino Effect.
Fink BN.J Public Health Manag Pract. 2026 Mar-Apr 01;32(2):165-166. doi: 10.1097/PHH.0000000000002310. Epub 2025 Jan 20.PMID: 41286594 No abstract available.

Biomimetic Cell Membrane-coated Nanovaccines in Anti-tumor Immunotherapy.
Chen Y, Zhang W, Huang X.Theranostics. 2026 Mar 3;16(9):5085-5104. doi: 10.7150/thno.128136. eCollection 2026.PMID: 41799199 **Free PMC article.** Review.

Clinical development of cancer vaccines.

Haanen JB, Schumacher TNM, Kagan JC, Fritsch EF, Wu CJ.Nat Med. 2026 Mar 11. doi: 10.1038/s41591-026-04241-9. Online ahead of print.PMID: 41814007 Review.

Perceptions and Interests of Dental Hygienists in Addressing Food Insecurity and HPV in Clinical Settings.
Khan T, Fleming A, Joyce JM, Porter KJ, Liebe RA.J Public Health Dent. 2026 Mar;86(1):21-33. doi: 10.1111/jphd.70030. Epub 2026 Jan 25.PMID: 41582600 **Free PMC article.**

Priming route and age at first vaccination shape prime and boost **vaccine** responses in rainbow trout (Oncorhynchus mykiss).
Abouismail A, Sapayeva S, Erhardt EB, Maxwell R, Cox M, Ma J, Salinas I.Vaccine. 2026 Mar 4;78:128403. doi: 10.1016/j.vaccine.2026.128403. Online ahead of print.PMID: 41785675 **Free article.**

Respiratory syncytial virus mRNA **vaccine**-induced immunity and protection against subgroups A and B in mice.
Lee S, Yoon J, Shooter S, Pak DS, Ha B, Rostad CA, Anderson LJ, Schinazi RF, Kim B.Immunohorizons. 2026 Mar 10;10(3):vlag006. doi: 10.1093/immhor/vlag006.PMID: 41808349 **Free PMC article.**

Serotype-specific immunity and association with pneumococcal carriage following 3+1, 3+0 and 2+1 schedules of 10-valent pneumococcal conjugate **vaccine**.
Ong DS, Toh ZQ, Temple B, Nguyen CD, Phan TV, Dai VTT, Balloch A, Higgins RA, Ortika BD, Beissbarth J, Bright K, Vientrung K, Spry L, Nation ML, Hong NVP, Toan NT, Hoan PT, Cheung YB, Smith-Vaughan H, Satzke C, Huu TN, Mulholland K, Licciardi PV.J Infect Dis. 2026 Mar 12:jiag157. doi: 10.1093/infdis/jiag157. Online ahead of print.PMID: 41818666

Impacts of Declining Hepatitis B **Vaccine** Birth Dose on Future Immunization Uptake.
Gargano LM, Dumont D.R I Med J (2013). 2026 Mar 2;109(3):37-40.PMID: 41740178 **Free article.**

Trends in hospitalizations for **vaccine**-preventable diseases in the United States from 2014 to 2024.
Money NM, Sullivan E, Rector H, McDaniel CE, Markham JL, Bryan MA.J Hosp Med. 2026 Mar 5. doi: 10.1002/jhm.70302. Online ahead of print.PMID: 41787753

Safety and immunogenicity of a 25-valent pneumococcal conjugate **vaccine** in pneumococcal **vaccine**-naive healthy adults: Results from 2 randomised, controlled clinical trials.
Langley JM, Sadarangani M, Ockenhouse C, Barreto L, Ye L, Tang Y, Breeze JL, Feser J, Hosken NA, Andi-Lolo I, Tasker SA, Halperin SA; Canadian Immunization Research Network.Vaccine. 2026 Mar 7;75:128236. doi: 10.1016/j.vaccine.2026.128236. Epub 2026 Jan 22.PMID: 41576705 **Free article.** Clinical Trial.

Adherence to national vaccination guidelines among pediatric cancer patients: a retrospective study from two tertiary care centers in Switzerland.

Barbey FA, Otth M, Kroiss S, Drozdov D, Berger C.Vaccine. 2026 Mar 7;75:128265. doi: 10.1016/j.vaccine.2026.128265. Epub 2026 Jan 22.PMID: 41570445 **Free article.**

Fathers' reports of within-household **vaccine** decision making and young children's COVID-19 vaccination status.
Park IY, Cantu-Aldana A, Grafft N, Lo BK, Bauer KW, McBride BA, Haneuse SJ, Haines J, Davison KK.Vaccine. 2026 Mar 7;75:128282. doi: 10.1016/j.vaccine.2026.128282. Epub 2026 Jan 31.PMID: 41621117

Health Misinformation in Ethiopia: Myths, Media Dynamics, Public Response, and Policy Implications: A Narrative Review.
Berhe TT, Jara D, Kifle D.Public Health Chall. 2025 Dec 31;5(1):e70181. doi: 10.1002/puh2.70181. eCollection 2026 Mar.PMID: 41480490 **Free PMC article.** Review.

Insights to Action: Supporting Parental Trust and **Vaccine** Literacy.
Nair S, Nadkarni G.J Public Health Manag Pract. 2026 Mar-Apr 01;32(2):284-286. doi: 10.1097/PHH.0000000000002322. Epub 2025 Jan 20.PMID: 41576410 No abstract available.

Typhoid knowledge, prevention practices, and **vaccine** awareness in high-risk communities of Lilongwe, Malawi.
Lubanga AF, Bwanali AN, Moyo C, Kamanga W, Chrispin E, Kambili F, Kambewa LN, Chung JS, Chung S, Chung D, Choe K, Choi J, Mkandawire V, Msonthi CC, Nyirenda T.Trans R Soc Trop Med Hyg. 2026 Mar 5:trag023. doi: 10.1093/trstmh/trag023. Online ahead of print.PMID: 41783922

Measuring the Impacts of RNA **Vaccine** Research and the Consequences of Defunding.
Kelvin AA, Rasmussen AL.JAMA Netw Open. 2026 Mar 2;9(3):e260032. doi: 10.1001/jamanetworkopen.2026.0032.PMID: 41770569 **Free article.** No abstract available.

Design and computational evaluation of a cross-protective multi-epitope **vaccine** candidate against Bartonella henselae and Bartonella clarridgeiae pathogens causing the zoonotic cat scratch disease in humans.
Şeflekçi Y, Köseoğlu AE, Erdoğdu Sever R, Işıksal EN, Özgül F, Ece A.Comput Biol Med. 2026 Mar;204:111509. doi: 10.1016/j.compbiomed.2026.111509. Epub 2026 Jan 30.PMID: 41619363

A systematic literature review of methodologies used in economic evaluations of combination vaccines.
Di Fusco M, Vaghela S, Mateus C, Janke K.J Med Econ. 2026 Dec;29(1):740-760. doi: 10.1080/13696998.2026.2637396. Epub 2026 Mar 9.PMID: 41801186 **Free article.**

Antibiotic misuse and **vaccine** hesitancy: A hidden relation?
Hilário AP, Augusto FR.Health (London). 2026 Mar 12:13634593261425701. doi: 10.1177/13634593261425701. Online ahead of print.PMID: 41817150

MtrE Loop2-specific multiple antigenic peptide **vaccine** and monoclonal antibody confer complement-dependent protection against Neisseria gonorrhoeae.
Song S, Ge H, Yuan D, Gu X, Lu W, Ding C, Qin Y, Gao S, Lin X, Cheng H, van der Veen S.NPJ Vaccines. 2026 Mar 3. doi: 10.1038/s41541-026-01412-0. Online ahead of print.PMID: 41776223 **Free article.**

Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus **Vaccine** in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 Trial.
Athan E, Greenberg RN, Baker DA, Shah R, Dubhashi S, Badat A, Thurlow C, Schlessinger J, Wronski A, Zakrzewski M, Turner D, Bindi I, Basile V, Galletti B, Spensieri F, Brazzoli M, Zigon G, Cilio GL, Ranzato G, Lattanzi M, Pellegrini M; Staph aureus 208833 study group.Clin Infect Dis. 2026 Mar 9:ciag162. doi: 10.1093/cid/ciag162. Online ahead of print.PMID: 41800789

Mitigating **Vaccine** Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster **Vaccine** Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities.
Abdul-Mutakabbir JC, Abdul-Mutakabbir R, Casey SJ.Infect Dis Ther. 2026 Mar 5. doi: 10.1007/s40121-026-01310-x. Online ahead of print.PMID: 41784913

Mechanisms Are Emerging for COVID-19 **Vaccine**-Associated Myocarditis.
Abbasi J.JAMA. 2026 Mar 3;335(9):744-745. doi: 10.1001/jama.2025.25866.PMID: 41649806

An age-gender-structured mathematical model to study the optimization of COVID-19 vaccination programs.
González-Parra G, Luebben G, Villanueva RJ, Navarro-González FJ, Bhakta B.Math Comput Simul. 2026 Mar;241(Pt B):293-311. doi: 10.1016/j.matcom.2025.10.015. Epub 2025 Oct 18.PMID: 41497763 **Free PMC article.**

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue **vaccine**.
Kallás EG, Moreira JA, Patiño EG, Braga PE, Tenório JCV, Alves LBO, Infante V, Silveira DHR, Miraglia JL, Cintra MAT, Pereira DB, da Fonseca AJ, Gurgel RQ, Coelho IC, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Boaventura VS, Ramos F, Júnior EE, Cassio de Moraes J, Estofolete CF, Freitas AC, Dos Santos CLS, Timenetsky MDCST, Whitehead SS, Durbin AP, Esteves-Jaramillo A, Shekar T, Lee JJ, Chen Q, Macey J, Vaidya S, Coller BG, Boulos FC, Nogueira ML, Lacerda MVG.Nat Med. 2026 Mar 4. doi: 10.1038/s41591-026-04255-3. Online ahead of print.PMID: 41781546

Fibrin gel-based co-delivery of self-adjuvant tumor **vaccine** and PD-1 blockade for post-surgical gastric cancer immunotherapy.
Yang J, Chen C, Ding D, Ren J, Lan T, Li Y, Jiang G, Liang R, You J, Abdullaev B, Ryabtseva S, Huang H, Shuai X, Wei B.J Control Release. 2026 Mar 10;391:114629. doi: 10.1016/j.jconrel.2026.114629. Epub 2026 Jan 14.PMID: 41544668

Gonococcal outer membrane vesicle vaccines: bacterial population biology, clinical trials, immune profiling, and **vaccine** design.
Gu Z, Unitt A, Harrison OB, Derrick JP, Jerse AE, McKeand SA, Tang CM.NPJ Vaccines. 2026 Mar 5. doi: 10.1038/s41541-026-01410-2. Online ahead of print.PMID: 41786782 **Free article.** Review.

T and B cell targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques.
Rahman SA, Gangadhara S, Gridley J, Mala U, Elrod EJ, Bédard N, Bruneau J, Shoukry NH, Grakoui A, Amara RR.Hepatology. 2026 Mar 6. doi: 10.1097/HEP.0000000000001732. Online ahead of print.PMID: 41790984

Risk factors for loss of Varicella immunity after pediatric kidney transplantation.
Pizzo H, Soni PR, Nadipuram S, Mirocha J, Garrison J, Hilario S, Puliyanda D.Pediatr Nephrol. 2026 Mar;41(3):837-844. doi: 10.1007/s00467-025-07022-7. Epub 2025 Nov 13.PMID: 41225196 **Free PMC article.**

Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal **Vaccine** Schedule in the United States.
Herrera-Restrepo O, Jutlla G, Graham J, Carrico J, Grace M, Kocaata Z, Clements DE, Burman C, Andani A, Shah H.Pharmacoeconomics. 2026 Mar 6. doi: 10.1007/s40273-026-01599-z. Online ahead of print.PMID: 41790381

COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
Sharma AJ, Smoots AN, Madni SA, Zauche LH, Waters A, Machefsky A, Shay DK, Hinrichsen C, Chambless J, Norris K, Thompson SA, Johnson T, Ellington S, Olson CK.Vaccine. 2026 Mar 7;75:128268. doi: 10.1016/j.vaccine.2026.128268. Epub 2026 Feb 2.PMID: 41633278 **Free PMC article.**

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.
Ogbogu U, Albrecht L.Dev World Bioeth. 2026 Mar;26(1):66-78. doi: 10.1111/dewb.70004. Epub 2025 Sep 10.PMID: 40928580

Lipid nanoparticle-encapsulated microRNA-192: An anti-inflammatory adjuvant that enhances **vaccine** efficacy in aged mice.
Takagi Y, Nishimura T, Aktar S, Katayama D, Takashima K, Kawakita T, Sekiya T, Shingai M, Tanaka H, Akita H, Miyashita Y, Nakamura K, Kouwaki T, Oshiumi H.Mol Ther Nucleic Acids. 2025 Nov 26;37(1):102784. doi: 10.1016/j.omtn.2025.102784. eCollection 2026 Mar 12.PMID: 41458877 **Free PMC article.**

Specialist physician perspectives on clinical decision support to address secondary **vaccine** hesitancy.

Nemorin A, Norton DT, Green CV, Jerry MS, Wurcel AG, Blumenthal KG.J Allergy Clin Immunol Glob. 2025 Dec 22;5(2):100636. doi: 10.1016/j.jacig.2025.100636. eCollection 2026 Mar.PMID: 41550090 **Free PMC article.**

Altered Cytokine-Induced STAT3 and STAT5 Activation of Peripheral T Follicular Helper Cells Contributes to **Vaccine**-Non-Responsiveness in Aging and HIV.
Davis S, Kupritz J, Singh P, Pahwa S, Pallikkuth S.Aging Cell. 2026 Mar;25(3):e70438. doi: 10.1111/acel.70438.PMID: 41801310 **Free PMC article.**

Information sources and COVID-19 vaccination in pregnancy: an exploratory survey from health facilities in São Paulo state, Brazil.
Maudonnet B, Tosetto M, Lima B, Silveira C, Cecatti JG, Costa ML, Tedesco RP, Matias JP, Limaye RJ, Schue JL, Miller E, Gottlieb SL, Brizuela V, Belayneh G, Souza RT.Vaccine. 2026 Mar 3:128412. doi: 10.1016/j.vaccine.2026.128412. Online ahead of print.PMID: 41781222 **Free article.**

Effectiveness of 2024/25 KP.2 **Vaccine** Against Outpatient COVID-19 in Canada.
Separovic L, Sabaiduc S, Zhan Y, Kaweski SE, Carazo S, Olsha R, Mather RG, Lacroix C, Hasso M, Levade I, Meunier I, Jassem AN, Dover K, Gao R, Bastien N, Skowronski DM.Influenza Other Respir Viruses. 2026 Mar;20(3):e70222. doi: 10.1111/irv.70222.PMID: 41784466 **Free PMC article.**

Immunoinformatics-based design of a multi-epitope **vaccine** for Marburg virus.
Thangamariappan E, Sivakumar P, Marimuthu SCV, Kunjiappan S, Sundar K.J Biomol Struct Dyn. 2026 Mar;44(4):2159-2176. doi: 10.1080/07391102.2024.2446673. Epub 2024 Dec 29.PMID: 41765043

Characterization of bronchiolitis and **vaccine**-induced enhanced respiratory disease in Syrian hamsters caused by respiratory syncytial virus infection.
Zhao B, Zhang G, Wu J, Zhang W, Ding X, Wei X, Peng W, Rong N, Yang H, Liu J.J Infect Dis. 2026 Mar 4:jiag136. doi: 10.1093/infdis/jiag136. Online ahead of print.PMID: 41776988

What leads to **vaccine** compliance? Evidence from healthcare workers.
Demichelis A, Marini M, Menicagli D, Mancini G, Bilancini E, Panizza F, Bellandi T, Boncinelli L, Pin P, Galletti G, Caldesi R, Cevolani G.J Public Health Res. 2026 Mar 5;15(1):22799036251401950. doi: 10.1177/22799036251401950. eCollection 2026 Jan.PMID: 41798092 **Free PMC article.**

Increases in inflammation are associated with decreased trust of racial out-group members.
Antenucci NM, Feldman MJ, Jolink TA, West TN, Cardenas MN, Alvarez GM, Muscatell KA.Brain Behav Immun. 2026 Mar;133:106242. doi: 10.1016/j.bbi.2025.106242. Epub 2025 Dec 22.PMID: 41443482

Potent and Long-Lasting Immunogenicity Generated by LNP-mRNA gE Antigen Against Varicella Zoster Virus via an AI-Assisted Pipeline.

Dong K, Liu F, Wang D, Li Y, Zhang M, Zhou Y, Song G.Adv Sci (Weinh). 2026 Mar;13(14):e10913. doi: 10.1002/advs.202510913. Epub 2025 Dec 25.PMID: 41449740 **Free PMC article.**

Scientific communication and **vaccine** hesitation: an analysis of the editorial line of a great Brazilian newspaper.
Silva HM.Oxf Open Immunol. 2026 Mar 2;7(1):iqaf012. doi: 10.1093/oxfimm/iqaf012. eCollection 2026.PMID: 41783324 **Free PMC article.**

Economic evaluation of the one-dose HPV vaccination program in Nigeria.
Gao T, Farag M, Agha S, Mobula L, Hou X, Li G, Zeng W.J Cancer Policy. 2026 Mar;47:100675. doi: 10.1016/j.jcpo.2025.100675. Epub 2025 Dec 6.PMID: 41360288

Dehydroevodiamine enhances PEDV **vaccine** efficacy through immune-gut microbiota modulation.
Zhang X, Wang H, Li K, Wang X, Hao Z.Vaccine. 2026 Mar 10;79:128411. doi: 10.1016/j.vaccine.2026.128411. Online ahead of print.PMID: 41812636

From Functional Group and Metabolite Analysis to Rational Design: Discovery of BXY-14 as a Highly Potent TLR2 Agonist with Enhanced **Vaccine** Adjuvants and Cancer Immunotherapy.
Jia H, Ma W, Gong Y, Gui H, Luo Z, Yang L, Li J, Li L, Wang X.J Med Chem. 2026 Mar 12;69(5):6158-6178. doi: 10.1021/acs.jmedchem.5c03709. Epub 2026 Mar 1.PMID: 41764631

Meningococcal carriage and transmission dynamics in college students in Louisville, Kentucky.
Arnold FW, Parrish LW, Marimuthu S, Findlow J, Quinn A, Salunkhe V, Sheikh D, Bressoud P, Ali T, Balcom D, Ali M, Doster RS, Deepti D, Tahboub M, Ndiaye F, Lucidarme J, Clark SA, Borrow R, Balmer P, Gootee S; CERID study group.PLoS One. 2026 Mar 5;21(3):e0344194. doi: 10.1371/journal.pone.0344194. eCollection 2026.PMID: 41785285 **Free PMC article.**

Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate **vaccine** in Chinese children aged 2-5 years: A phase III study.
Shi L, Chen J, Li H, Yan X, Shen F, Lai X, Yuan L, Mo Y.Vaccine. 2026 Mar 7;75:128244. doi: 10.1016/j.vaccine.2026.128244. Epub 2026 Jan 18.PMID: 41554243 **Free article.** Clinical Trial.

TEpiNom: A computational framework integrating population data to prioritize plasmodium falciparum T cell epitopes.
Laurenson AJ, Pierce BG, Takala-Harrison S, Laurens MB.Vaccine. 2026 Mar 2;77:128388. doi: 10.1016/j.vaccine.2026.128388. Online ahead of print.PMID: 41775037 **Free article.**

A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold.
Xue W, Wang H, Zeng Y, Zhang S, Cui L, Liu H, Li H, Hong M, Zhang H, Zhang Y, Li J, Chen Z, Zheng Q, Yu H, Zhu R, Zhou L, Gu Y, Li T, Xia N, Li S.PLoS Pathog. 2026 Mar 2;22(3):e1013983. doi: 10.1371/journal.ppat.1013983. eCollection 2026 Mar.PMID: 41770791 **Free PMC article.**

Structure-guided design of a PfCyRPA-based **vaccine** against blood-stage malaria.
Alam N, Wolfle C, Butkeviciute E, Quinkert D, King LDW, Higgins MK.EMBO Mol Med. 2026 Mar 2. doi: 10.1038/s44321-026-00376-x. Online ahead of print.PMID: 41772083 **Free article.**

Single-dose HPV vaccination in the United States - a multi-modeling analysis.
Burger EA, Laprise JF, Spencer JC, Sy S, Regan MC, Drolet M, Chamberland É, Brisson M, Kim JJ.Lancet Reg Health Am. 2026 Jan 10;55:101361. doi: 10.1016/j.lana.2025.101361. eCollection 2026 Mar.PMID: 41586382 **Free PMC article.**

CRISPR/Cas14a combined with RPA for visual detection of Marek's disease virus.
Zhu Z-J, Cui M-L, Liu Y, Yao X-Q, Lu M-J, Wang M-C, Liu J-H, Li J-F, Li E-Z.Microbiol Spectr. 2026 Mar 3;14(3):e0262525. doi: 10.1128/spectrum.02625-25. Epub 2026 Feb 6.PMID: 41649281 **Free PMC article.**

Does human papillomavirus vaccination status differ by disability status in New York city public schools?
Lyons AJ, Mhatre MM, Argenio K, Day S, Ternier A, McDermott S, Jones HE.Vaccine. 2026 Mar 4;78:128404. doi: 10.1016/j.vaccine.2026.128404. Online ahead of print.PMID: 41785680

Safety, immunogenicity, and effectiveness of the MAV/06 varicella **vaccine**: A comprehensive review of a new strain **vaccine**.
Shin Y, Ryu H, Kim G, Yang S, Lee J, Choi B.Hum Vaccin Immunother. 2026 Dec;22(1):2627097. doi: 10.1080/21645515.2026.2627097. Epub 2026 Mar 10.PMID: 41805639 **Free PMC article.** Review.

Tetanus Toxoid **Vaccine** Uptake and Associated Factors Among Reproductive Age Women in Mogadishu, Somalia: A Cross-Sectional Study.
Abdulle AA, Hassan SA.IJID Reg. 2025 Nov 13;18:100804. doi: 10.1016/j.ijregi.2025.100804. eCollection 2026 Mar.PMID: 41510494 **Free PMC article.**

Uptake of the Birth Dose HBV **Vaccine** and Associated Factors Among Children in Sub-Saharan Africa: An Analysis Using Recent Demographic and Health Survey Data.
Gebrehana AK, Asnake AA, Seifu BL, Fente BM, Melkam M, Bezie MM, Tsega SS, Negussie YM, Asebe HA, Asmare ZA.J Viral Hepat. 2026 Mar;33(3):e70147. doi: 10.1111/jvh.70147.PMID: 41631779

[How is confidence in vaccination against measles sustained?].
Herzig van Wees S, Nejat S, Mohamed F.Lakartidningen. 2026 Mar 6;123:25143.PMID: 41787917 **Free article.** Review. Swedish.

A **Vaccine** to Prevent Congenital Cytomegalovirus: Where Do We Go Next?

Schleiss MR, Plotkin SA, Permar SR.JAMA Pediatr. 2026 Mar 2. doi: 10.1001/jamapediatrics.2025.6432. Online ahead of print.PMID: 41770579

Associations of Serum PFAS with COVID-19 Antibody Levels among Fully Vaccinated Adults.
Bauer RA, Yang Z, Petriello M, Zhang S, Stapleton HM, Adgate JL, Carignan CC.Environ Res. 2026 Mar 3:124154. doi: 10.1016/j.envres.2026.124154. Online ahead of print.PMID: 41786118

Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate **Vaccine** (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged 56 Years: A Phase III, Open-Label Study.
Dbaibo GS, Balik I, Akdemir İ, Buzgan T, Guner R, Boutros CF, Damaj S, Zein ZE, Merhi S, Faour K, Tfaily N, Khafaja S, Dogu A, Ceyhan M.Infect Dis Ther. 2026 Mar;15(3):769-785. doi: 10.1007/s40121-025-01298-w. Epub 2026 Jan 28.PMID: 41604139 **Free PMC article.**

Combination of lytic phage Sal-P001 and RAST002 **vaccine** induces complete protection against homologous and heterologous Salmonella strains.
Zhang J, Zhang Z, Yang D, Ren Q, Cao S, Li Y, Zhou G.Vaccine. 2026 Mar 10;79:128451. doi: 10.1016/j.vaccine.2026.128451. Online ahead of print.PMID: 41812632

Association between vaccination prescription program and herpes zoster **vaccine** knowledge, intention, and coverage among residents aged 50 in Zhejiang Province: Repeated cross-sectional surveys.
Yan X, Zhang X, Xu Y, Xu J.Hum Vaccin Immunother. 2026 Dec 31;22(1):2633884. doi: 10.1080/21645515.2026.2633884. Epub 2026 Mar 10.PMID: 41805536 **Free PMC article.**

Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.
Wang L, Nangle SJ, Waller-Pulido A, McMahan K, Pereira J, Chaudhari J, Barrett LO, Bhowmik R, Farrugia K, Ramsamooj R, Sordillo EM, Simon V, van Bakel H, Mostafa H, Pekosz A, Collier AY, Barouch DH.JAMA. 2026 Mar 9:e262173. doi: 10.1001/jama.2026.2173. Online ahead of print.PMID: 41801760

An on-site cascading **vaccine** breaks tumor immune evasion and elicits systemic immunity.
Huang X, Li L, Zheng S, Wei G, Wang Y, Li X, Gong C, Li W, You Y.J Control Release. 2026 Mar 10;391:114641. doi: 10.1016/j.jconrel.2026.114641. Epub 2026 Jan 16.PMID: 41548668

Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus **Vaccine**: A Phase III Clinical Trial.
Huang T, Wu C, Ying Z, Zhang Z, Li Q, Lu W, Yu G, Hao P, Liu S, Guo H, Tao J, Yang Y, Tao C, Chen W, Zhang J, Li X.Scand J Immunol. 2026 Mar;103(3):e70097. doi: 10.1111/sji.70097.PMID: 41714818 Clinical Trial.

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit **vaccine** (IVX-121) in healthy young and older adults.

De Coster I, Leroux-Roels I, Withanage K, Suykens L, D'Onofrio V, Leroux-Roels G, van Damme P, Ciarlet M, Adams EM, Rida W, Wen J, MacDonald M, Price J, Kanesa-Thasan N.Hum Vaccin Immunother. 2026 Dec;22(1):2633021. doi: 10.1080/21645515.2026.2633021. Epub 2026 Mar 3.PMID: 41776715 **Free PMC article.** Clinical Trial.

[Prevention of herpes zoster infection in patients with chronic diseases: a necessity due to its sociosanitary impact].
Alfaro Greciano R, Menéndez Villanueva R, Ampudia-Blasco FJ, Bustos Guadamillas I, Montoro Montero I, Barrios V.Semergen. 2026 Mar;52(2):102682. doi: 10.1016/j.semerg.2025.102682. Epub 2026 Jan 28.PMID: 41610590 **Free article.** Review. Spanish.

The relationship between trust and compliance in the Italian NHS: Results of the People's Voice Survey.
Tarricone R, Armeni P, Arsenault C, Kruk ME.Health Policy. 2026 Mar;165:105544. doi: 10.1016/j.healthpol.2025.105544. Epub 2025 Dec 11.PMID: 41401572 **Free article.**

Effectiveness of the TYPHIBEV (Vi-CRM197 conjugate) **Vaccine** Introduction in Nepal: A Test-Negative, Case-Control Study.
Tamrakar D, Shahi SB, Jung E, Naga S, Shrestha B, Roka PB, Pokharel RS, Chapagain RH, Tamrakhar A, Mahato M, Madhup SK, Shrestha R, Doyle K, Bogoch II, Luby SP, Garrett DO, Cheirakul W, Andrews JR.J Infect. 2026 Mar 8:106719. doi: 10.1016/j.jinf.2026.106719. Online ahead of print.PMID: 41806875

Immunogenicity of HPV **Vaccine** in a High-Risk and Understudied Group: Female Sex Workers.
Van Nguyen T, Tuan LA, Mai CTN, Ly LTK, Lien THM, Chung NT, Huyen DTT, Uyen NTT, Thanh NTT, Nhung TTH, Quang C, Von Mollendorf C, Murray G, Garland SM, Bright K, Licciardi PV, Mulholland K, Toh ZQ.J Infect Dis. 2026 Mar 1:jiag112. doi: 10.1093/infdis/jiag112. Online ahead of print.PMID: 41764658

Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators.
Ito K, Manabe Y, Ohshima S, Maeki M, Tokeshi M, Inaba H, Matsuura K, Kabayama K, Kametani Y, Fukase K.Angew Chem Int Ed Engl. 2026 Mar 9;65(11):e20474. doi: 10.1002/anie.202520474. Epub 2025 Dec 17.PMID: 41403359 **Free PMC article.**

Lack of association between **vaccine**-induced immune thrombocytopenia and thrombosis and HLA loci in a large cohort.
Schönborn L, Tzvetkova A, Thiele T, Völker U, Ameling S, Franzenburg S, Kaderali L, Greinacher A.Br J Haematol. 2026 Mar 9. doi: 10.1111/bjh.70419. Online ahead of print.PMID: 41797449 No abstract available.

Juvenile-Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus **Vaccine** Uptake: A 19-Year Retrospective Cohort Study.

Corbin AF, Sahlollbey N, Varavenkataraman G, de Santana Hager M, Bacon BR, Carr MM.Otolaryngol Head Neck Surg. 2026 Mar;174(3):852-860. doi: 10.1002/ohn.70141. Epub 2026 Jan 31.PMID: 41618836

Plant-based production of virus-like particles from hepatitis C virus.
López-Castillo LM, Gonzalez-Castro R, Sánchez-Segura L, Aguilar-Barragán BA, Lim MAG.Planta. 2026 Mar 2;263(4):86. doi: 10.1007/s00425-026-04956-6.PMID: 41772112 **Free PMC article.**

VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit **vaccine**.
Adam A, Lee C, Jones MC, Harrington BR, Zou J, Peng BH, Xie X, Wang P, Wang T.Vaccine. 2026 Mar 7;75:128255. doi: 10.1016/j.vaccine.2026.128255. Epub 2026 Jan 22.PMID: 41576707 **Free PMC article.**

Electrochemical and spectrophotometric investigation of DNA interactions with TURKOVAC and Pfizer-BioNTech vaccines: Implications for biosensor sensitivity.
Aslan M, Levent A.Anal Chim Acta. 2026 Mar 1;1389:345060. doi: 10.1016/j.aca.2026.345060. Epub 2026 Jan 10.PMID: 41629043

CXCL20a promotes the immune protection of an inactivated **vaccine** against grass carp reovirus infection in grass carp (Ctenopharyngodon idella).
Lu Y, Wang S, Xu Y, Tang B, Chen G, Su J, Yang C.Fish Shellfish Immunol. 2026 Mar;170:111140. doi: 10.1016/j.fsi.2026.111140. Epub 2026 Jan 19.PMID: 41565090

Adjuvant combination enhances immune response of equine influenza virus **vaccine** in horses.
Dong-Ha L, Eun-Bee L, Jong-Pil S, Eun-Ju K.Equine Vet J. 2026 Mar;58(2):591-600. doi: 10.1111/evj.70090. Epub 2025 Sep 2.PMID: 40898646

Vogt-Koyanagi-Harada syndrome potentially associated with COVID-19 vaccination: a case report and literature review.
Cui Z, Luo Y, Yi Y, Guo X, Liu Y, Wang X, Liu X.Immunol Med. 2026 Mar;49(1):88-101. doi: 10.1080/25785826.2025.2528331. Epub 2025 Jul 9.PMID: 40631953 **Free article.** Review.

N1MΨU-modified mRNA vaccines break the mold in fish by enhancing innate immune activation.
Porter D, Jouneau L, Peruzzi M, Collet B, Verrier B, Boudinot P.Mol Ther Nucleic Acids. 2026 Feb 7;37(1):102862. doi: 10.1016/j.omtn.2026.102862. eCollection 2026 Mar 12.PMID: 41757374 **Free PMC article.**

Measles Outbreak - New Mexico, 2025.
Stanislawski E, Romero A, Holzinger N, Healy R, Webb NJ, Cruz K, Sievers M, Aung S, Swisher S, Stefanos R, Yara-Zelenski J, Kofman AD, Pierce R, Onyeuku C, Pilote KM, Leung J, Smelser C.MMWR Morb Mortal Wkly Rep. 2026 Mar 12;75(9):111-115. doi: 10.15585/mmwr.mm7509a1.PMID: 41818136

A missed opportunity: faith leaders and the HPV vaccination effort in Addis Ababa, Ethiopia.
Berhanu W, Yigremachew S, Hanson C, Avermark H, Addissie A, Herzig van Wees S.Glob Health Action. 2026 Dec;19(1):2635822. doi: 10.1080/16549716.2026.2635822. Epub 2026 Mar 4.PMID: 41778439 **Free PMC article.**

Impact of CRM197-based conjugate vaccines, schedules, and regions on pneumococcal immunogenicity in young children: systematic review.
Chen X, Tavlian S, Carville KS, Tellioglu N, Spirkoska V, Carvalho N, Price DJ, Campbell PT, McVernon J.NPJ Vaccines. 2026 Mar 6. doi: 10.1038/s41541-026-01395-y. Online ahead of print.PMID: 41792146 **Free article.**

Vaccine hesitancy in the school community and among health personnel: a cross-sectional study.
Guzman-Barrera LS, Garcia J, Fantinato FFST, Prosdocimi EC, Santiago-Vieira C, da Silva Lopes Ferreira FC, de Oliveira SR, Veloso GA, Palmieri M, Cunha CLF, da Silva TPR, Matozinhos FP.BMC Public Health. 2026 Mar 3. doi: 10.1186/s12889-026-26409-1. Online ahead of print.PMID: 41772474 **Free article.** No abstract available.

A protein-based self-assembled nanoparticle provides an improved malarial **vaccine**.
Groves MR, Chen S.Trends Parasitol. 2026 Mar;42(3):160-161. doi: 10.1016/j.pt.2026.02.002. Epub 2026 Feb 28.PMID: 41763917

Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis.
Hahm HC, Tang M, Lupaczyk L, Lee J, Lapa Y, Lam J, Nguyen UDT, Cozier YC.Vaccine. 2026 Mar 7;75:128283. doi: 10.1016/j.vaccine.2026.128283. Epub 2026 Jan 28.PMID: 41610461

Potential of Vgamma9Vdelta2T cells in tuberculosis: integration of innate and adaptive immunity for **vaccine** development.
Di D, Gao C, Deng Y, Li Y, Zhang Y.PeerJ. 2026 Mar 4;14:e20904. doi: 10.7717/peerj.20904. eCollection 2026.PMID: 41800127 **Free PMC article.** Review.

Erratum to "A systematic review of the impact of **vaccine** reactogenicity on willingness to accept influenza vaccination in adults" [**Vaccine** 74 (2026) 128195].
Lister H, Farquharson K, Seale H, Smith LE, Poletti T, Amin F, Rubin GJ.Vaccine. 2026 Mar 7;75:128252. doi: 10.1016/j.vaccine.2026.128252. Epub 2026 Jan 21.PMID: 41570442 **Free article.** No abstract available.

In vitro expression and seroreactivity of Toxoplasma gondii GRA1 protein encoded by unmodified and nucleoside-modified mRNA constructs.
Şahinci MN, Döşkaya M, Karakavuk M, Kaplan S, Mutlu G, Perçin TG, Erkunt Alak S, Günay-Esiyok Ö, Gül Mete A, Değirmenci Döşkaya A, Kantarcı AG, Gürüz AY, Can H.Gene. 2026 Mar 10;982:149965. doi: 10.1016/j.gene.2025.149965. Epub 2025 Dec 16.PMID: 41412557

Clinico-virological investigation of measles complications in immunocompromised pediatric patients.
Vaidya SR, Sharma S, Kamble MB, Sreedeep KS, Deepthi B, Kulkarni S, Gade S, Pandey PG, Joshi M, Divatia J, Dhamne CA.Infect Genet Evol. 2026 Mar 5;139:105918. doi: 10.1016/j.meegid.2026.105918. Online ahead of print.PMID: 41794164 **Free article.**

Mapping the continuum of COVID-19 **vaccine** acceptance and hesitancy in Chile: Insights from qualitative research among nationals and migrants.
Cabieses B, Obach A, Madrid P, Blukacz A, Sadler M, Carreño A, Campaña C, Mezones-Holguín E.Vaccine. 2026 Mar 10;79:128433. doi: 10.1016/j.vaccine.2026.128433. Online ahead of print.PMID: 41812635

A Monoclonal Antibody ELISA-Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines.
Odin M, Schmeisser F, Soto J, Weir JP.Influenza Other Respir Viruses. 2026 Mar;20(3):e70206. doi: 10.1111/irv.70206.PMID: 41736687 **Free PMC article.**

Feasibility and Acceptability of Using Private Facebook Groups to Promote COVID-19 Vaccination Among Latino Parents.
Andrade EL, González-Salinas AI, Wysota CN, Favetto C, Gomez K, Broniatowski D, Abroms LC.Health Promot Pract. 2026 Mar 10:15248399261428468. doi: 10.1177/15248399261428468. Online ahead of print.PMID: 41805375

Beyond the Scar: What Can a Persistent BCG **Vaccine** Reaction in Infants Tell Us in an Immunological Point of View?
Keskindemirci G, Aslan E, Yücel E, Törün SH, Cetişli Ş, Aşkan ÖÖ, Kayı AB, Gökçay G.Scand J Immunol. 2026 Mar;103(3):e70099. doi: 10.1111/sji.70099.PMID: 41724721

A multilevel clinic- and community-based intervention to increase COVID-19 vaccination among Latinos in San Diego County: Protocol description of the **vaccine** promotion program.
Crespo NC, Elder J, Oren E, Arredondo E, Lin CJ, Godino J, Madanat H, Cervantes G, Patron A, Fraga K, Vargas-Tequida B, Ramers CB.Contemp Clin Trials. 2026 Mar;162:108227. doi: 10.1016/j.cct.2026.108227. Epub 2026 Jan 19.PMID: 41565103 **Free article.**

A U.S.-linked HSV-2 clinical isolate from China reveals global transmission and informs region-specific **vaccine** design.
Xie J, Lin D, Yang K, Zhang Z, Li J, Qian Y, Ding K, Xu J, Du Y, Shi J.Infect Genet Evol. 2026 Mar;138:105890. doi: 10.1016/j.meegid.2026.105890. Epub 2026 Jan 29.PMID: 41619925 **Free article.**

HTS-based control of Salmonella Enteritidis vaccines for chickens - pilot study.
Pasik K, Iwan E, Bomba A, Blicharz KD.Vaccine. 2026 Mar 7;75:128297. doi: 10.1016/j.vaccine.2026.128297. Epub 2026 Jan 31.PMID: 41621113

Indirect effect of pneumococcal conjugate vaccines on pneumococcal colonization: persistence and dynamics of **vaccine** serotypes in Sicily (Italy) eleven years post-introduction, 2009 to 2020.
Tramuto F, Randazzo G, Santino A, Sferlazza G, Previti A, Graziano G, Costantino C, Mazzucco W, Amodio E, Vitale F, Maida CM.J Infect Dis. 2026 Mar 7:jiag150. doi: 10.1093/infdis/jiag150. Online ahead of print.PMID: 41791422

In situ generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy.
Chen L, Xu Y, Hu X, Pan Y, She P, Chen X, Peng Q, Li Q, Rao L.Natl Sci Rev. 2026 Jan 20;13(5):nwag037. doi: 10.1093/nsr/nwag037. eCollection 2026 Mar.PMID: 41710125 **Free PMC article.**

Pathways to COVID-19 **vaccine** initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
Yigit I, Stoner MCD, Muessig KE, Hightow-Weidman LB, Budhwani H.Vaccine. 2026 Mar 7;75:128253. doi: 10.1016/j.vaccine.2026.128253. Epub 2026 Jan 18.PMID: 41548529

Development and Validation of a Health Belief Model-Based Health Education Toolkit in Measles Vaccination for Parents in Malaysia.
Azlan AM, Ayu Said M, Mohd Salleh NA.Asia Pac J Public Health. 2026 Mar 5:10105395261425341. doi: 10.1177/10105395261425341. Online ahead of print.PMID: 41782562

Coverage and associated factors of inactivated polio **vaccine** uptake among children aged 12-23 months in Sub-Saharan Africa.
Wondie WT, Zemariam AB, Gebreegziahber ZA, Legesse BT, Belete KT, Mekonnen GB, Gedefaw GD, Atinafu WT, Seifu BL, Tazeb W.Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-40258-3. Online ahead of print.PMID: 41807465 **Free article.** No abstract available.

mGem: Fungal adhesins in *Candidozyma auris* confer unique fitness for skin colonization.
Balakumar A, Thangamani S.mBio. 2026 Mar 9:e0380525. doi: 10.1128/mbio.03805-25. Online ahead of print.PMID: 41801002 **Free article.**

High-dose influenza **vaccine** augments serological and cellular immunity of older people with HIV.
Kupritz J, Davis S, Liu T, Singh P, Díaz-Pachón DA, Rodriguez A, Boyd SD, Pahwa R, Pallikkuth S, Pahwa SG.JCI Insight. 2026 Mar 5:e199232. doi: 10.1172/jci.insight.199232. Online ahead of print.PMID: 41785036 **Free article.**

Immunization Coverage and Clinical Documentation of **Vaccine** Refusal in Pediatric Clinics: A Retrospective Analysis in the Midwestern United States, 2022-2024.
Luff A, Rivelli A, Hirschtick J, Ingle M, Crosh C, Romain C, Okafor C, Fitzpatrick V.J Pediatr Clin Pract. 2025 Nov 11;19:200193. doi: 10.1016/j.jpedcp.2025.200193. eCollection 2026 Mar.PMID: 41445538 **Free PMC article.**

Oral rotavirus **vaccine** effectiveness among malnourished children in 19 countries: Findings from the MNSSTER-V project.
Burnett E, Ticklay I, Umana J, Mandomando I, Robinson AL, Omore R, Goldfarb DM, Safi N, Trang NV, Kisakye A, Uwimana J, N'Zue K, Groome MJ, Enweronu-Laryea C, Bonkoungou I, Iniguez V, McCracken J, Lungayo CL, Michael F, Sahakyan G, Rey-Benito G, Weldegebriel G, Mwenda JM, Parashar UD, Tate JE; Multi-national Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V) Project Working Group.J Pediatr Gastroenterol Nutr. 2026 Mar;82(3):790-800. doi: 10.1002/jpn3.70322. Epub 2026 Jan 4.PMID: 41486460 **Free PMC article.**

Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study.
Kalra S, Jenkinson D, Goddard S, Banavathi K, Salim O, Abraham RJ, Jordan KP.Mult Scler Relat Disord. 2026 Mar;107:106947. doi: 10.1016/j.msard.2025.106947. Epub 2025 Dec 24.PMID: 41518821

Increasing HPV **vaccine** promotion by dental providers: A clinical trial protocol.
Rindal DB, Asche S, Kharbanda E, Michalowicz B, Worley D, Jaka M, Kromrey K, Fletcher L, Gillesby A, Basile S, Mabry PL.Contemp Clin Trials. 2026 Mar;162:108222. doi: 10.1016/j.cct.2026.108222. Epub 2026 Jan 13.PMID: 41539537

Immunogenicity and safety of a recombinant spike protein COVID **vaccine** in patients with inflammatory bowel disease and transplant recipient.
Vattoth AL, Hayney MS, Forati AM, Warren B, Kalkeri R, Cai MR, Cai Z, Zhu M, Cloney-Clark S, Plested JS, Parajuli S, Caldera F.Vaccine. 2026 Mar 7;75:128208. doi: 10.1016/j.vaccine.2026.128208. Epub 2026 Jan 16.PMID: 41547111 **Free article.**

Estimates of SARS-CoV-2 **vaccine** effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study.
Okoli GN, Kwan MYW, Chan ELY, Murphy C, Wong JSC, Chua H, Peiris M, Cowling BJ, Lee SL.Vaccine. 2026 Mar 7;75:128262. doi: 10.1016/j.vaccine.2026.128262. Epub 2026 Jan 23.PMID: 41579753

Personalized Cancer **Vaccine** Shows Durable Benefit at 5 Years.
[No authors listed]Cancer Discov. 2026 Mar 2;16(3):OF1. doi: 10.1158/2159-8290.CD-NW2026-0009.PMID: 41632561

Unraveling vaccination behavior under misinformation in homogeneous and heterogeneous populations via integrated dynamical and network models.
Tanwar K, Kumar V, Shrimali MD, Tripathi JP.Comput Biol Med. 2026 Mar;204:111530. doi: 10.1016/j.compbiomed.2026.111530. Epub 2026 Feb 11.PMID: 41678953

Immunological responses to tetanus, diphtheria, pertussis (Tdap) **vaccine** in Brazilian hematopoietic stem cell transplant recipients.
Paternina-De La Ossa R, Oliveira MC, Achcar JA, Zanin-Silva DC, Costa TCM, Darrigo-Junior LG, Bellissimo-Rodrigues F.Vaccine. 2026 Mar 7;75:128250. doi: 10.1016/j.vaccine.2026.128250. Epub 2026 Jan 15.PMID: 41544367 **Free article.**

Development of duck hepatitis A virus type 1 attenuated **vaccine** E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks.
Li J, Kyaw PE, Tan C, Wen K, Zhang J, Tian Y, Feng D, Liu W, Liu S, Song S, Yan L.Vaccine. 2026 Mar 7;75:128258. doi: 10.1016/j.vaccine.2026.128258. Epub 2026 Jan 23.PMID: 41576706

Oncofetal reprogramming in hepatocellular carcinoma: Linking developmental programs to cancer vaccines and immunotherapy.
Hassanel DNBP, Sharma A.Clin Mol Hepatol. 2026 Mar 4. doi: 10.3350/cmh.2025.1410. Online ahead of print.PMID: 41780553 **Free article.**

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.
Hausdorff WP, Cavaleri M, Gruber MF, Nyarko KA, Pollard AJ, Hasso-Agopsowicz M, Joseph J, Aggarwal R, Agyei-Kwame E, Dull PM, Neels P, Bogaerts HH, Gill CJ, Salts N, Tang W, Giersing BK.Vaccine. 2026 Mar 7;75:128257. doi: 10.1016/j.vaccine.2026.128257. Epub 2026 Jan 23.PMID: 41579754

Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances **vaccine** potency quantification by single radial immunodiffusion assay.
Jeong O, Choi W, Ahn H, Lee S, Park YW, Kim H, Nam JH.Vaccine. 2026 Mar 7;75:128235. doi: 10.1016/j.vaccine.2026.128235. Epub 2026 Jan 16.PMID: 41547112

Better and closer glycan-independent anti-V3 antibodies to help HIV-1 **vaccine**.
Blanco J.Nat Immunol. 2026 Mar;27(3):390-392. doi: 10.1038/s41590-025-02409-y.PMID: 41634486 No abstract available.

Preliminary safety evaluation of a diphtheria, tetanus, acellular component pertussis, Sabin inactivated poliovirus and Haemophilus influenzae type b combination **vaccine** (DTacP-sIPV/Hib).
Cai L, Fu Y, Li J, Wang X, Ma Y, Gu Q, Ji Q, Liao G, Ouyang S, Chen H, Yang L, Wang M, Hu W, Liao H, Ji G, Wen J, Gao N, Ping L, Fu Y, Chu H, Kong W, Zheng H, Qin X, Liang J, Zhao T, Yang J.Vaccine. 2026 Mar 7;75:128277. doi: 10.1016/j.vaccine.2026.128277. Epub 2026 Jan 29.PMID: 41616649 **Free article.**

The Squalene Oil-in-Water Nanoemulsion **Vaccine** Carrier AddaVax Potentiates TLR-Induced B-Cell Responses.
Pone EJ, Felgner J, Hernandez-Davies J, Davies DH.Cytometry A. 2026 Mar 9. doi: 10.1002/cyto.a.70018. Online ahead of print.PMID: 41797644

Biosynthesis of a Polysaccharide-based Glycoconjugate **Vaccine** against Neonatal Meningitis-Causing Escherichia coli O45.
Wang Y, Liu H, Wang Y, Wang B, Fang X, Wang H, Liu L, Tan H.ACS Synth Biol. 2026 Mar 4. doi: 10.1021/acssynbio.5c00829. Online ahead of print.PMID: 41779879

Dibenzocyclooctyne Conjugation Enhances Antigen Cross-Presentation and T-Cell Killing for Potent Cancer Vaccines.
Li Z, Wang T, Li W, Yu P, Wu K, Su C, Wang F, Zhou H, Lan F, Zhou Y, Cai K, Xiong M, Huang S, Cheng J, Xiong M, Yang K, Bao Y.J Am Chem Soc. 2026 Mar 4;148(8):8223-8235. doi: 10.1021/jacs.5c17189. Epub 2026 Feb 17.PMID: 41701113

HPV genotype prevalence in low- and high-**vaccine** coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay.
Morel D, Parvu V, Andrews J, Stephenson P, Bull J, Woodward A, Vaughan L.Gynecol Oncol. 2026 Mar 4;207:40-47. doi: 10.1016/j.ygyno.2026.02.016. Online ahead of print.PMID: 41785531

Horse immune response of recombinant Lawsonia intracellularis **vaccine**: Assessing the immunomodulatory impact of probiotic supplementation.
Conrad NL, Mazzoleni I, Abreu MC, Costa AV, Di Giácomo CP, Zorzi VSG, Leite FPL.Res Vet Sci. 2026 Mar 2;204:106132. doi: 10.1016/j.rvsc.2026.106132. Online ahead of print.PMID: 41793861

Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate **vaccine**.
Chellappan G, Seal F, Balasundaram WU, Zhao Y, Chalke G, Guo S, Penumaka GJ, Karengil G, Grewal A, Ghayal R, Gan J, Puri R, Machado DR, Bajracharya A, Ghate P, Datta A, Kapre SV.Vaccine. 2026 Mar 7;75:128242. doi: 10.1016/j.vaccine.2026.128242. Epub 2026 Jan 18.PMID: 41554248 **Free article.**

Protective efficacy of heat-killed Leishmnaia donovani **vaccine** adjuvanted with Toll Like Receptor 7/8 agonist in BALB/c mice.
Thakur S, Kaur S, Kaushik D, Kumar K, Salunke DB, Kaur S.Int J Biol Macromol. 2026 Mar;349:150931. doi: 10.1016/j.ijbiomac.2026.150931. Epub 2026 Feb 13.PMID: 41692212

In-silico design of a therapeutic multi-epitope peptide candidate **vaccine** against rheumatoid arthritis.
Mohammadi Sepahvand A, Azarbani N, Zare F, Negahdaripour M, Dehshahri A.Hum Immunol. 2026 Mar;87(3):111654. doi: 10.1016/j.humimm.2025.111654. Epub 2026 Jan 12.PMID: 41529662

High levels of nonblocking anti-interferon and anticytokine autoantibodies in individuals with mRNA **vaccine**-induced systemic allergic reactions.
Kalaycioglu M, Feng A, Dhingra S, Khalid MB, Nadeau KC, Utz PJ, Frischmeyer-Guerrerio PA.J Allergy Clin Immunol Glob. 2025 Dec 4;5(2):100622. doi: 10.1016/j.jacig.2025.100622. eCollection 2026 Mar.PMID: 41550089 **Free PMC article.**

The Prevalence and Impact of Vaccination Programs: Differences Between Nursing Homes and Assisted Living Communities.
Berner KJ, Mese PO, Bowblis JR, Applebaum R.J Am Med Dir Assoc. 2026 Mar;27(3):106107. doi: 10.1016/j.jamda.2025.106107. Epub 2026 Feb 4.PMID: 41577334

Intranasal MyD88-adjuvanted DNA **vaccine** against P. gingivalis in rat periodontitis.
Wang R, Li X, Chen B, Wang Y, Bai G.BMC Oral Health. 2026 Mar 3. doi: 10.1186/s12903-026-07995-3. Online ahead of print.PMID: 41776487 **Free article.** No abstract available.

Coronary Artery Disease and Axillary Lymphadenopathy Post COVID-19 **Vaccine** Administration: Insights from Tl-201 Myocardial Perfusion Imaging.
Chen TY, Tseng TC, Shen DH, Shiue YL, Yang JH, Chan HP.In Vivo. 2026 Mar-Apr;40(2):1228-1237. doi: 10.21873/invivo.14278.PMID: 41760323 **Free PMC article.**

Exploring the impact of reimbursement ratios on willingness to vaccinate: A mixed-effects modeling approach using panel data.
Xie L, Xing J, Yan M, Li P, Xu J, Fang X, Guo Z, Yuan M, Zhu J.Hum Vaccin Immunother. 2026 Dec 31;22(1):2609339. doi: 10.1080/21645515.2025.2609339. Epub 2026 Mar 3.PMID: 41774860 **Free PMC article.**

Molecular insights into viral agents of acute gastroenteritis detected among under five children in Assam, India.
Rajbongshi G, Sharma A.Diagn Microbiol Infect Dis. 2026 Mar;114(3):117235. doi: 10.1016/j.diagmicrobio.2025.117235. Epub 2025 Dec 17.PMID: 41478230

Adjuvants enhance protective antibodies against seasonal influenza viruses following a single vaccination of Fluzone.
Thomas MH, Carlock MA, Ross TM.Virology. 2026 Mar;616:110787. doi: 10.1016/j.virol.2026.110787. Epub 2026 Jan 6.PMID: 41520499 **Free article.**
250
Cite

Lysinibacillus macroides 38352 isolated from traditional Chinese fermented foods: a dual effect on ochratoxin A detoxification and immune suppression alleviation.
Wang J, Duan H, Zhang W, Li H, Yang Z, Zhang C, Zhang S, Guo J, Ge J, Wang F, Gao M.Microbiol Spectr. 2026 Mar 3;14(3):e0236325. doi: 10.1128/spectrum.02363-25. Epub 2026 Jan 21.PMID: 41562645 **Free PMC article.**

IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients.
Nellore A, Goepfert P, Tan CS, Bajema K, Belden K, Blumberg D, Katz MJ, Kaul D, Sharma T, Anjan S, Ariza-Heredia EJ, Magana F, Minniear T, Loveless J, Kaur D, York E, Falck-Ytter Y, Baden L.Clin Infect Dis. 2026 Mar 2:ciag114. doi: 10.1093/cid/ciag114. Online ahead of print.PMID: 41766454

Host immune dysfunction and Mycoplasma pneumoniae immune evasion: dual drivers of pathogenesis in Mycoplasma pneumoniae pneumonia.
Xiang H, Zheng C, Wang Y, Sun Y, Li C, Cai M, Zhang Y.Inflamm Res. 2026 Mar 3;75(1):45. doi: 10.1007/s00011-026-02198-6.PMID: 41774154 Review. No abstract available.

Computational prediction and molecular simulation-based development of a multi-epitope mRNA **vaccine** targeting capsule polysaccharide proteins of Enterobacter cloacae.
Singh S, Swaminathan P.Comput Biol Chem. 2026 Mar 2;123:108994. doi: 10.1016/j.compbiolchem.2026.108994. Online ahead of print.PMID: 41791271

An oral Eimeria-vectored **vaccine** induces protective immunity against chicken infectious anemia.
Liao Y, Wang L, Shi Y, Liang L, Liang R, Ding J, Song X, Tang X.NPJ Vaccines. 2026 Mar 5. doi: 10.1038/s41541-026-01416-w. Online ahead of print.PMID: 41786736 **Free article.**

Serotype diversity and risk factors for pneumococcal carriage among healthy children in Klang Valley, Malaysia: A pre-vaccination cross-sectional study.
Arushothy R, Tan CN, Nor Amdan NA, Mohd Ali MR, Mohd Tap R, Paliappan PA, Liow YL, Maniam S, Mohamed Sukur S, Hashim R.IJID Reg. 2025 Nov 25;18:100814. doi: 10.1016/j.ijregi.2025.100814. eCollection 2026 Mar.PMID: 41487597 **Free PMC article.**

Evaluation of SARS-CoV-2 antibody levels in Greek healthcare workers with diverse vaccination and infection histories.
Kontopoulou K, Nakas C, Tsekoura M, Tsorbatzoglou M, Papazisis G.Acta Microbiol Immunol Hung. 2026 Jan 14;73(1):110-117. doi: 10.1556/030.2026.02784. Print 2026 Mar 5.PMID: 41533030

Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term **vaccine** efficacy: a pooled logistic regression modeling study.
Dudášová J, Valenta Z, Măgălie A, Nieddu GT, Sachs JR.Vaccine. 2026 Mar 6;78:128326. doi: 10.1016/j.vaccine.2026.128326. Online ahead of print.PMID: 41793964

Synthetic TRAC478 emulsion and saponin based adjuvant systems enhance humoral and cellular immune responses elicited by computationally optimized H1 and H3 hemagglutinin subunit vaccines.
Allen JD, Caetano C, Sands CM, Medina JM, Thomas MH, Lynch A, Ross TM.Vaccine. 2026 Mar 10;79:128421. doi: 10.1016/j.vaccine.2026.128421. Online ahead of print.PMID: 41812633

New, Shorter Small-Sample Intervals for **Vaccine** Efficacy.
Gasparini M, Trani VD, Ratta M.Pharm Stat. 2026 Mar-Apr;25(2):e70077. doi: 10.1002/pst.70077.PMID: 41705638 **Free PMC article.**

Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic.

Shaver N, Colijn C, Heffernan J, Asamoah GD, Piggott T, Cooper C, Bagheri S, Crawley AM, Kagina BM, Bowdish DME, Langlois MA, Little J.EBioMedicine. 2026 Mar 10;126:106204. doi: 10.1016/j.ebiom.2026.106204. Online ahead of print.PMID: 41812294 **Free article.** Review.

Safety of Matrix-M-adjuvanted COVID-19, seasonal influenza, combination influenza-COVID-19, and malaria vaccines: a review of the evidence.
Fix J, Lee S, Nachbar J, Sadadia P, Lövgren Bengtsson K, Stertman L, Palm AE, Walker R, Draghia Akli R, Sellers S.Expert Rev Vaccines. 2026 Mar 12:2638828. doi: 10.1080/14760584.2026.2638828. Online ahead of print.PMID: 41814863 Review.

Development of dectin-1-binding peptides targeting dendritic cells for antigen delivery via ribosome display.
Kawaguchi Y, Sarker MS, Yokoyama M, Nakaya M, Hosokawa T, Kamiya N, Goto M.J Biosci Bioeng. 2026 Mar;141(3):158-164. doi: 10.1016/j.jbiosc.2025.11.005. Epub 2025 Dec 7.PMID: 41354566

Tumor antigen only (TAO) **vaccine** platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials.
Chen HC, Wong ET, Sarangi S, Elinzano H, Kuburich NA, Mani SA, Ali R, Cielo D, Svokos KA, Sampath P, Malik AN, Lee CK, Doberstein CE, Lawler SE, Seyhan A, El-Deiry WS, Chen CC.EClinicalMedicine. 2026 Feb 26;93:103774. doi: 10.1016/j.eclinm.2026.103774. eCollection 2026 Mar.PMID: 41783089 **Free PMC article.** Review.

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an $N332_{gp120}$ glycan-independent epitope.
Gieselmann L, DeLaitsch AT, Rohde M, Radford C, Worczinski J, Ashurov A, Ahmadov E, Burger JA, Havenar-Daughton C, Deshpande S, Giovannoni F, Corti D, Kreer C, Ercanoglu MS, Schommers P, Georgiev IS, West AP Jr, Knüfer J, Stumpf R, Kroidl A, Geldmacher C, Maganga L, William W, Ntinginya NE, Hoelscher M, Yang Z, Wei Q, Renfrow MB, Green TJ, Novak J, van Gils MJ, Gristick HB, Gruell H, Bloom JD, Seaman MS, Bjorkman PJ, Klein F.Nat Immunol. 2026 Mar;27(3):572-585. doi: 10.1038/s41590-025-02385-3. Epub 2026 Feb 3.PMID: 41634487 **Free PMC article.**

Peripheral rotavirus-specific T-cell responses following monovalent oral rotavirus **vaccine** in infants.
Nicols AR, Lee Y, Congrave-Wilson Z, Kim M, Cheng WA, Jumarang J, Navarro J, Navarro R, Rodriguez-Angeles Y, Durand D, Taylor ZW, De León RG, Ochoa TJ, Sette A, da Silva Antunes R, Pannaraj PS.NPJ Vaccines. 2026 Mar 5. doi: 10.1038/s41541-026-01405-z. Online ahead of print.PMID: 41786777 **Free article.**

Hybrid microneedle patch for administration of measles and rubella **vaccine** with an on-patient medical record.
Sadeqi A, Lee JW, Gomaa Y, Nguyen TC, Azizoglu E, Hasin T, Ryu YJ, Dixon JB, Kanelli M, Han J, Langer R, Jaklenec A, Prausnitz MR.J Control Release. 2026 Mar 10;391:114635. doi: 10.1016/j.jconrel.2026.114635. Epub 2026 Jan 14.PMID: 41544667 **Free article.**

Short- and Long-term Humoral Response of Immunosuppressed Children to SARS-CoV-2 BNT162b2 **Vaccine**.
Tagarro A, Gastesi I, Hotterbeekx A, Aguilera-Alonso D, Konnova A, Gupta A, Salso S, Berkell M, Plata MDC, Domínguez-Rodríguez S, Ballesteros Á, Manzanares Á, Oltra M, Villanueva S, Pinto C, Guillén R, Giaquinto C, Moraleda C, Kumar-Singh S.Pediatr Infect Dis J. 2026 Mar 1;45(3):258-263. doi: 10.1097/INF.0000000000005042. Epub 2025 Dec 5.PMID: 41345863

[Response to hepatitis b vaccination in at-risk group patients].
García Martín V, Jiménez González de Buitrago E, Arana Aragón B, Moratilla Monzó L, Fernández Jiménez I.Rev Esp Salud Publica. 2026 Mar 3;100:e202603013.PMID: 41773892 **Free article.** Spanish.

Pulmonary delivery of glycine-induced outer membrane vesicles as in situ vaccines for metastatic lung cancer.
Xu W, Wei L, Zhao X, Zhao Y, Zhang T, Zhang J, Sun S, Ma YJ, Wu L, Yang M, Cun D.J Control Release. 2026 Mar 10;391:114578. doi: 10.1016/j.jconrel.2025.114578. Epub 2025 Dec 25.PMID: 41455501 **Free article.**

Strategies for enhancing **vaccine** uptake among children under two years of age in low and middle-income countries (LMICs): A scoping review.
Hakim M, Afaq S, Khan BA, Imtiaz S, Ali F, Ul Haq Z.Int J Infect Dis. 2026 Mar;164:108376. doi: 10.1016/j.ijid.2026.108376. Epub 2026 Jan 13.PMID: 41539411 **Free article.** Review.

Parental Attitudes on Childhood Vaccinations: A Qualitative Study on Hesitancy and Motivations.
Tüzün Z, Altaş ZM, Hıdıroğlu S, Çörekci FB, Avcı A, Kaya ZA, Çavuş G.J Eval Clin Pract. 2026 Mar;32(2):e70390. doi: 10.1111/jep.70390.PMID: 41764768

Leveraging community insights and navigating logistical challenges: a case study of the 2024 polio vaccination campaign in Gaza, State of Palestine.
Dwyer H, Hasan MR, Abeshu M, Tsega A, Farrukh S, Kadandale S, Lainez J, Galvin M, Gough J, Higgins E, Wishah I, Onitolo E, Seyam N, Ibrahim AR, Young H, Said S, Achari AP, Goundara AM, Girma T, Lauwerier S, Beckmann N, Palmer J, Enria L, McIntosh R.BMJ Glob Health. 2026 Mar 2;11(3):e022927. doi: 10.1136/bmjgh-2025-022927.PMID: 41771665 **Free article.**

Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan.
Barber C, Barber M, Lee JSW, Ting J, MacDonald SE.Vaccine. 2026 Mar 7;75:128261. doi: 10.1016/j.vaccine.2026.128261. Epub 2026 Jan 25.PMID: 41587510 **Free article.**

Trends in Streptococcus pneumoniae serotypes and antimicrobial resistance in Italy (2007-2023): A mixed-effects model analysis of invasive pneumococcal disease.

Amoruso I, Fonzo M, Agostini S, Russo F, Baldo V, Baldovin T, Bertoncello C.J Infect Public Health. 2026 Mar;19(3):103145. doi: 10.1016/j.jiph.2026.103145. Epub 2026 Jan 9.PMID: 41534477 **Free article.**

New-Onset Vitiligo and Change in Disease Status Following COVID-19 Vaccination and COVID-19 Infection-An Online Survey.
Islam R, Frew J, Kok C, Gupta M.Australas J Dermatol. 2026 Mar;67(2):109-113. doi: 10.1111/ajd.70027. Epub 2025 Dec 22.PMID: 41431160

Validating Georgia's **Vaccine** Registry for the COVID-19 2023-2024 Season: True GRITS.
Roebling AD, Barrera-Nitz NE, Tobin-D'Angelo M, Openo KP, Witt LS.Am J Public Health. 2026 Mar;116(3):368-371. doi: 10.2105/AJPH.2025.308325.PMID: 41671540

Adult respiratory vaccination in the Indian armed forces: Uptake, awareness, and opportunities for policy reform.
Chopra M, Shajahan S, Jagtap K, Tyagi R, Kishore K, Yadav A, Tripathi S.Lung India. 2026 Mar 1;43(2):158-162. doi: 10.4103/lungindia.lungindia_418_25. Epub 2026 Feb 21.PMID: 41721666 **Free article.**

Serological and molecular investigation of suspected chickenpox cases from India, 2016-2025.
Vaidya SR, Kamble SS, Kamble MB, George RP, Pandey PG, Walimbe AM.J Infect Public Health. 2026 Mar;19(3):103147. doi: 10.1016/j.jiph.2026.103147. Epub 2026 Jan 12.PMID: 41534476 **Free article.**

mRNA vaccination overcomes haemozoin-mediated impairment of whole-parasite malaria vaccines in mice.
Hassert M, Drewry LL, Pewe LL, Hancox LS, He R, Arumugam S, Mix MR, Salem AK, Harty JT.Nat Microbiol. 2026 Mar;11(3):718-730. doi: 10.1038/s41564-026-02263-0. Epub 2026 Feb 2.PMID: 41629565 **Free PMC article.**

A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes.
Jones M, Reilly M, Simanek A, Stewart A, Seshadri R, Dowd JB, Ritter AZ.PLoS One. 2026 Mar 12;21(3):e0344258. doi: 10.1371/journal.pone.0344258. eCollection 2026.PMID: 41818244 Clinical Trial.

Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant.
Ye C, Huang X, Hong W, Shi J, Ao D, Zhang Y, Lu Y, Zhou Y, Song Z, Zhang Y, Liu Y, Cheng P, Lu G, Li J, Song X, Wei X.Mol Biomed. 2026 Mar 12;7(1):29. doi: 10.1186/s43556-026-00410-x.PMID: 41817653

Need for Real-World Evaluation of Malaria Vaccines and Reliable Vaccination Records in Africa.

Ko YK, Alfvén T, Okomo GO, Kagaya W, Shioda K, Kaneko A, Gitaka J.Am J Trop Med Hyg. 2025 Dec 30;114(3):407-409. doi: 10.4269/ajtmh.25-0501. Print 2026 Mar 4.PMID: 41666438 **Free PMC article.**

Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant.
Hong H, Eom TH, Lee E, Lee E, Lee HY, Won S, Lee DS, Kim MI, Park H, Yeo SJ.Vaccine. 2026 Mar 7;75:128279. doi: 10.1016/j.vaccine.2026.128279. Epub 2026 Jan 29.PMID: 41616650 **Free article.**

Engineered Streptococcus suis Bacterial Ghosts via Lytic Plasmid and Cell-Penetrating Peptides for Enhanced Protective Immunity.
Liu J, Pan X, Pu W, Li P, Li C, Zhang Z, Yao H, Zhu Y, Ma J.Adv Healthc Mater. 2026 Mar;15(9):e03790. doi: 10.1002/adhm.202503790. Epub 2025 Dec 1.PMID: 41327849

Knowledge, attitude, and associated factors toward human papillomavirus vaccination among female secondary school students in Nifas Silk Lafto Sub-City, Addis Ababa, Ethiopia: Multicenter cross-sectional study.
Shumet Y, Wogie G, Melsew A, Bedore B, Zerihun E.SAGE Open Med. 2026 Mar 9;14:20503121251409642. doi: 10.1177/20503121251409642. eCollection 2026.PMID: 41815358 **Free PMC article.**

National Institutes of Health Funding for RNA **Vaccine** Research.
Chandrabhatla AS, Narahari AK, Jin K, Mazurek B, Bell TD.JAMA Netw Open. 2026 Mar 2;9(3):e260046. doi: 10.1001/jamanetworkopen.2026.0046.PMID: 41770567 **Free PMC article.**

Leveraging Mycobacterium tuberculosis Rv1507A Protein for Improved Immunogenicity in Mycobacterium bovis BCG **Vaccine**.
Naqvi N, Alam A, Shariq M, Ahuja Y, Mitra DK, Hasnain SE, Ehtesham NZ.Immunology. 2026 Mar;177(3):526-539. doi: 10.1111/imm.70063. Epub 2025 Nov 8.PMID: 41205149

Resolving the mRNA Encapsulation-Release Trade-off via Compensatory Forces in Engineered Ionizable Lipids.
Gao W, An K, Ma Y, Xu X, Wang Z, Liu J, Shan X, Liu Y, Chen W, Wang P, Zhou C, Ren Y, Huang X, Xia Y.Adv Mater. 2026 Mar;38(14):e12235. doi: 10.1002/adma.202512235. Epub 2025 Nov 16.PMID: 41243603

Vaccinia virus-based SARS-CoV-2 **vaccine** prevents lung immunopathology without antibody-dependent enhancement in female rhesus macaques.
Nguyen CT, Nakayama M, Yasui F, Ishigaki H, Otaki K, Yamamoto N, Sanada T, Yamaji K, Honda T, Matsumoto Y, Kitagawa N, Ishii K, Kusayanagi T, Yagi Y, Kohara M, Itoh Y.Virology. 2026 Mar;616:110778. doi: 10.1016/j.virol.2025.110778. Epub 2025 Dec 18.PMID: 41429087

[Breakthrough measles - risk factors and clinical manifestations; low transmission rate and less complications than in primary measles].
Dotevall L, Sundell N, Bergström T, Studahl M.Lakartidningen. 2026 Mar 6;123:25142.PMID: 41787923 **Free article.** Review. Swedish.

Engineered bacteriophage nanoassemblies in vivo stabilize DC-T cell immune synapse for high-performance influenza vaccination.
Xia Y, Xu Z, Song R, Wang W, Li Y, Xu L, Huan C, Cao P, Chen G.Biomaterials. 2026 Mar 4;331:124113. doi: 10.1016/j.biomaterials.2026.124113. Online ahead of print.PMID: 41795404

Protective efficacy of the optimized GluB-MTAP fusion subunit **vaccine** against Nocardia seriolae infection in largemouth bass (Micropterus salmoides).
Pan K, Peng X, Li Y, Bai T, Zhang Z, Qi X, Liu T, Wang G, Ling F.Fish Shellfish Immunol. 2026 Mar;170:111117. doi: 10.1016/j.fsi.2026.111117. Epub 2026 Jan 9.PMID: 41520909

mRNA vaccines for hepatocellular carcinoma: mechanisms, therapeutic strategies, and clinical perspectives.
Teng Z, Cui X, He C.Hepatol Int. 2026 Mar 9. doi: 10.1007/s12072-026-11071-x. Online ahead of print.PMID: 41803605 Review.

Advancing the use of **vaccine** impact modeling for immunization decisions in low- and middle-income countries.
Sim SY, Silal S, Hutubessy RC, Bar-Zeev N, O'Brien KL, Lambach P.Vaccine. 2026 Mar 7;75:128239. doi: 10.1016/j.vaccine.2026.128239. Epub 2026 Jan 18.PMID: 41554247 No abstract available.

Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022.
Ordóñez-Mena JM, Gu X, Joy M, Fan X, Meza-Torres B, Hinton W, Wimalaratna R, Jamie G, Forbes A, Kar D, Byford R, Anand S, Ferreira F, Mather L, Lee A, Hobbs FDR, Layton D, de Lusignan S.Int J Infect Dis. 2026 Mar;164:108289. doi: 10.1016/j.ijid.2025.108289. Epub 2025 Dec 9.PMID: 41380832 **Free article.**

IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273.
Kaplonek P, Bertera H, Lee DW, Cizmeci D, Yu WH, Wu K, Chalkias S, Wahid R, Edwards D, Alter G, Henry C.Infect Dis Ther. 2026 Mar;15(3):859-874. doi: 10.1007/s40121-026-01303-w. Epub 2026 Feb 1.PMID: 41622397 **Free PMC article.**

Cost Effectiveness of the Adjuvanted Recombinant Zoster **Vaccine** in Older Adults in Portugal.
Zarkadoulas E, Silva F, Alves J, Madeira F, Postma MJ.Pharmacoecon Open. 2026 Mar 2. doi: 10.1007/s41669-026-00640-3. Online ahead of print.PMID: 41772293 **Free article.**

Isolation, Identification, and Analysis of the Genetic Characteristics of Human Rotavirus of G3P10 Genotype.
Chen R, Yin X, Hu X, Kuang X, Wu J, Ye J, Lin X, Yi S, Yin N, Zhang G, Zhou Y, Li H.J Med Virol. 2026 Mar;98(3):e70873. doi: 10.1002/jmv.70873.PMID: 41816919

Machine learning-driven identification of serotype-independent pneumococcal **vaccine** candidates using samples from human infection challenge studies.
Cheliotis KS, Gonzalez-Dias P, German EL, Gonçalves ANA, Mitsi E, Nikolaou E, Pojar S, Miyaji EN, Tostes R, Reiné J, Collins AM, Nakaya HI, Gordon SB, Lu YJ, Pennington SH, Pollard AJ, Malley R, Jochems SP, Urban B, Solórzano C, Ferreira DM.Vaccine. 2026 Mar 7;75:128280. doi: 10.1016/j.vaccine.2026.128280. Epub 2026 Jan 31.PMID: 41621114 **Free article.**

Assessing the Impact of Decentralization on COVID-19 Containment Measures, Public Trust in Government, and Trust in the **Vaccine**: A Multi-Country Study.
Durmuş V.J Public Health Manag Pract. 2026 Mar-Apr 01;32(2):218-226. doi: 10.1097/PHH.0000000000002302. Epub 2025 Nov 24.PMID: 41286592

Effectiveness of 10-valent pneumococcal conjugate **vaccine** against radiologically confirmed pneumonia and invasive pneumococcal disease among young children in Mozambique.
Sigaúque B, Vilanculos L, Chaúque A, Moiane B, Mucavele H, Massora S, Acácio S, Sacoor C, Quintó L, Matsinhe B, Pimenta F, Whitney CG, Lessa FC, da Glória Carvalho M, Verani JR.Vaccine. 2026 Mar 7;75:128237. doi: 10.1016/j.vaccine.2026.128237. Epub 2026 Jan 19.PMID: 41558205 **Free article.**

SVA virus-like vesicle **vaccine** based on VEEV-VSVG vector elicits efficient immune responses and protection in swine.
Rong Z, Jiao M, Cao N, Lu M, Liu S, Zhang C, Wei L, Li Y, Chen H, Li X, Qian P.Vet Microbiol. 2026 Mar;314:110862. doi: 10.1016/j.vetmic.2025.110862. Epub 2026 Jan 14.PMID: 41544331

Participation Beyond Compliance: Who Tried to Influence Other People's Vaccination Behaviour During the COVID-19 Crisis?
Touzet H, Giry B, Ward JK.Sociol Health Illn. 2026 Mar;48(3):e70170. doi: 10.1111/1467-9566.70170.PMID: 41795812 **Free PMC article.**

Real-world effectiveness of sequential pneumococcal vaccination in older adults: a cohort study.
Tan YY, Ho RWL, Lim JT, Chiew CJ, Lim SK, Lye DCB, Tan KB, Wee LE.J Infect Dis. 2026 Mar 6:jiag147. doi: 10.1093/infdis/jiag147. Online ahead of print.PMID: 41790729

Mosquito-borne viruses, **vaccine**-borne hope.
May M.Nat Med. 2026 Mar 9. doi: 10.1038/d41591-026-00014-6. Online ahead of print.PMID: 41803489 No abstract available.

Reconstructing the incidence rate and immune fraction of the population via a single snapshot survey: A case study of COVID-19 in Japan.
Okada Y, Nishiura H.PLoS Comput Biol. 2026 Mar 6;22(3):e1013990. doi: 10.1371/journal.pcbi.1013990. Online ahead of print.PMID: 41790774 **Free article.**

Co-administration of recombinant zoster **vaccine** with other recommended vaccines among older adults in the United States of America.
Gatwood J, Zhu Y, Steffens A, Gallagher S, Le L, Lamers A, Stempniewicz N.Prev Med. 2026 Mar;204:108521. doi: 10.1016/j.ypmed.2026.108521. Epub 2026 Jan 26.PMID: 41605320 **Free article.**

Pathogenicity of Aeromonas hydrophila Isolated From Diseased Largemouth Bass (Micropterus salmoides) and Development of an Inactivated **Vaccine**.
He G, Tang X, Zhou Q, Wu Z, Li Y.J Fish Dis. 2026 Mar;49(3):e70051. doi: 10.1111/jfd.70051. Epub 2025 Sep 3.PMID: 40899581

Real-world effectiveness of oral cholera **vaccine** amid fragility: A case-control study from Eastern Sudan, 2024.
Izzoddeen A, Abolgassim A, Yousif W, Elhussein EA, ElBushra E, Eltayeb D, Elhassan MMO, El-Bushra H.IJID Reg. 2026 Jan 10;18:100842. doi: 10.1016/j.ijregi.2026.100842. eCollection 2026 Mar.PMID: 41704803 **Free PMC article.**

Influenza vaccination willingness and influencing factors among older adults in Chongqing China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework.
Yang J, Yang S, Xiong Y, Li B, Fu X, Jia M, Qi L.Expert Rev Vaccines. 2026 Dec;25(1):2638826. doi: 10.1080/14760584.2026.2638826. Epub 2026 Mar 2.PMID: 41764422 **Free article.**

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF **vaccine** against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
Anywaine Z, Serwanga J, Ggayi AM, Abaasa AM, Wright D, Gombe B, Ejou P, Namata T, Kigozi A, Tukamwesiga N, Basajja V, Ankunda V, Mulondo DJ, Nambaziira F, Kakande A, Kakeeto W, Nabaggala P, Jenkin D, Lawrie A, Folegatti P, Tran N, Hansen C, Elliott AM, Hill AVS, Warimwe GM, Kaleebu P.Lancet Infect Dis. 2026 Mar;26(3):302-313. doi: 10.1016/S1473-3099(25)00565-1. Epub 2025 Nov 11.PMID: 41237791 **Free article.** Clinical Trial.

[Knowledge and attitudes toward the HPV **vaccine** among parents at a vulnerable educational institution in Peru].
Aliaga Pichardo SA, Acosta-Román M, Garcia Curo G.Aten Primaria. 2026 Mar;58(3):103390. doi: 10.1016/j.aprim.2025.103390. Epub 2026 Jan 27.PMID: 41605097 **Free PMC article.** Spanish. No abstract available.

Past behavior predicts future protection: uncovering key drivers of influenza **vaccine** acceptance in Italy in the post-pandemic era.
Amodio E, Aiello R, Battisti M, Casuccio A, Costantino C, Khugputh P, Coco GL, Maggio G, Moscelli G, Palermo M, Salerno L, Tinervia G, Vella G, Vitale F.Int J Infect Dis. 2026 Mar;164:108379. doi: 10.1016/j.ijid.2026.108379. Epub 2026 Jan 8.PMID: 41519374 **Free article.**

13-valent pneumococcal conjugate **vaccine**-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.
Tembo G, Hoving D, de Kroon AC, Chimgoneko L, Nthandira T, Galafa B, Thole F, Nsomba E, Dula D, Ngoliwa C, Toto N, Makhaza L, Muyaya A, Kudowa E, Chirwa AE, Henrion MYR, Chikaonda T, Urban BC, Ferreira DM, Jambo KC, Jochems SP, Gordon SB.Vaccine. 2026 Mar 7;75:128269. doi: 10.1016/j.vaccine.2026.128269. Epub 2026 Jan 22.PMID: 41576701 **Free article.** Clinical Trial.

Enhancing vibriosis vaccination in fish: genetically modified Nannochloropsis sp. as an oral **vaccine** carrier.
Abidin AAZ, Noorhisham NIH, Md Yusoff F, Omar AR, Yusoff K, Ismail S, Khayat ME, Abd Karim MM, Md Yasin IS, Chong CM, Yusof ZNB.World J Microbiol Biotechnol. 2026 Mar 3;42(3):114. doi: 10.1007/s11274-026-04843-y.PMID: 41774280

Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice.
Slein MD, Jiménez LM, Backes IM, Turnbaugh EM, Garland CR, MacDonald SW, Balazs AB, Leib DA, Ackerman ME.J Virol. 2026 Mar 9:e0005026. doi: 10.1128/jvi.00050-26. Online ahead of print.PMID: 41800909

Stability and bifurcation of Mpox transmission model with population heterogeneity and booster vaccination.
Lei X, Meng XY, Wang JG.Math Biosci. 2026 Mar 4;396:109659. doi: 10.1016/j.mbs.2026.109659. Online ahead of print.PMID: 41791591

Post-licensing evaluation of Porvac subunit **vaccine** against classical swine fever in two pig genetic development farms in Cuba.
Sordo-Puga Y, Sardina-González T, Méndez-Orta MK, Hernández-García M, Vargas-Hernández M, Santana-Rodríguez E, Olivera-Caro A, González-Suárez F, Zulueta-Miranda J, Estrada MP, Hochman O, Benaragama I, Brawerman G, Ambagala A, Pérez-Pérez D, Duarte CA, Rodríguez-Moltó MP, Suárez-Pedroso M.Vaccine. 2026 Mar 7;78:128386. doi: 10.1016/j.vaccine.2026.128386. Online ahead of print.PMID: 41797173

Production and characterization of norovirus virus-like particles **vaccine** candidates in a genetically modified Ogataea minuta system.
Tsuda M, Nakatani Y, Baba S, Yoshida K, Someya K, Onodera Y, Nonaka K, Chiba Y.J Biosci Bioeng. 2026 Mar;141(3):165-171. doi: 10.1016/j.jbiosc.2025.11.008. Epub 2025 Dec 20.PMID: 41423396

Multigenic single-chain mRNA **vaccine** provides full protection against Dabie bandavirus infection.
Costa da Silva GH, Carvalho Costa PA, Pires Goulart Guimarães P.Mol Ther Nucleic Acids. 2026 Feb 4;37(1):102841. doi: 10.1016/j.omtn.2026.102841. eCollection 2026 Mar 12.PMID: 41696512 **Free PMC article.** No abstract available.

Probiotic-Driven Therapeutic **Vaccine** for in Vivo Reprogramming of Tumor Cells To Elicit Postoperative Antitumor Immunity.
Gu Y, Xu P, Wu Y, Tan M, Xu Y, Zhang LW, Wang Y, Wang Y.ACS Nano. 2026 Mar 3;20(8):6783-6797. doi: 10.1021/acsnano.5c16193. Epub 2026 Feb 16.PMID: 41693546

Design and assessment of dimeric trehalose glycolipids as a strategy to enhance Mincle-mediated **vaccine** adjuvanticity.
Dangerfield EM, Manthrirathna MATP, Robinson JC, Luong BS, Palmer OR, Connor LM, Timmer MSM, Stocker BL.Org Biomol Chem. 2026 Mar 4;24(9):1822-1836. doi: 10.1039/d5ob01835h.PMID: 41685415

Tuning the in vivo transfection efficiency of mRNA-Loaded lipoplexes by PEG-Lipid structure and ratio.
Markov OV, Antropov DN, Shmendel EV, Puchkov PA, Yakovlev OA, Kerbitskaya MD, Zhuravlev ES, Dome AS, Goncharova EP, Shcherbakov DN, Zenkova MA, Maslov MA, Stepanov GA.Eur J Pharm Biopharm. 2026 Mar;220:114981. doi: 10.1016/j.ejpb.2026.114981. Epub 2026 Jan 3.PMID: 41490599

Is a Planned Newborn Hepatitis B **Vaccine** Trial in Guinea-Bissau Unethical?
Schuklenk U.Dev World Bioeth. 2026 Mar;26(1):3-4. doi: 10.1111/dewb.70025. Epub 2026 Feb 1.PMID: 41622720 No abstract available.

A supranational volunteer registry as a model for sustained **vaccine** research continuity and inclusive pandemic preparedness in Europe.
Pana ZD, Wipfler P, Salmanton-García J, Bethe U, Albus K, Cornely OA.Clin Microbiol Infect. 2026 Mar;32(3):496-497. doi: 10.1016/j.cmi.2025.11.021. Epub 2025 Nov 25.PMID: 41308742 No abstract available.

Inhalable Respiratory Driven Penetration of Porous Microsphere-Based Mucosal **Vaccine** for Long-Term Immune Protection.
Xiao Z, Wu Z, Li Q, Zhu J, Liu B, Miao Y, Yang Y, Zhu J, Chen L, Bai B, Pan F, Yang Y, Chen Q.Adv Mater. 2026 Mar 5:e72696. doi: 10.1002/adma.72696. Online ahead of print.PMID: 41784347

Nudges to Clinicians and Patients for Influenza Vaccines During Visits: The BE IMMUNE Randomized Clinical Trial.
Mehta SJ, Waddell KJ, Linn KA, Brophy C, Liang J, Park SH, Reitz C, Williams K, Couzens C, Staloff J, White AA, Rhodes C, Liao JM, Navathe AS.JAMA Intern Med. 2026 Mar 1;186(3):304-310. doi: 10.1001/jamainternmed.2025.7133.PMID: 41490010 **Free PMC article.** Clinical Trial.

Effectiveness of monovalent vaccines in preventing death and severe disease among Omicron-infected and hospitalized patients in China.
Liu MJ, Zhang W, Shan CX, Tian Y, Xu Q, Mu M, Bao PT, Yang Y, Fang LQ.J Infect Public Health. 2026 Mar;19(3):103109. doi: 10.1016/j.jiph.2025.103109. Epub 2025 Dec 11.PMID: 41435561 **Free article.**

Enhanced passive safety surveillance during the first use of the meningococcal **vaccine** A/C/W/Y/X conjugate for outbreak response in Niger and Nigeria.
Menang O, Gambo M, Keoulon KC, Babale SM, Elemuwa U, Who MD, Hamzat O, Agbenu E, Baruch J, Pezzoli L, Camara I, Dadjo CH, Bwaka A, Fouda AAB.Vaccine. 2026 Mar 5;79:128390. doi: 10.1016/j.vaccine.2026.128390. Online ahead of print.PMID: 41791242

SlpA-driven enhancement of immunogenicity and protection against Trypanosoma cruzi using a non-recombinant Lactobacillus acidophilus platform.
Zabala BA, Vázquez ME, Corbalán NS, Ramos F, Uncos A, Brandán CP, Acuña L.Int J Biol Macromol. 2026 Mar 5;353:151284. doi: 10.1016/j.ijbiomac.2026.151284. Online ahead of print.PMID: 41794233

Development and evaluation of a live-attenuated novel duck reovirus **vaccine** strain E232-P100 conferring complete protection in ducklings.
Fang S, Xu C, Zhang J, Yin H, Liu W, Xu B, Li J, Kyaw PE, Liu S, Song S, Yan L.Vet Microbiol. 2026 Mar;314:110929. doi: 10.1016/j.vetmic.2026.110929. Epub 2026 Feb 3.PMID: 41653781

Two-year prognosis of mRNA **vaccine**-related myocarditis compared with historical conventional myocarditis: a population-based cohort study.
Song S, Hui DSC, Wong SYS, Lau CS, Hung IFN, Lai FTT.Clin Microbiol Infect. 2026 Mar;32(3):504-506. doi: 10.1016/j.cmi.2025.11.031. Epub 2025 Dec 2.PMID: 41344573 No abstract available.

SARS-CoV-2 T-cell **vaccine** VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
Tøndel C, Jenum S, Tonby K, Christensen EE, Cox RJ, Onyango TB, Skeie LG, Robins H, Klinger M, Banbury B, Bello T, Osborne EJ, Jørgensen MJ, Pourpe S, Leikfoss IS, Jürgens T, Wold H, Torhaug S, Makvandi-Nejad S, Edo-Matas D, Schjetne K, Fredriksen AB, Norheim G, Dyrhol-Riise AM.Vaccine. 2026 Mar 7;75:128290. doi: 10.1016/j.vaccine.2026.128290. Epub 2026 Feb 1.PMID: 41628524 **Free article.** Clinical Trial.

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection.
Anderson AM, Tjärnhage E, Hinke DM, Braathen R, Grodeland G, Bogen B.Mol Ther Nucleic Acids. 2025 Dec 26;37(1):102814. doi: 10.1016/j.omtn.2025.102814. eCollection 2026 Mar 12.PMID: 41568167 **Free PMC article.**

Physical activity patterns and vaccination attitudes among thermal spa attendees: a cross-sectional study.
Noviello C, Riformato G, Latorre MD, Lattanzio S, Porcelli D, Resta E, Tafuri S.BMC Public Health. 2026 Mar 4. doi: 10.1186/s12889-026-26906-3. Online ahead of print.PMID: 41781955 **Free article.** No abstract available.

Eliminating the Hepatitis B **Vaccine** Birth Dose-A New Threat to Pediatric Transfusion Safety.
Adkins BD, Booth GS, Jacobs JW.JAMA Pediatr. 2026 Mar 9. doi: 10.1001/jamapediatrics.2026.0052. Online ahead of print.PMID: 41801193

Association between ambient temperature and childhood vaccination coverage in low- and middle-income countries.
Zheng H, Zhu Y, Chu H, Xu Z, Jit M, Ding Z, Zhou X, Bachwenkizi J, Chen R, Hou Z.BMC Med. 2026 Mar 11. doi: 10.1186/s12916-026-04743-w. Online ahead of print.PMID: 41814320

Recombinant phage-display monoclonal antibody against starry flounder (Platichthys stellatus) IgM enables quantitative ELISA for **vaccine**-induced humoral responses.
Sohn MY, Hikima JI, Kang G, Kim KH, Son HJ, Park CI.Fish Shellfish Immunol. 2026 Mar;170:111127. doi: 10.1016/j.fsi.2026.111127. Epub 2026 Jan 12.PMID: 41534741

Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women.
Bartmann C, Schmidt V, Mörz M, Schwab M, Rehn M, Blau-Schneider B, Wöckel A, Kämmerer U.PLoS One. 2026 Mar 5;21(3):e0344185. doi: 10.1371/journal.pone.0344185. eCollection 2026.PMID: 41785286 **Free PMC article.**

The power of powerful others: health locus of control and vaccination behavior in rural Namibian pastoralists.
Prall S, Scelza B, Lopes A.BMC Glob Public Health. 2026 Mar 1;4(1):20. doi: 10.1186/s44263-026-00251-4.PMID: 41764592 **Free PMC article.**

Cost-effectiveness analysis of influenza vaccination with high-dose **vaccine** versus standard-dose quadrivalent **vaccine** in older adults in Spain.
Abellan-Perpiñan JM, Redondo Margüello E, Gil de Miguel Á, Sanz Muñoz I, Diaz-Aguiló A, Palomo P, Farré M, Callejo D, Pinel M, López-Belmonte JL.Eur J Health Econ. 2026 Mar 4. doi: 10.1007/s10198-026-01894-8. Online ahead of print.PMID: 41776120

Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience.
Onavbavba G, Adigwe OP, Wilson DO, Ene EC.Health Res Policy Syst. 2026 Mar 5. doi: 10.1186/s12961-026-01442-z. Online ahead of print.PMID: 41787399 **Free article.**

Susceptibility of Gecko Cell Line for Cultivation and Adaptation of Infectious Bursal Disease Virus as an Experimental **Vaccine**.
Dolatabad SA, Namavari M, Behbahan NGG.Vet Med Sci. 2026 Mar;12(2):e70856. doi: 10.1002/vms3.70856.PMID: 41707044 **Free PMC article.**

Multiscale Simulations and Cryo-Electron Microscopy Reveal the Transition Pathway of Dengue Virus-like Particle Nanoassembly.
Palur VR, Chen GW, Chao DY, Kuo WS, Wu YN, Galula JU, Wang CH, Chen FC, Bond PJ, Marzinek JK, Wu SR.ACS Nano. 2026 Mar 3;20(8):6845-6863. doi: 10.1021/acsnano.5c17047. Epub 2026 Feb 15.PMID: 41693305 **Free PMC article.**

Intranasal vaccination with gB adjuvanted by poly(I:C) induces complete protection against pseudorabies virus in swine.
Li S, Liu Y, Zhang Q, Gao Q, Liu J, Zhu Y, Bao Y, Zhang Y, Yang Q.Vet Microbiol. 2026 Mar;314:110935. doi: 10.1016/j.vetmic.2026.110935. Epub 2026 Feb 5.PMID: 41666694 **Free article.**

Ferroptosis-driven in situ **vaccine**-like antitumor effects: NIR-triggered IFBM hydrogel synergizes with sorafenib to unleash systemic antitumor immunity.
Jiang Z, Fu R, Li P, Zhang J, Cheng Y, Yang K, Chen J, Zhang Y, Su L, Lei Y, Chen B, Cao G.J Nanobiotechnology. 2026 Mar 8. doi: 10.1186/s12951-026-04262-z. Online ahead of print.PMID: 41795072 **Free article.**

MMR and the EMR: Hunting for National-level **Vaccine** Data in Transplant Recipients.
Werbel WA, Avery RK.Transplantation. 2026 Mar 5. doi: 10.1097/TP.0000000000005673. Online ahead of print.PMID: 41784437 No abstract available.

Test-negative Designs with Various Reasons for Testing: Statistical Bias and Solution.
Yu M, Liu TH, Li KQ, Jewell N, Tchetgen Tchetgen E, Small D, Shi X, Wang B.Epidemiology. 2026 Mar 1;37(2):228-236. doi: 10.1097/EDE.0000000000001940. Epub 2025 Dec 29.PMID: 41474934

Primary evaluation of immune responses in mice after a single mRNA immunization with Echinococcus granulosus Eg95 and Coenurus cerebralis TM16.
Meng CN, Li TT, Li WH, Wang M, Chen WG, Yan HB, Li L, Sun XL, Fu BQ, Zhang NZ.Vaccine. 2026 Mar 7;75:128232. doi: 10.1016/j.vaccine.2026.128232. Epub 2026 Jan 21.PMID: 41570444

Addressing RSV infection in older adults: implications for public health policy.
D'Ambrosio F, Lomazzi M, Moore M, Ricciardi R, Mourino S, Ricciardi W, Calabrò GE; WFPHA RSV engagement forum.Expert Rev Vaccines. 2026 Mar 11:2644348. doi: 10.1080/14760584.2026.2644348. Online ahead of print.PMID: 41811346 **Free article.**

Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 **vaccine** antigens.

Guardalini LGO, Martins IM, Bernardino TC, Quintilio W, de Farias KM, Jorge SAC, Maria DA.Vaccine. 2026 Mar 9;79:128406. doi: 10.1016/j.vaccine.2026.128406. Online ahead of print.PMID: 41806759

A critical analysis of the Australian public consultation on childhood **vaccine** mandate introduction.
Gore S, Attwell K, Campbell E, Williams J, Carter SM, Leask J, Wiley K.Soc Sci Med. 2026 Mar;393:119037. doi: 10.1016/j.socscimed.2026.119037. Epub 2026 Jan 29.PMID: 41650896 **Free article.**

Direct comparison of three herpes simplex virus-2 **vaccine** candidates using peripheral or mucosal routes of vaccination.
Wang K, Jordan T, Suzuki-Williams L, Qin J, Knipe DM, Cohen JI.Vaccine. 2026 Mar 7;75:128107. doi: 10.1016/j.vaccine.2025.128107. Epub 2026 Feb 1.PMID: 41628523 **Free PMC article.**

Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX **vaccine** as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786].
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Thammireddy K, Ningaiah S, Dhar C, Binayke A, Zaheer A, Awasthi A, Narang S, Reddy NC, Pandey AK, Anjaneylu CS.IJID Reg. 2026 Jan 2;18:100831. doi: 10.1016/j.ijregi.2025.100831. eCollection 2026 Mar.PMID: 41551849 **Free PMC article.**

Adherence to the Mediterranean diet, particularly olive oil intake, and metabolic health parameters are independently associated with SARS-CoV-2 **vaccine**-induced IgG responses.
Petropoulou D, Tsilingiris D, Karras SN, Ioannidis A, Petropoulou G, Chatzigeorgiou A, Kassi E, Karampela I, Diamantopoulou A, Panagiotopoulos K, Dalamaga M.Metabol Open. 2026 Jan 21;29:100446. doi: 10.1016/j.metop.2026.100446. eCollection 2026 Mar.PMID: 41631199 **Free PMC article.**

The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England.
Ku CC, Rosello A, Walker J, Pouwels KB, Baguelin M, Davies NG, Jit M.Vaccine. 2026 Mar 4;78:128405. doi: 10.1016/j.vaccine.2026.128405. Online ahead of print.PMID: 41785676 **Free article.**

Genomic comparison reveals single-nucleotide polymorphic sites and attenuation-associated site combinations specific to Chinese live attenuated varicella-zoster virus vaccines.
Zhang Y, Duan X, Cai Y, Wang M, Wang Z, Song M, Qiu T, Wang X, Shao H.Hum Vaccin Immunother. 2026 Dec 31;22(1):2611644. doi: 10.1080/21645515.2025.2611644. Epub 2026 Mar 9.PMID: 41797638 **Free PMC article.**

Oral cholera **vaccine** uptake, acceptance and confidence among residents of a high-risk township in Zambia: key insights for future vaccination programs.
Miti E, Mukosha M, Mwaba J, Mulavu M, Meyer JC, Mudenda S, Godman B, Mwila C, Hamachila A, Kalungia AC.Int Health. 2026 Mar 3;18(2):254-263. doi: 10.1093/inthealth/ihaf087.PMID: 40796201 **Free article.**

Outer membrane vesicles from *Aeromonas veronii*: biological properties and synergistic immunity enhancement with inactivated bacteria in crucian carp.
Wu Z-X, An D-J, Kou Y-X, Yang Q, Zhang Z-Q, Chen L, Gao G-P, Gao G-S, Yang B-T, Kang Y-H.Microbiol Spectr. 2026 Mar 3;14(3):e0249725. doi: 10.1128/spectrum.02497-25. Epub 2026 Jan 22.PMID: 41568962 **Free PMC article.**

Long-term immunogenicity of alternative HPV **vaccine** schedules and the effect of an additional dose given three to five years post-primary vaccination.
Sauvageau C, Ionescu IG, Ouakki M, Panicker G, Gilca V, Unger ER, Mayrand MH.Vaccine. 2026 Mar 7;75:128287. doi: 10.1016/j.vaccine.2026.128287. Epub 2026 Feb 4.PMID: 41643232 **Free article.** Clinical Trial.

Conformation-Transformable, Spiked Polypeptide Enables *In Situ* Cancer Vaccination via Conditional Antigen Capture and STING Activation.
Ge C, Wu F, Zhang X, Yin M, He J, Yan J, Qian Y, Ye H, Yang K, Yin L.J Am Chem Soc. 2026 Mar 2. doi: 10.1021/jacs.5c22249. Online ahead of print.PMID: 41772751

Impact of reminder messages, with and without financial incentives, on influenza vaccination: A randomized trial in a California health system.
Chang TY, Jacobson M, Shah M, Pramanik R, Shah SB.Vaccine. 2026 Mar 7;75:128263. doi: 10.1016/j.vaccine.2026.128263. Epub 2026 Jan 27.PMID: 41604808 **Free article.** Clinical Trial.

Provincial stratification and equity-weighted cost-effectiveness of malaria vaccines in Zambia under climate variability.
Phiri AE.BMJ Public Health. 2026 Mar 5;4(1):e004172. doi: 10.1136/bmjph-2025-004172. eCollection 2026.PMID: 41808900 **Free PMC article.**

Surface-displayed MCP-3 **vaccine** in Bacillus subtilis elicits protective immune responses against LMBV infection in largemouth bass.
Lin R, Jiang Z, Zhang Q, Li S, Qin X, Wang X, Cheng G, Xu Z, Kong W.Fish Shellfish Immunol. 2026 Mar;170:111126. doi: 10.1016/j.fsi.2026.111126. Epub 2026 Jan 12.PMID: 41534737

In silico design of the multi-epitope **vaccine** for lung adenocarcinoma based on hub gene-derived neoantigens.
Li S, Huang M, Jia L, Liu S, Sun X, Cai D, Su Y, Chen M, Lu C, Huang J, Tu J, Ji J.BMC Cancer. 2026 Mar 6. doi: 10.1186/s12885-026-15765-1. Online ahead of print.PMID: 41792674 **Free article.** No abstract available.

Evaluation of immune response in calves vaccinated with baculovirus vectored inactivated **vaccine** expressing 2.3.4.4b H5 protein of highly pathogenic Avian Influenza virus.
Lee CW, Glover S, Olivier T, Lee Y, Erickson S, Gustafson B, Sharma B, Young AJ, Schueler A.Vet Microbiol. 2026 Mar 3;316:110970. doi: 10.1016/j.vetmic.2026.110970. Online ahead of print.PMID: 41793873 **Free article.**

Examining the interaction between area-level immunity coverage and individual-level immunity to help quantify indirect herd benefits: a population-based retrospective cohort study of COVID-19 diagnoses and deaths.
Wang L, Swayze S, Siddiqi A, Baral SD, Sander B, Sbihi H, Kwong JC, Mishra S.Am J Epidemiol. 2026 Mar 7:kwag047. doi: 10.1093/aje/kwag047. Online ahead of print.PMID: 41791763

US doctors withdraw from CDC **vaccine** committee, as RFK Jr appoints Bhattacharya as acting director.
Tanne JH.BMJ. 2026 Mar 2;392:s422. doi: 10.1136/bmj.s422.PMID: 41771643 No abstract available.

An Rv1471-expressing chimpanzee adenovirus **vaccine** confers protection against tuberculosis by inducing alveolar macrophage trained immunity and polyfunctional T-cell responses.
Wang H, Zhang Y, Li J, Wu J, Huang S, Xie S, Huang X, Wang J, Fan XY, Hu Z.Emerg Microbes Infect. 2026 Dec;15(1):2637292. doi: 10.1080/22221751.2026.2637292. Epub 2026 Mar 10.PMID: 41734270 **Free PMC article.**

The Cinderella tree, *Quillaja saponaria* - A soap story.
Osbourn A.Plants People Planet. 2026 Mar;8(2):439-451. doi: 10.1002/ppp3.70108. Epub 2025 Nov 25.PMID: 41743997 **Free PMC article.**

Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 **vaccine** in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
Yesenia Rodríguez-Tanta L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, Lozada GA, Veramendi-Espinoza LE, Espinoza-Ildefonso V, Saromo-Meléndez V, Lazarte-Ramos A, Aldave JC, Pimentel MM, Torres CG, Valdiviezo CR, Lechuga-Noa VE.Vaccine. 2026 Mar 7;75:128227. doi: 10.1016/j.vaccine.2026.128227. Epub 2026 Jan 17.PMID: 41548527

Two divergent VAR2CSA lineages with distinct evolutionary signatures circulate in plasmodium falciparum from Thailand.
Chaikitgosiyakul S, Kuamsab N, Tia T, Putaporntip C, Jongwutiwes S.Infect Genet Evol. 2026 Mar 4:105916. doi: 10.1016/j.meegid.2026.105916. Online ahead of print.PMID: 41791500 **Free article.**

Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 **vaccine** enhances humoral immunity and growth performance in piglets.

Shuai W, Sun Q, Li J, Shen W, Zhu J, Guo Z, Luo M, Zeng Y, Wang J, Tong G, Zhou Y, Gao F.Vaccine. 2026 Mar 7;75:128247. doi: 10.1016/j.vaccine.2026.128247. Epub 2026 Jan 20.PMID: 41564839

Subtle Genetic Shifts of African Swine Fever Virus Among Vietnamese Domestic Swine Following Live-Attenuated **Vaccine** Commercialization.
Nguyen TC, Tantitaveewattana P, Pamornchainavakul N, Do DT, Kedkovid R, Thanawongnuwech R.Transbound Emerg Dis. 2026 Mar 3;2026:8776906. doi: 10.1155/tbed/8776906. eCollection 2026.PMID: 41789191 **Free PMC article.**

Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal **vaccine** for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
Thakkar K, Kefalogianni R, Zhang J, Yung CF, Tagore S, Dashraath P, Law AW, Mendes D.Vaccine. 2026 Mar 7;75:128285. doi: 10.1016/j.vaccine.2026.128285. Epub 2026 Jan 30.PMID: 41619355

Severe flare of genital warts after intralesional nonvalent HPV **vaccine** and development of multiple nodules at the sites of injection.
Stefanaki C, Karousos G, Sachanas S.Int J STD AIDS. 2026 Mar;37(4):438-440. doi: 10.1177/09564624251394549. Epub 2025 Nov 11.PMID: 41216745

Development of a lymph node-homing peptide **vaccine** targeting C-C chemokine receptor 7-positive dendritic cells with enhanced antitumor immunity.
Pang L, Wang M, Fan J, Sun Y, Han J, Shen W, Yang B, Hu X, Sun Y, Kong Y, Qi Y, Wu Y, Gao Y.J Control Release. 2026 Mar 10;391:114645. doi: 10.1016/j.jconrel.2026.114645. Epub 2026 Jan 22.PMID: 41580130

Immunologic Evaluation of First and Second Doses of SARS-CoV-2 XBB.1.5 and the KP.2 Monovalent Booster Vaccines in Nursing Home Residents.
Olagunju OJ, Oyebanji OA, Keresztesy D, Dickerson E, Wallace T, Holland L, Payne M, See E, Li CJ, Lim E, Abul Y, Nugent C, Perez I, Davidson HE, Han L, Balazs A, Bosch J, King CL, Wilson B, Gravenstein S, Canaday DH.J Am Geriatr Soc. 2026 Mar;74(3):807-813. doi: 10.1111/jgs.70243. Epub 2025 Dec 14.PMID: 41392023

Integrative bioinformatics approach to the mRNA **vaccine** development for the human papillomavirus using the capsid protein.
He S, Zubair A, Ahmad F, Shahani MY, Zeng L, Afghan N.Biol Direct. 2026 Mar 2. doi: 10.1186/s13062-026-00740-4. Online ahead of print.PMID: 41772595 **Free article.** No abstract available.

Hepatitis B virus (HBV) revaccination in MSM who were born in the nationwide neonatal HBV vaccination era: A randomized clinical trial.

Huang YC, Yang CJ, Li CW, Sun HY, Huang SH, Kuo PH, Liu WC, Su YC, Ko WC, Hung CC.Int J Infect Dis. 2026 Mar;164:108330. doi: 10.1016/j.ijid.2025.108330. Epub 2025 Dec 23.PMID: 41448530 **Free article.** Clinical Trial.

Measles seroprevalence among health care professionals during a period of increased transmission: A pilot study in Southern Italy.
Anzà D, Restivo V, Cirillo F, Sasso BL, Martínez-Jarreta B, Senia P, Vitale E.IJID Reg. 2025 Dec 27;18:100833. doi: 10.1016/j.ijregi.2025.100833. eCollection 2026 Mar.PMID: 41608115 **Free PMC article.**

Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal **Vaccine** and Checkpoint Inhibitor Responses.
Sidiropoulos DN, Zhang Z, Durham JN, Charmsaz S, Gross NE, Lee JW, Sun Y, Perikala S, Tandurella JA, Lvovs D, Mitschang A, Lemson G, Shin SM, Hernandez AG, Mitchell S, Leatherman JM, Danilova L, Wang H, Fertig EJ, Jaffee EM, Bever KM, Le DT, Ho WJ.Cancer Immunol Res. 2026 Mar 4;14(3):399-410. doi: 10.1158/2326-6066.CIR-25-1126.PMID: 41524578 **Free PMC article.**

APC-targeted DNA vaccines: the role of CCL19 in immune cell recruitment and early onset of the immune response.
Barrio-Calvo M, Friis S, Kofoed SV, Holste SC, Andersen RO, Rønø B, Hjortø GM.Cancer Immunol Immunother. 2026 Mar 10;75(4):101. doi: 10.1007/s00262-026-04339-6.PMID: 41806188 **Free PMC article.**

Evaluation of an Accelerated Hepatitis B Vaccination Schedule in Post-Hematopoietic Stem Cell Transplant Pediatric Patients.
Ong RYL, Loe MWC, Chan SB, Loh KM, Kwek SS, Chong CY, Li J, Thoon KC, Nadua KD, Kam KQ, Yung CF, Soh SY, Tan AM, Liew WK, Huang CJ, Seow CW, Shetty S, Tan NWH.Pediatr Blood Cancer. 2026 Mar;73(3):e70006. doi: 10.1002/pbc.70006. Epub 2025 Nov 18.PMID: 41254854

Evaluating the delivery costs and operational context of a single-dose human papillomavirus (HPV) **vaccine** regimen administered to a multi-age cohort of adolescent girls in Ethiopia.
Mvundura M, Slavkovsky R, Dagnew B, Hunduma A, Ayalew M, Bedada D.Vaccine. 2026 Mar 7;75:128248. doi: 10.1016/j.vaccine.2026.128248. Epub 2026 Jan 21.PMID: 41570443

Induction of a Th1-Type Polyfunctional T Cell Response by the four-segmented Rift Valley Fever candidate **vaccine** in humans.
Aregay A, Friese J, Porrez S, Leroux-Roels I, Meineke R, Osterhaus ADME, Wichgers Schreur PJ, Rimmelzwaan GF, Prajeeth CK.J Infect Dis. 2026 Mar 9:jiag138. doi: 10.1093/infdis/jiag138. Online ahead of print.PMID: 41800800

Mannose-Modified Zif-8 Nanoparticles Promote Macropinocytosis-Mediated Dendritic Cell Uptake and Induce Potent Humoral/Cellular Immunity Against Klebsiella pneumoniae.

Hu G, Yang J, Li Y, Luo X, Yin L, Wang W, Fu Y.Biotechnol J. 2026 Mar;21(3):e70202. doi: 10.1002/biot.70202.PMID: 41761991

Perceived Threat of COVID-19 and Vaccination Coverage Among Nurses: A Multicentre Cross-Sectional Study.
Moreno-Martínez M, Feijoo-Cid M, Manresa-Dominguez JM, Arreciado Marañón A, Zuriguel-Pérez E, Ponce-Ruíz S, Torrente-Jimenez RS, Fernández-Cano MI.Nurs Open. 2026 Mar;13(3):e70469. doi: 10.1002/nop2.70469.PMID: 41800485 **Free PMC article.**

Immunoinformatic approach to design T cell epitope-based chimeric **vaccine** targeting multiple serotypes of dengue virus.
Manocha N, Jha P, Kumar P, Khanna M, Chopra M, Pai SS.J Biomol Struct Dyn. 2026 Mar;44(4):1706-1724. doi: 10.1080/07391102.2024.2428828. Epub 2024 Nov 28.PMID: 39610038

Stabilization of the H5 clade 2.3.4.4b hemagglutinin improves **vaccine**-elicited neutralizing antibody responses in mice.
Dosey A, Dadonaite B, Gillespie RA, Leaf EM, Vukovich MJ, McGowan J, Grey E, Muramatsu H, Jun RHJ, Pardi N, Kanekiyo M, Bloom JD, King NP.Sci Transl Med. 2026 Mar 4;18(839):eaea8770. doi: 10.1126/scitranslmed.aea8770. Epub 2026 Mar 4.PMID: 41779867

Retraction notice to "Association of polymorphisms in the interleukin-4 gene with response to hepatitis B **vaccine** and susceptibility to hepatitis B virus infection: a meta-analysis" [Gene 525 (2013) 35-40].
Cui W, Sun CM, Deng BC, Liu P.Gene. 2026 Mar 5;981:149947. doi: 10.1016/j.gene.2025.149947. Epub 2025 Dec 17.PMID: 41412914 No abstract available.

STING-activating & ICD dual-response whole tumor cell **vaccine** amplifies TNBC immunotherapy.
Lu Z, Gu W, Jiang F, Chen L, Chen S, Feng J, Hu Q, Jin Y.Biomaterials. 2026 Mar 2;331:124112. doi: 10.1016/j.biomaterials.2026.124112. Online ahead of print.PMID: 41785630

Therapeutic Limitations of the Human Papillomavirus **Vaccine** in Conjunctival Papilloma: A Case Series.
Hernandez-Lopez V, Caro R, Zhang M, Stacey A.Ocul Oncol Pathol. 2026 Mar;12(1):40-43. doi: 10.1159/000549836. Epub 2025 Dec 1.PMID: 41521973 **Free PMC article.**

High Risk of Incident-Persistent Human Papillomavirus Infection With 9-Valent **Vaccine** Types in Young Men With an HPV Infection.
Broshkevitch CJ, Tota JE, Palefsky JM, Nahhas GJ, Goldstone SE, Dubin B, Saah A, Luxembourg A, Velicer C, Giuliano AR.Open Forum Infect Dis. 2026 Feb 2;13(3):ofag045. doi: 10.1093/ofid/ofag045. eCollection 2026 Mar.PMID: 41783602 **Free PMC article.**

Conjunctival administration of H38deltawbkF rough **vaccine** as an effective strategy to protect against Brucella ovis infection while minimizing serological interference.

Lopez N, Andrés-Barranco S, De Miguel MJ, Zúñiga-Ripa A, Elizalde-Bielsa A, Salvador-Bescós M, Iriarte M, Barberán M, Blasco JM, Moriyón I, Conde-Álvarez R, Muñoz PM.Vet Res. 2026 Mar 8. doi: 10.1186/s13567-025-01693-8. Online ahead of print.PMID: 41794734 **Free article.**

In silico profiling of the plasmodium knowlesi 32 kDa antigen: Diversity, epitope prediction, and structural modeling.
Saif A, Baruah P, Alghamdi JM, Acharyya R, Lau YL, Han JH, Ahmed MA.Infect Genet Evol. 2026 Mar;138:105871. doi: 10.1016/j.meegid.2025.105871. Epub 2025 Dec 31.PMID: 41482080 **Free article.**

An oral multivalent fusion **vaccine** based on antigenic fragment VP56(310-500) and FlaC adjuvant confers effective protection against grass carp reovirus.
Tang B, Cheng G, Lu Y, Li W, Xu Y, Yang C, Xu Z, Kong W, Su J.Fish Shellfish Immunol. 2026 Mar;170:111145. doi: 10.1016/j.fsi.2026.111145. Epub 2026 Jan 21.PMID: 41571162

Phase I/II clinical trial of a melanoma **vaccine** targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).
Ninmer EK, Petroni GR, Gastman BR, Gaughan EM, Isaacs JM, Haden K, Kaur V, Wages NA, Chianese-Bullock KA, Smith KT, Wright P, Bryant J, Dunlap-Brown M, Engel JA, Bekiranov S, Mauldin IS, Truong TG, Bullock TNJ, Slingluff CL Jr.J Immunother Cancer. 2026 Mar 3;14(3):e013613. doi: 10.1136/jitc-2025-013613.PMID: 41775435 **Free PMC article.** Clinical Trial.

Design, synthesis and immunological evaluation of novel monosaccharide TLR4 agonists.
Zhang ZM, Wen Y, Luo MQ, Sun HL, Ding D, Liao CM, Guo J.Bioorg Chem. 2026 Mar 3;174:109717. doi: 10.1016/j.bioorg.2026.109717. Online ahead of print.PMID: 41795437

A novel hypothetical protein (SAUSA300_1684) confers excellent protection against multi-drug-resistant Staphylococcus aureus infection in the murine model.
Mishra PM, Chaudhary S, Manhas RS, Lokwani SR, Sharma D, Dutta D, Baranwal MK, Mishra RPN.Vaccine. 2026 Mar 7;75:128220. doi: 10.1016/j.vaccine.2026.128220. Epub 2026 Jan 17.PMID: 41548530

"Cancer Prevention Is Typically My Top One": A Qualitative Study of Public Health Nurses' Experiences With and Perceptions of Human Papillomavirus (HPV) Vaccination in Montana.
Thaker J, Avery T, Caringi J, Newcomer SR.J Public Health Manag Pract. 2026 Mar-Apr 01;32(2):E69-E79. doi: 10.1097/PHH.0000000000002286. Epub 2025 Nov 7.PMID: 41286573 **Free PMC article.**

Repeated COVID-19 **vaccine** boosters elicit variant-specific memory B cells in humans.
Tortorici MA, Sprouse KR, Addetia A, Brown JT, Lee J, Stewart C, Merz B, Harteloo A, Elias-Warren A, Chu HY, Veesler D.Cell Rep. 2026 Mar 6;45(3):117052. doi: 10.1016/j.celrep.2026.117052. Online ahead of print.PMID: 41800618 **Free article.**

Factors related to immunization uptake among the hill tribe and stateless children in northern Thailand: A mixed methods study.
Apidechkul T, Smith Fawzi MC, Wilson KA.Vaccine. 2026 Mar 7;75:128254. doi: 10.1016/j.vaccine.2026.128254. Epub 2026 Jan 18.PMID: 41554245

Cross-Cultural Differences in Public Discourse on COVID-19 Vaccination in the United States and South Korea: Cross-Sectional Analysis Using Natural Language Processing.
Youm S, Jang SH, Kwak H, Choi J, Yi YJ.JMIR Form Res. 2026 Mar 5;10:e84791. doi: 10.2196/84791.PMID: 41785455 **Free article.**

Invasive Meningococcal Disease in Australian Children 2016-2022: A Multicenter, Prospective Surveillance Study of Serogroup Distribution and Clinical Presentation in the Meningococcal **Vaccine** Era.
Wositzky M, Louise J, D'Angelo N, Wood N, Richmond P, Blyth CC, Buttery J, Clark J, Elliott EJ, Francis JR, Macartney K, Marshall HS, Wang B; PAEDS investigators and Nurses.Pediatr Infect Dis J. 2026 Mar 10. doi: 10.1097/INF.0000000000005214. Online ahead of print.PMID: 41803075

A new era of coccidiosis control: Eimeria and Clostridium perfringens dynamics in vaccinated broiler flocks after the ionophore phase-out in Norway.
Estensmo EL, Granstad S, Stevens KB, Ptochos S, Økland M, Nordmark M, Sjurseth SK, Gossé S, Hansen M, Smith AL, Blake DP, Sekse C, Øines Ø.Prev Vet Med. 2026 Mar;248:106786. doi: 10.1016/j.prevetmed.2026.106786. Epub 2026 Jan 15.PMID: 41558264 **Free article.**

Comparison of the Efficacy of Cell Wall Disruption Methods for Saccharomyces cerevisiae INVSc1 cells Expressing Toxoplasma gondii Recombinant ROP6 Protein.
Karakavuk T, Karakavuk M, Gül C, Can H, Gul-Mete A, Erkunt Alak S, Döşkaya AD, Kaplan S, Yavuz İ, Akbaba H, Erel Akbaba G, Köseoğlu AE, Ovayurt T, Gürüz AY, Ün C, Kantarci AG, Döşkaya M.Protein Expr Purif. 2026 Mar 7:106914. doi: 10.1016/j.pep.2026.106914. Online ahead of print.PMID: 41802616

Signals of disproportionate reporting of events supposedly attributable to COVID-19 vaccines in children and adolescents: case-non-case study, Brazil, 2022.
Silva RMA, Nóbrega MEBD, Percio J, Martins AF, Almeida SLR, Porto VBG.Epidemiol Serv Saude. 2026 Mar 6;35:e20250843. doi: 10.1590/S2237-96222026v35e20250843.en. eCollection 2026.PMID: 41810634 **Free PMC article.**

CaIRF1 promotes antibacterial immune defense and acts as a **Vaccine** Adjuvant in Chromileptes altivelis.
Wang G, Wu Y, Lin J, Zhang C, Cao Z, Ao J, Zhou Y, Sun Y.Fish Shellfish Immunol. 2026 Mar 7:111263. doi: 10.1016/j.fsi.2026.111263. Online ahead of print.PMID: 41802480

Interim Estimates of 2025-26 Seasonal Influenza **Vaccine** Effectiveness - California, October 2025-January 2026.
Zhu S, Quint J, León TM, Li NJ, Muldrew S, Porse C, Flannery B, Ellington S, Murray EL, Sachdev D, McCullough K, Schechter R.MMWR Morb Mortal Wkly Rep. 2026 Mar 12;75(9):124-128. doi: 10.15585/mmwr.mm7509a3.PMID: 41818142

Protective properties of a candidate C-terminal domain OspA **vaccine** for prevention of Lyme disease.
Embers ME, Hasenkampf NR, Tardo AC, Timofeyeva Y, Wellnitz S, Li Y, Gribenko A, Park JJ, Esadze A, Tran S, Sun J, Dane J, Giordano-Schmidt D, Singh G, Gaylord M, Baranova D, Meinke A, Lundberg U, Hochreiter R, Jost S, Bartuschka U, Seidel S, Fritzer A, Kalina W, Kanevsky I, Anderson AS, Simon R.Vaccine. 2026 Mar 7;75:128231. doi: 10.1016/j.vaccine.2026.128231. Epub 2026 Jan 29.PMID: 41616647 **Free article.**

Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates the allergic responses in a murine allergic rhinitis model.
Park YM, Kim H, Kim JA, Lee HJ, Chun YH.Hum Vaccin Immunother. 2026 Dec;22(1):2612810. doi: 10.1080/21645515.2026.2612810. Epub 2026 Mar 10.PMID: 41805230 **Free PMC article.**

No more than three PlpE non-overlapping epitopes trigger significant antibody production in individuals vaccinated with the *Pasteurella multocida* epitope-chimeric proteins.
Geng B, Zhou B, Zhang Z, Jiang G, Zhu W.Microbiol Spectr. 2026 Mar 3;14(3):e0287825. doi: 10.1128/spectrum.02878-25. Epub 2026 Feb 3.PMID: 41631837 **Free PMC article.**

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate **vaccine** (PNEUBEVAX 14) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial.
Thuluva S, Matur RV, Gunneri S, Ningaiah S, Yerroju V, Mogulla RR, Dhar C, Thammireddy K, Paliwal P, Kawade A, Nanjappa P, Pramod J, Narang M, Chakravarthy BS, Virupakashappa PM.Lancet Reg Health Southeast Asia. 2026 Mar 3;46:100746. doi: 10.1016/j.lansea.2026.100746. eCollection 2026 Mar.PMID: 41808691 **Free PMC article.**

Tonic for your GIN: gastrointestinal nematode immunomodulator vaccines.
McSorley HJ, Smyth DJ, Fisher G.Trends Parasitol. 2026 Mar 7:S1471-4922(26)00033-4. doi: 10.1016/j.pt.2026.01.012. Online ahead of print.PMID: 41796458 **Free article.** Review.

Discovery of novel, high-affinity HBV T-cell epitopes by molecular dynamics-augmented proteome-wide screening.
Yan M, Jin M, Xia W, Sun J, Zhong Z, Wan G, Wang J, Huang JD, Zhang JZH.Protein Sci. 2026 Mar;35(3):e70503. doi: 10.1002/pro.70503.PMID: 41711273

Enhancement of the efficiency of a DNA **vaccine** construct harboring HSP70 mini-chaperones linked to HIV-1 Nef antigen using IL-7 cytokine and REV peptide.

Tajvidi N, Bolhassani A, Heshmati M, Naseroleslami M, Hosseini Shokouh SJ.Microb Pathog. 2026 Mar;212:108293. doi: 10.1016/j.micpath.2026.108293. Epub 2026 Jan 8.PMID: 41519445

Assessment of parental knowledge, attitude, and acceptance toward malaria **vaccine** for children under five years in Sudan, 2025.
Hassan AAE, Ali NAH, Elshareef MAA, Sidahmed TSM, Elobied HES, Ali AEO, Salih DAD, Al Rahma AMM, Abdallha AWA, Hussain AMS, Hussain AMS, Mohammed EYM, Ahmed KAH, Awadallah SYM.BMC Public Health. 2026 Mar 5. doi: 10.1186/s12889-026-26904-5. Online ahead of print.PMID: 41787369 **Free article.** No abstract available.

Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study.
Vicic N, Bogdanov A, Zheng Z, Ryan T, Zeng N, Joshi K, Lu T, Bonafede M, Araujo AB, Wilson A.Infect Dis Ther. 2026 Mar;15(3):701-714. doi: 10.1007/s40121-025-01292-2. Epub 2026 Jan 10.PMID: 41518551 **Free PMC article.**

Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines.
Versiani AF, McCaffrey P, Ribeiro-Filho HV, Silva NIO, Lopes-de-Oliveira PS, Carrera JP, Nogueira ML, Marques RE, Rossi SL, Vasilakis N.Sci Adv. 2026 Mar 13;12(11):eaeb2066. doi: 10.1126/sciadv.aeb2066. Epub 2026 Mar 11.PMID: 41811958 **Free PMC article.**

HepB-boost: Implementation of free-of-charge health care worker hepatitis B testing and vaccination at Kilifi County Referral Hospital, Kenya.
Downs LO, Tinga L, Andersson MI, Matthews PC, Madia J, Gathua L, Tajbhai MU, Kagwanja N, Aliyan N.Int J Infect Dis. 2026 Mar;164:108418. doi: 10.1016/j.ijid.2026.108418. Epub 2026 Jan 22.PMID: 41579938 **Free article.**

Inhibition of *Neisseria gonorrhoeae* complement-mediated killing during acute gonorrhea is dependent upon the IgG2:IgG3 antibody ratio.
McKeand SA, Faustini SE, Cook A, Kennett N, Drayson MT, Cunningham AF, Henderson IR, Tang CM, Ross JDC, Cole JA, Rossiter-Pearson AE.mBio. 2026 Mar 11;17(3):e0336723. doi: 10.1128/mbio.03367-23. Epub 2026 Jan 30.PMID: 41615163 **Free PMC article.**

Immunoinformatics approach to engineer a multi-epitope **vaccine** against SdrG in skin commensal Staphylococcus epidermidis.
Akter S, Silva GVR, Oliveira JIN, Fulco UL, Xu X, Fu YV.PLoS One. 2026 Mar 5;21(3):e0327534. doi: 10.1371/journal.pone.0327534. eCollection 2026.PMID: 41785290 **Free PMC article.**

Prevalence and Determinants of Hepatitis B Vaccination Coverage Among Medical Students in Tanzania: A Multicenter University-Based Survey.
Sindato EM, Mwalimu SM, Nkuwi EJ, Bintabara D.Health Sci Rep. 2026 Feb 26;9(3):e71919. doi: 10.1002/hsr2.71919. eCollection 2026 Mar.PMID: 41767365 **Free PMC article.**

Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate **vaccine** on invasive pneumococcal disease in England.
Nikhab A, Patel T, Rooney G, Wasti S, Abdullahi F, D'Aeth JC, Eletu S, Litt D, Ladhani SN.Vaccine. 2026 Mar 7;75:128246. doi: 10.1016/j.vaccine.2026.128246. Epub 2026 Jan 18.PMID: 41554244 **Free article.**

Maximizing public health benefits: Policy perspectives on coverage and cell-based influenza vaccines in the US.
Nguyen VH, Mould-Quevedo JF.Hum Vaccin Immunother. 2026 Dec;22(1):2640759. doi: 10.1080/21645515.2026.2640759. Epub 2026 Mar 12.PMID: 41817279

Vaccine effectiveness against medically-attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25.
Lucaccioni H, Pozo F, Pérez-Gimeno G, Dürrwald R, Uras M, Domegan L, Oroszi B, Meijer A, Trobajo-Sanmartín C, Ujvari D, Rodrigues AP, Mlinarić I, Lazar M, Rivas Wagner E, Erdwiens A, Enouf V, McKenna A, Túri G, de Lange M, Martínez-Baz I, Latorre-Margalef N, Guiomar R, Kurečić Filipovic S, Dinu S, Mokoroa O, Tolksdorf K, Masse S, Bennett C, Kristóf K, Hooiveld M, Castilla J, Santos J, Višekruna Vučina V, Popescu R, Bacci S, Kaczmarek M, Kissling E.Expert Rev Vaccines. 2026 Mar 12:2645378. doi: 10.1080/14760584.2026.2645378. Online ahead of print.PMID: 41816931

Neonatal intensive care unit admission among infants born full-term to CDC's COVID-19 **Vaccine** Pregnancy Registry participants: A matched cohort study.
Zauche LH, Madni SA, Shay DK, Olson CK, Machefsky A, Godfred Cato SE, Sharma AJ.Hum Vaccin Immunother. 2026 Dec;22(1):2636365. doi: 10.1080/21645515.2026.2636365. Epub 2026 Mar 3.PMID: 41774852 **Free PMC article.**

Uptake of Newly Licensed Influenza **Vaccine** Formulations Among Patients Receiving Chronic Hemodialysis During the 2010/2011 to 2021/2022 Influenza Seasons.
Sahrmann JM, Layton JB, Nickel KB, Davis JW, Dharnidharka VR, Weber DJ, Butler AM.Kidney Med. 2026 Jan 6;8(3):101243. doi: 10.1016/j.xkme.2026.101243. eCollection 2026 Mar.PMID: 41675207 **Free PMC article.** No abstract available.

Impaired neutralizing antibody responses against the BA1.1, BA.2, and BA.5 Omicron SARS-CoV-2 subvariants in hospitalized adults infected with pre-Omicron variants in Argentina.
Sachithanandham J, Sitaras IA, Albertini RA, Capra RH, Marquez J, Sadino-Vallve GB, Gargantini PR, Cortes PR, Ponce NE, van de Guchte A, Gonzalez-Reiche AS, Olivero NB, Zappia VE, Hernandez-Morfa M, Echenique-Nunez A, Nunez-Fernandez M, Raya-Plasencia L, van Bakel H, Pekosz A, Perez DR, Echenique J.Microbiol Spectr. 2026 Mar 3;14(3):e0347925. doi: 10.1128/spectrum.03479-25. Epub 2026 Jan 21.PMID: 41562622 **Free PMC article.**

A phase 4, open-label, single arm, multi-center study to evaluate the safety of a smallpox **vaccine** in previously vaccinated individuals.
Cassie D, Komlenovic V, Parrera G, Drobic B.Vaccine. 2026 Mar 7;75:128289. doi: 10.1016/j.vaccine.2026.128289. Epub 2026 Jan 31.PMID: 41621115 **Free article.** Clinical Trial.

Development and Immunoprotective Evaluation of a Chitosan-Based Nanovaccine against Aeromonas hydrophila in Yangtze Sturgeon (Acipenser dabryanus).
Chen Y, Qin Y, Zhou J, Zhang Y, Yu C, Hu Y, Yang Y, Xu D.Fish Shellfish Immunol. 2026 Mar 9:111259. doi: 10.1016/j.fsi.2026.111259. Online ahead of print.PMID: 41812959

Knowledge, attitudes and factors associated with the awareness of caregivers of under-five children regarding the malaria **vaccine** in the Tiko Health District, Cameroon: A community-based cross-sectional study.
Idang MA, Nsobinenyui D, Ukah CE, Yunika LK, Ngu CN, Fuanghene Wefuan R, Dang SZ, Ndip NE, Feguem MP, Shei CM, Nsagha DS.PLOS Glob Public Health. 2026 Mar 4;6(3):e0004659. doi: 10.1371/journal.pgph.0004659. eCollection 2026.PMID: 41779824 **Free PMC article.**

Fgl2-knockout tumor cells serve as a **vaccine** inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges.
Zhang S, Jin Y, Jia Z, Xia X, Li Y, Wang Q, Wang J, Wang J, Chandra J, Friedman GK, Li S.Cancer Lett. 2026 Mar 1;640:218215. doi: 10.1016/j.canlet.2025.218215. Epub 2025 Dec 9.PMID: 41380903 **Free article.**

Current and Emerging Approaches to Evaluating Influenza **Vaccine** Performance.
[No authors listed]N Engl J Med. 2026 Mar 12;394(11):1144. doi: 10.1056/NEJMx260005.PMID: 41812213 No abstract available.

Are Coronavirus Disease 2019 Vaccinations Causing Fatal Adverse Event? A Comprehensive Case Discussion Based on WHO Adverse Events Following Immunization Causality Criteria.
Debnath D, Tripura U, Debbarma J.Ann Afr Med. 2026 Mar 1;25(2):480-483. doi: 10.4103/aam.aam_106_25. Epub 2025 Jun 27.PMID: 40576404 **Free article.** English, French.

mGem: Progress on the development of conjugate vaccines for *Cryptococcus neoformans* infections.
Stempinski PR, Rodrigues Dos Santos Junior S, Casadevall A.mBio. 2026 Mar 10:e0353825. doi: 10.1128/mbio.03538-25. Online ahead of print.PMID: 41805207 **Free article.**

Autologous Tumor Vaccination in Melanoma and Colon Cancer Patients With Recurrent Liver Metastases: A Case Series.
Maimon O, Nisman B, Ben-David I, Kuznetz A, Gelfand Y, Lotem M, Popovtzer A, Salaymeh N, Khutsurauli S, Peretz T.Anticancer Res. 2026 Mar;46(3):1569-1575. doi: 10.21873/anticanres.18051.PMID: 41760242

DNA origami **vaccine** nanoparticles improve humoral and cellular immune responses to infectious diseases.
Zeng YC, Young OJ, Xiong Q, Si L, Ku MW, Bernier SG, Dembele H, Isinelli G, Gilboa T, Swank Z, Seok SH, Rajwar A, Jiang A, Zhai Y, Williams LD, Hellman CA, Wintersinger CM, Graveline AR, Vernet A, Sanchez M, Bardales S, Tomaras GD, Ryu JH, Kwon IC, Goyal G, Ingber DE, Shih WM.Nat Biomed Eng. 2026 Mar 11. doi: 10.1038/s41551-026-01614-w. Online ahead of print.PMID: 41813804

Non-cytolytic re-engineering of a viral **vaccine** vector enables durable effector-memory T cell immunity by reinforcing type I IFN induction.
Ciancaglini M, Avanthay R, Marx AF, Abreu-Mota T, Finozzi D, Fixemer J, Geier F, Burri D, Wagner I, Vincenti I, Kreuzfeldt M, Merkler D, Zimmer G, Pinschewer DD.Mol Ther Nucleic Acids. 2026 Feb 2;37(1):102852. doi: 10.1016/j.omtn.2026.102852. eCollection 2026 Mar 12.PMID: 41732204 **Free PMC article.**

Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate **vaccine** serotype specific urinary antigen detection assay.
Cintrón M, Gali V, Li Y, Jani K, Cander S, Kaltsas A, Kamboj M, Seo SK, Papanicolaou GA, Lee YJ.Int J Infect Dis. 2026 Mar;164:108360. doi: 10.1016/j.ijid.2025.108360. Epub 2025 Dec 28.PMID: 41468971 **Free article.**

Assessing **vaccine** cold chain storage and transport in Ukraine: a cross-sectional study.
Gaievskyi S, Grechukha Y, Khomenko O, Musa NMW, Benes O, Habicht J, Zaika O, Starychenko I, Kizin I.BMC Health Serv Res. 2026 Mar 10. doi: 10.1186/s12913-026-14332-5. Online ahead of print.PMID: 41808080 **Free article.** No abstract available.

Lack of molecular mimicry between HPV **vaccine** L1 antigen and human proteins by a computational analysis.
Nishioka K, Sekiyama K, Shiro R, Tsunoda I, Matsumura N.Int J Clin Oncol. 2026 Mar;31(3):494-503. doi: 10.1007/s10147-026-02961-z. Epub 2026 Jan 8.PMID: 41507632 **Free PMC article.**

Development of an inactivated H9N2 subtype avian influenza serological DIVA **vaccine** using the chimeric A/B NA epitope approach.
Zhang J, Fan Z, Pan Q, Yu F, Sun H, Sun M, Fu J, Song J.Vet Microbiol. 2026 Mar;314:110917. doi: 10.1016/j.vetmic.2026.110917. Epub 2026 Feb 3.PMID: 41653783

A Novel Prophylaxis Strategy Using Ecotin as A Promising Adjuvant for Fc-RBD Fusion Protein **Vaccine** of SARS-CoV-2.
Sun Y, Zheng R, Li D, Fang Y, Zhang L, Yang X, Yu W, Tu Y, Lu D, Li T, Luo D, Wang H.Immunology. 2026 Mar;177(3):441-444. doi: 10.1111/imm.70092. Epub 2025 Dec 28.PMID: 41456870

Protection against HPAI-H5N8 early challenge in commercial broilers with maternal immunity: prime-boost vs. single vaccination of a trivalent H5-inactivated **vaccine**.
Elfeil WMK, Safwat M, Abaza MA, Elbestawy AR, Arafa E, Afify M, Elkady MF, Kilany WH.Avian Pathol. 2026 Mar 10:1-8. doi: 10.1080/03079457.2025.2603919. Online ahead of print.PMID: 41392899

In older adults, high- vs. standard-dose influenza **vaccine** reduced hospitalization for influenza or pneumonia in those with CKD.
Sacks HS; ACP Journal Club Editorial Team at McMaster University.Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-26-00324-JC. Online ahead of print.PMID: 41771129

Interim Estimates of 2025-26 Seasonal Influenza **Vaccine** Effectiveness - United States, September 2025-February 2026.
Maloney P, Reeves EL, Wielgosz K, Price AM, Natarajan K, DeSilva MB, Dascomb K, Klein NP, Tartof SY, Irving SA, Grannis SJ, Ong TC, Weber ZA, Schuster JE, Zerr DM, Michaels MG, Boom JA, Halasa NB, Staat MA, Weinberg GA, House SL, Saade EA, Geffel KM, Gaglani M, Wernli KJ, Murugan V, Martin ET, Bontrager NAB, Kirby MK, Payne AB, Dawood FS, Tannis A, Moline HL, Zhao SK, Adams K, DeCuir J, Olson SM, Chung JR, Lewis N, Flannery B, Reed C, Garg S, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators; CDC Influenza Vaccine Effectiveness Collaborators.MMWR Morb Mortal Wkly Rep. 2026 Mar 12;75(9):116-123. doi: 10.15585/mmwr.mm7509a2.PMID: 41818161

Evaluating the Psychometric Properties of the 7C Vaccination Readiness Scale: Evidence from Slovenia.
Vrdelja M, Branilović S, Lamot M, Kirbiš A.Zdr Varst. 2026 Mar 1;65(1):25-33. doi: 10.2478/sjph-2026-0004. eCollection 2026 Mar.PMID: 41783758 **Free PMC article.**

Introducing the Concept of Small Vulnerable Newborns (SVN) as an Additional Endpoint to Evaluate Birth Outcomes in the Context of RSV Immunization Studies-A Commentary.
Gerstenberg J, Helbig C, Schleenvoigt BT.Influenza Other Respir Viruses. 2026 Mar;20(3):e70244. doi: 10.1111/irv.70244.PMID: 41784331 **Free PMC article.**

Comment on: Pettersson et al. Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the **vaccine**, with two amino acid substitutions in the E protein.
Tricou V, Livengood J, Sharma M, Zent O, Rauscher M, Setoh YX, Brünner C, Biswal S, Kandeil W.J Travel Med. 2026 Mar 2;33(2):taaf127. doi: 10.1093/jtm/taaf127.PMID: 41528889 No abstract available.

Vaccine hesitancy among 0-6-year-olds' guardians in Chongqing: a cross-sectional survey revealing how immunization program managers' robust comprehensive capacity for adverse events following immunization (AEFI) management mitigates hesitancy.

Xu B, Wang Q, Xu J, Li J, Bai N, Zhou C.Expert Rev Vaccines. 2026 Dec;25(1):2640140. doi: 10.1080/14760584.2026.2640140. Epub 2026 Mar 6.PMID: 41769823 **Free article.**

In healthy adults, a modified RNA vs. inactivated influenza **vaccine** reduced laboratory-confirmed influenza-like illness at 14 d.
Anand R, Glatt AE; ACP Journal Club Editorial Team at McMaster University.Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05681-JC. Online ahead of print.PMID: 41771121

Rolling circle amplification-based self-assembled CpG nanoparticles: Immune activation and prevention of Edwardsiella piscicida.
Li W, Guo C, Wu K, Xie Q, Yang J, Shen A, Liu Q, Ren Y.Fish Shellfish Immunol. 2026 Mar 5;173:111260. doi: 10.1016/j.fsi.2026.111260. Online ahead of print.PMID: 41794159

Reining in strangles: Absence of disease in horses vaccinated with a DIVA-compatible recombinant fusion protein **vaccine**, Strangvac, following natural exposure to Streptococcus equi subspecies equi.
Gröndahl G, Righetti F, Aspán A, Bjerketorp J, Frosth S, Frykberg L, Jacobsson K, Guss B, Paillot R, Flock JI, Henriques-Normark B, Waller AS.Equine Vet J. 2026 Mar;58(2):476-485. doi: 10.1111/evj.70125. Epub 2025 Nov 23.PMID: 41276995 **Free PMC article.**

Chicken vaccination reduces colonization and dissemination of Salmonella serovar Enteritidis with decreased susceptibility to ciprofloxacin.
Bearson BL, Whelan SJ, Encinosa MPN, Neupane DP, Bradshaw DJ 2nd, Monson MS, Anderson CL, Bearson SMD.NPJ Vaccines. 2026 Mar 9. doi: 10.1038/s41541-026-01414-y. Online ahead of print.PMID: 41803165 **Free article.**

A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle **vaccine** in adults 60-85 years of age.
Davis M, Shapiro C, Ciarlet M, Adams EM, Hourguettes N, Engram AE, Wen J, Bansal H, Shoemaker K, Rida W, Aksyuk AA, Price J, Oyedele T, Chang LJ, Kanesa-Thasan N.Vaccine. 2026 Mar 4;77:128345. doi: 10.1016/j.vaccine.2026.128345. Online ahead of print.PMID: 41785514 **Free article.**

Modification of N-glycosylation site in the spike protein enhances the neutralizing antibody response against PEDV.
Pan S, Wei L, Xiang Y, Mou C, Liu H, Chen Z.Vet Microbiol. 2026 Mar 3;316:110972. doi: 10.1016/j.vetmic.2026.110972. Online ahead of print.PMID: 41793877

Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
Qaseem A, Obley AJ, Harrod CS, Wilt TJ, Carroll K, Humphrey LL; Population Health and Medical Science Committee of the American College of Physicians; Haeme R, Jackson CD, Kansagara D, Krain A, Mackey K, Poonacha T, Saini S, Vigna C.Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05485. Online ahead of print.PMID: 41771137 **Free article.**

A Phase 4 Trial to Describe the Immunogenicity, Safety, and Tolerability of MenB-fHbp in Participants > 10 Years of Age With Asplenia or Complement Deficiency.
Homola L, Korbal P, Thomsen I, Wang E, Liu Y, Murthy A, O'Neill R, Maguire JD, Moughan B, Peyrani P, Anderson AS, Beeslaar J.Am J Hematol. 2026 Mar 2. doi: 10.1002/ajh.70261. Online ahead of print.PMID: 41771600 No abstract available.

Do tailored infographics increase flu shot intentions in hesitant individuals?
Matthijssen MAM, van Leeuwen F, Cloin M, van de Goor I, Achterberg P.Health Psychol. 2026 Mar 9. doi: 10.1037/hea0001582. Online ahead of print.PMID: 41801714

Correction: HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic **Vaccine**.
Lecointre M, Guillot J, Marcone R, Ozdoganlar D, Cayatte M, Gyllenbäck EJ, Liberg D, Fournier N, Homicsko K, Hanahan D.Cancer Discov. 2026 Mar 2;16(3):611. doi: 10.1158/2159-8290.CD-26-0046.PMID: 41766435 **Free PMC article.** No abstract available.

T-cell epitope supplementation enhanced cross-protection against H7N9 AIV in chickens via upregulated HA epitope-specific T cell and CD4 T cell-mediated help.
Hao X, Yuan X, Wang J, Song Z, Li X, Meng C, Yang Y, Qin T, Hu J, Gu M, Hu S, Wang X, Liu X, Peng D, Liu X, Shang S.J Adv Res. 2026 Mar 9:S2090-1232(26)00232-8. doi: 10.1016/j.jare.2026.03.012. Online ahead of print.PMID: 41812709 **Free article.**

Application of Causal Inference to Establish Assay Effect in the Absence of a Bridging Study: A Case Study of MenACWY-CRM Conjugate **Vaccine** Data.
Adani M, Noirjean S, Callegaro A, Keshavan P, Costantini M.Pharm Stat. 2026 Mar-Apr;25(2):e70069. doi: 10.1002/pst.70069.PMID: 41615237 **Free PMC article.**

Strengthening measles immunity in Thailand: Rationale for a third **vaccine** dose to avert outbreaks.
Nilyanimit P, Suntronwong N, Puenpa J, Thongmee T, Klinfueng S, Wanlapakorn N, Poovorawan Y.Vaccine. 2026 Mar 10;79:128438. doi: 10.1016/j.vaccine.2026.128438. Online ahead of print.PMID: 41812631

The 4 Pillars of Childhood **Vaccine** Policy-1 Year Later.
Sharfstein J, Despres S.JAMA Health Forum. 2026 Mar 6;7(3):e260924. doi: 10.1001/jamahealthforum.2026.0924.PMID: 41817509

B cell imprinting in children impairs antibodies to the haemagglutinin stalk.
Sun J, Jo G, Troxell CA, Fu Y, Hoezl R, Lv H, Abozeid HH, Teo QW, Pholcharee T, McGrath JJC, Changrob S, Nelson SA, Yasuhara A, Huang M, Zheng NY, Chervin JC, Li L, Fernández-Quintero ML, Loeffler JR, Rodriguez AJ, Huang J, Swanson OM, Balmaseda A, Kuan G, Campredon L, Kaitlynn Allen E, Neumann G, Wu NC, Kawaoka Y, Krammer F, Mejias A, Ramilo O, Thomas PG,

Gordon A, Ward AB, Han J, Wilson PC.Nature. 2026 Mar 11. doi: 10.1038/s41586-026-10248-6. Online ahead of print.PMID: 41813896

Differential Odds of COVID-19 Infection Associated With Household and Workplace Exposures in US Health Care Personnel.
Kontowicz E, Irish AK, Plumb ID, Briggs-Hagen M, Harland KK, Krishnadasan A, Talan DA, Ten Eyck P, Steele MT, Kean ER, Mohr NM; Project PREVENT Network.J Occup Environ Med. 2026 Mar 1;68(3):e245-e251. doi: 10.1097/JOM.0000000000003586. Epub 2025 Oct 21.PMID: 41118238 **Free PMC article.**

Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024.
Brady M, Brouwer L, O' Brien K, Carton M, Whitton L, Dillon C, Finucane J, Culkin F, Perry E, Brabazon E, Gee S, Browne K, Burke D, De Gascun C, Leonard A, Cunney R, O' Connor L.Euro Surveill. 2026 Mar;31(9). doi: 10.2807/1560-7917.ES.2026.31.9.2500313.PMID: 41788028

The adaptive large language models for **vaccine** prediction: A novel approach to **vaccine** demand prediction with engineered deviation prompts.
Chen M, Wu Q, Wang Z, Qi Q, Hu Y, Li T.PLOS Digit Health. 2026 Mar 9;5(3):e0001273. doi: 10.1371/journal.pdig.0001273. eCollection 2026 Mar.PMID: 41801983 **Free PMC article.**

Evaluation of **vaccine** immunity against tetanus, hepatitis B, measles, mumps, rubella and varicella, in migrant adolescents aged 13 to 18 years arriving in Geneva in 2023.
Mühlstein-Barasche J, Gualtieri R, Wagner N, Chamay-Weber C, Posfay-Barbe K, Blanchard-Rohner G.Eur J Pediatr. 2026 Mar 12;185(4):177. doi: 10.1007/s00431-026-06843-4.PMID: 41817808

A Redox-Responsive beta-Glucan-Based **Vaccine** Recruiting Endogenous Antibodies to Potentiate Antifungal Immunity.
Zhou Z, Qu M, Lin H, Li M, Wang P, Ding J, He Y, Shi J, Wu Z.Chemistry. 2026 Mar 12:e03568. doi: 10.1002/chem.202503568. Online ahead of print.PMID: 41816982

Utilizing large-scale produced exosomes in a hepatocellular carcinoma model as an antigen delivery system.
Kimiz-Gebologlu I, Kantarci AG, Oncel SS.Eur J Pharm Biopharm. 2026 Mar 9:115051. doi: 10.1016/j.ejpb.2026.115051. Online ahead of print.PMID: 41812777

Serum Perfluoroalkyl Substances and Infant Measles Antibody Concentrations Before and After Vaccination: Results from Burkina Faso.
Mikkelsen SD, Fisker AB, Nebie EI, Zakane SA, Sie A, Coulibaly B, Trans KL, Jensen KJ, Pedersen M, Tolstrup J, Nielsen F, Benn CS, Timmermann A.Environ Toxicol Pharmacol. 2026 Mar 7:104979. doi: 10.1016/j.etap.2026.104979. Online ahead of print.PMID: 41802651

Factors Associated with Mpox Vaccination Uptake Among Women of Transgender Experience and Transfeminine People in New York City, 2024.
Rivera AV, Rodriguez K, Shelton M, Edelstein Z.AIDS Behav. 2026 Mar 3. doi: 10.1007/s10461-026-05090-w. Online ahead of print.PMID: 41776118

Sociodemographic Risk Factors for Incomplete Routine Childhood Immunizations Among Children Born During the COVID-19 Pandemic, Louisiana, March 1, 2020-July 1, 2021.
Bakshi A, Zhao N, Kar S, Truong A, Sheikh F.Public Health Rep. 2026 Mar 9:333549261423153. doi: 10.1177/00333549261423153. Online ahead of print.PMID: 41797619 **Free PMC article.**

Nanobodies® for veterinary health: multifunctional roles in diagnostics, therapeutics, and vaccines.
Ji P, Zheng C, Sun Y.Trends Microbiol. 2026 Mar 9:S0966-842X(26)00001-6. doi: 10.1016/j.tim.2026.01.001. Online ahead of print.PMID: 41807231

Ecological vaccination: A strategy to prevent zoonotic spillover from bats.
Li H, Yuan F, Yao Y, Wang J, Li C, Liu Y, Yang J, Zhang Z, Liu J, Liu J, Yang Z, Jin W, Wen D, Shan C, Zheng A.Sci Adv. 2026 Mar 13;12(11):eaec0269. doi: 10.1126/sciadv.aec0269. Epub 2026 Mar 11.PMID: 41811941 **Free PMC article.**

Transcriptional regulation of the pneumococcal capsule can dictate serotype-specific infection.
Marra M, Gazioglu O, Glanville DG, Harper-Cummings VM, Santana-Krimskaya S, Kroken AR, D'Mello A, Ganaie FA, Nahm MH, Tettelin H, Orihuela CJ, Yesilkaya H, Ulijasz AT.Nat Commun. 2026 Mar 9. doi: 10.1038/s41467-026-69722-4. Online ahead of print.PMID: 41803082 **Free article.**

Poliomyelitis, the years before vaccination. A reading through art.
Martini M, Brigo F, Minet C, Orsini D.Neurol Sci. 2026 Mar 12;47(4):336. doi: 10.1007/s10072-026-08887-8.PMID: 41813971 No abstract available.

Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19-Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study.
Zhao D, Ma Y, Li J, Li X, Cao Z, Yao W, Wu J, Suo L.JMIR Public Health Surveill. 2026 Mar 11;12:e82915. doi: 10.2196/82915.PMID: 41812145 **Free PMC article.**

Structural dynamics and immunogenicity of the recombinant and outer membrane vesicle-embedded Meningococcal antigen NadA.
Calvaresi V, Dello Iacono L, Borghi S, Luzzi E, Biolchi A, Ferlenghi I, Peschiera I, Giusti F, Fontana LE, Kan ZY, Spinello Z, Merola M, Delany I, Rand KD, Norais N.Nat Commun. 2026 Mar 11. doi: 10.1038/s41467-026-70059-1. Online ahead of print.PMID: 41807399 **Free article.**

Evaluating the effect of immunization with DNA encoding Phlebotomus sergenti apyrase protein (PsSP42) against Leishmania tropica infection in BALB/c mouse model.

Hosseinpour Jahednia S, Rezvan H, Sarvnaz H, Habibzadeh S, Nourian A, Taheri T, Seyed N, Gholami E, Rafati S.Parasit Vectors. 2026 Mar 9. doi: 10.1186/s13071-026-07255-x. Online ahead of print.PMID: 41803904 **Free article.**

Determinants of incomplete childhood vaccination among children aged 0-23 months in Ghana: a facility-based cross-sectional study.
Dadzie LA, Ayisah C, Naabil DT, Adoboe IE, Sagbo FM, Dartey AF, Ananga MK.BMC Pediatr. 2026 Mar 5. doi: 10.1186/s12887-026-06688-8. Online ahead of print.PMID: 41782098 **Free article.** No abstract available.

Human papillomavirus awareness and vaccination willingness among male community residents in Beijing based on the Health Belief Model.
Xing Y, Shi R, Li Y, Cai R, Ma T, Yuan X, Li L, Jiang Z, Gao W.Hum Vaccin Immunother. 2026 Dec 31;22(1):2641328. doi: 10.1080/21645515.2026.2641328. Epub 2026 Mar 9.PMID: 41802941 **Free PMC article.**

Molecular modeling of Streptococcus pneumoniae serogroup 23 capsular polysaccharide conformations provides insight into antibody binding and cross-reactivity.
Yerolemou N, Richardson NI, Ravenscroft N, Kuttel MM.Carbohydr Res. 2026 Mar 5;564:109882. doi: 10.1016/j.carres.2026.109882. Online ahead of print.PMID: 41812523

Adverse drug reaction due to concomitant **vaccine** administration of Covishield and Hepatitis-B in a patient with multidrug allergies.
Sharma A, Bano G.Indian J Pharmacol. 2026 Mar 1;58(2):153-155. doi: 10.4103/ijp.ijp_611_21. Epub 2026 Mar 2.PMID: 41766243 **Free article.**

An Fc-silent OspA monoclonal antibody passively protects mice from tick and intradermal Borrelia burgdorferi challenge.
Palmer D, Shemshadian A, Berman K, Nobles A, Willsey GG, Piazza CL, Freeman-Gallant G, Rudolph MJ, Bourgeois J, Hu L, Vance DJ, Mantis NJ.PLoS One. 2026 Mar 12;21(3):e0339749. doi: 10.1371/journal.pone.0339749. eCollection 2026.PMID: 41818320

Influenza **Vaccine** Effectiveness Against Influenza A(H1N1)pdm09-Associated Hospitalizations With SARI in Beijing, China, in the 2024-2025 Season.
Ma C, Sun Y, Ma J, Wang Y, Hu X, Shen Y, Zhang L, Zhang J, Zhang L, Duan W, Li J, Wang Q, Zhang D, Yang P.Influenza Other Respir Viruses. 2026 Mar;20(3):e70248. doi: 10.1111/irv.70248.PMID: 41814873

Practices and impact of biosecurity on pig performance in the West Region of Cameroon.
Vougat Ngom R, Mafokemg Z, Assana E.Porcine Health Manag. 2026 Mar 5. doi: 10.1186/s40813-026-00493-6. Online ahead of print.PMID: 41787569 **Free article.** No abstract available.

Suspension Adaptation of Immortalized Lamb Testis (iLT) Cells in Serum-Reduced Media and Evaluation of Goatpox Virus (GTPV-AV41) Replication.
Sun F, Yu H, Zhang T, Wu S, Lin X, Wang C, Yang Z, Feng C.J AOAC Int. 2026 Mar 9:qsag019. doi: 10.1093/jaoacint/qsag019. Online ahead of print.PMID: 41803622

Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 **vaccine** efficacy against breakthrough symptoms" [**Vaccine** 68 (2025) 127942].
Saito T, Couzinet A, Suzuki T, Shimomura M, Ryo A, Miyakawa K, Katayama Y, Nakatsura T.Vaccine. 2026 Mar 7;75:128267. doi: 10.1016/j.vaccine.2026.128267. Epub 2026 Jan 29.PMID: 41616652 No abstract available.

A systematic review of **vaccine**-induced immune thrombosis and thrombocytopenia triggered by nonadenoviral vector vaccination: ultra-rare or non-existent?
Ker YW, Ghataure AS, Montague SJ, Nicolson PLR, Buka RJ.Haematologica. 2026 Mar 12. doi: 10.3324/haematol.2025.300357. Online ahead of print.PMID: 41816821

An Engineered Extracellular Vesicle With Enhanced Tumor and Lymph Nodes Targeting as siRNA Delivery System for Robust Tumor Immunotherapy.
Wang Y, Zhang R, Zhou X, Tang L, Hu D, Zhang Y, Yang Y, Zhou B, Yang L.MedComm (2020). 2026 Mar 9;7(3):e70673. doi: 10.1002/mco2.70673. eCollection 2026 Mar.PMID: 41815210 **Free PMC article.**

A Biomimetic Nanovesicle-Based Synthetic **Vaccine** Platform Through Co-Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice.
Miao F, Lu J, Zhao Y, Wang W, Zhang T, Liu J, Zhang X, Wu L, Yan H, Wang R, Tai Z, Chen Z, Zhu Q.Angew Chem Int Ed Engl. 2026 Mar 10:e22249. doi: 10.1002/anie.202522249. Online ahead of print.PMID: 41804694

Reverse genetic rescue and propagation of human influenza A(H3N2) master virus seed in HEK-293 suspension cells.
Barman S, Iyengar R, Miller L, Turner JCM, Franks J, Willis C, Vadali S, Medrano G, Rubrum A, Meagher M, Webby RJ.Virology. 2026 Mar 3;618:110862. doi: 10.1016/j.virol.2026.110862. Online ahead of print.PMID: 41785633 **Free article.**

The prevalence and nature of anti-vaccination legislation in ten midwestern states: Implications for public health and policy.
Viskupič F, Wiltse DL, Liebl Z, Kinslow T.Vaccine. 2026 Mar 10;79:128452. doi: 10.1016/j.vaccine.2026.128452. Online ahead of print.PMID: 41812630

Molecular characterization of Eimeria necatrix surface antigen SAG8 and SAG36 genes and their immunoprotective efficacy in chicken.

Wang F, Zhang C, Feng Y, Yan D, Liu D, Su S, Hou Z, Xu J, Tao J.BMC Vet Res. 2026 Mar 11. doi: 10.1186/s12917-026-05404-z. Online ahead of print.PMID: 41808143 **Free article.** No abstract available.

Therapy With Doxycycline and Hydroxychloroquine Enables Surgical Excision of Ulcerated Cutaneous Granulomas in a Patient With Ataxia Telangiectasia.
Murguía-Favela L, Maruschak-Love S, Harrop RA, Brundler MA, Kurek K, Fonseca K, Ramien ML.Pediatr Dermatol. 2026 Mar 9. doi: 10.1111/pde.70174. Online ahead of print.PMID: 41802860

Impact of inactivated SARS-CoV-2 vaccination on blastocyst euploidy status: a prospective cohort study of patients undergoing preimplantation genetic testing for aneuploidy in China.
Wei JJ, Qiu Y, Chen FR, Leng M, Deng X, Liang MY, Chen SQ, Hei J, Ma RN, Li-Ling J, Li JJ, Gong Y.BMC Pregnancy Childbirth. 2026 Mar 11. doi: 10.1186/s12884-026-08930-8. Online ahead of print.PMID: 41814216 No abstract available.

A stable two-component cationic liposome platform for mRNA delivery induces CD8⁺ T-cell responses and protection in a murine lymphoma model.
Pedersen GK, Alhakeem RS, Tami A, Christensen D, Shabanian Z, Jensen RF, Wørzner K, Schmidt ST.J Nanobiotechnology. 2026 Mar 7. doi: 10.1186/s12951-026-04234-3. Online ahead of print.PMID: 41792746 **Free article.**

Income transfers and vaccination: impact on COVID-19 mortality and hospitalizations in Brazil. A longitudinal ecological study.
Silva Monteiro de Castro M, Andrade de Souza A, Lopes de Oliveira G, Marques da Silva GD, Lemos Jardim L, Debôrtoli Miranda W, Sousa-Paes R.Gac Sanit. 2026 Mar 2;40:102580. doi: 10.1016/j.gaceta.2026.102580. Online ahead of print.PMID: 41775017 **Free article.**

Estimating Risk Differences Using Large Healthcare Data Networks for Medical Product Post-Market Safety Outcomes in a Distributed Data Setting and Allowing for Active Post-Market Surveillance.
Cook AJ, Wellman RD, Marsh T, Tiwari RC, Nguyen MD, Russek-Cohen E, Peng Y, Nelson JC.Stat Med. 2026 Mar;45(6-7):e70440. doi: 10.1002/sim.70440.PMID: 41760378

Drug-induced Aseptic Meningitis: Pharmacovigilance Analysis of Japanese Adverse Event Reporting Database.
Masago S, Kotake K, Yamaoka K, Yorifuji K, Shimizu T.In Vivo. 2026 Mar-Apr;40(2):1220-1227. doi: 10.21873/invivo.14277.PMID: 41760314 **Free PMC article.**

Production and characterization of rNGFSP: a recombinant fusion immunogen eliciting dual anti-NGF and anti-Substance P therapeutic antibodies for Degenerative Joint Disease.
Varela V, Costa M, Maciel C, Barbeito J, Barrera EE, Gutierre E, Correa A, Elgue M, Carrasco S, Larrosa MD, Pereira M, Correa J, Crosignani N, Beckman JS, Barbeito L, Trias E.Biotechnol Rep

(Amst). 2026 Jan 12;49:e00946. doi: 10.1016/j.btre.2026.e00946. eCollection 2026 Mar.PMID: 41608074 **Free PMC article.**

Modelling approaches for estimating **vaccine** effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.
Antunes L, Nunes B, Núñez O, Martínez-Baz I, Dockx Y, Borg ML, Oroszi B, Duffy R, Dürwald R, Kuliešė M, Machado A, Petrović G, Lazăr M, Guiomar R, Río VÁ, Castilla J, Magerman K, Džiugytė A, Túri G, Fitzgerald M, Hackmann C, Jančorienė L, Gomez V, Makarić ZL, Popovici O, Rojas-Castro M, Rose AMC; and the European Hospital Vaccine Effectiveness Group.PLoS One. 2026 Mar 9;21(3):e0343988. doi: 10.1371/journal.pone.0343988. eCollection 2026.PMID: 41801885 **Free PMC article.**

Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
Handy AB, Ren B, Seidman LC, Granger SW, Payne LA.Vaccine. 2026 Mar 7;75:128226. doi: 10.1016/j.vaccine.2026.128226. Epub 2026 Jan 18.PMID: 41554246

Mortality for causes unrelated to COVID-19 by number of doses and time since administration of COVID-19 vaccines: a retrospective cohort analysis in the Treviso Province, Italy (2021-2025).
Piovesan C, Fabiani M, Pezzotti P, Ramigni M.Int J Infect Dis. 2026 Mar;164:108392. doi: 10.1016/j.ijid.2026.108392. Epub 2026 Jan 11.PMID: 41529808 **Free article.**

Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016-2023): A Retrospective Study.
Brochado-Kith O, Gil-Prieto R, Gil-de-Miguel A.Infect Dis Ther. 2026 Mar 7. doi: 10.1007/s40121-026-01317-4. Online ahead of print.PMID: 41795059

High detection rate and genetic diversity of feline caliciviruses in an island population of feral cats with/without oral lesions.
Kulberg JL, Toka FN, Malik YS, Ghosh S.Infect Genet Evol. 2026 Mar;138:105892. doi: 10.1016/j.meegid.2026.105892. Epub 2026 Feb 4.PMID: 41651320 **Free article.**

Short report: association between self-reported COVID-19 experience and contemptuous beliefs about pandemic management among German citizens and healthcare professionals.
Wegwarth O, Hertwig R.J Public Health (Oxf). 2026 Mar 6;48(1):332-337. doi: 10.1093/pubmed/fdaf144.PMID: 41206715

Integrating gender equity and social inclusion into forecasting and supply planning (FSP): a policy commentary.
Faramand TH, Pappa S, Renfroe SJ, Akhlaghi L.Int Health. 2026 Mar 11:ihag020. doi: 10.1093/inthealth/ihag020. Online ahead of print.PMID: 41810545

Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
Mallah N, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Giné-Vázquez I, Mirás-Carballal S, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, González-Pérez JM, Razzini JL, Rivero-Calle I, Dacosta-Urbieta AI, Harris RC, Loiacono MM, van Aalst R, Farre JM, Dufournet M, Johansen ND, Modin D, Biering-Sørensen T, Duran-Parrondo C, Martinón-Torres F; GALFLU trial team.Vaccine. 2026 Mar 9;79:128435. doi: 10.1016/j.vaccine.2026.128435. Online ahead of print.PMID: 41806760

Leveraging Naturally Assembled Tumor Extracellular Vesicles as Self-Adjuvanting Nanovaccines to Potentiate Cancer Immunotherapy via cGAS/STING Activation.
Gong J, Liang K, Sun Y, Xie L, Huang Y, Song Q, Xie J, Li J, Zhou S, Chen J.ACS Nano. 2026 Mar 3;20(8):6742-6756. doi: 10.1021/acsnano.5c15637. Epub 2026 Feb 18.PMID: 41706104

Dengue in deployed military personnel, 1905-2024: a systematic review of incidence, diagnostics and prevention.
Agboli E, Jöst H, Frangoulidis D, Song LH, Anh DD, Katsounas A, Velavan TP, Schmidt-Chanasit J.J Travel Med. 2026 Mar 2;33(2):taaf120. doi: 10.1093/jtm/taaf120.PMID: 41283862

Potential induction of protective anti-tumor immune response in cancer patients by oncolytic viruses containing the GGTA1 gene.
Galili U, Zhao Y.Eur J Cancer. 2026 Mar 11;236:116251. doi: 10.1016/j.ejca.2026.116251. Epub 2026 Jan 23.PMID: 41707512 Review.

Development and evaluation of recombinant protective antigen (rPA)-based indirect-ELISA for sero-monitoring of anthrax-specific antibodies in sheep.
Sairam S, Hemanth RA, Bindu S, Namrutha MR, Shirisha A, Pooja PS, Prajapati A, Yogisharadhya R, Mohanty NN, Singh SK, Chanda MM, Shivachandra SB.Res Vet Sci. 2026 Mar;201:106058. doi: 10.1016/j.rvsc.2026.106058. Epub 2026 Jan 6.PMID: 41512639

Population-Level Impact of the Enterovirus A71 Vaccination Program on Hand, Foot, and Mouth Disease: Ecological Time-Series Study.
Tong Y, Fan H, Wang J, Zeng X, Cheng X, Bao C, Zhu L, Ji H, Huo X.JMIR Public Health Surveill. 2026 Mar 10;12:e85604. doi: 10.2196/85604.PMID: 41805655 **Free PMC article.**

Validation of Guillain-Barré syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria.
Sabaté M, Riera-Arnau J, Ballarín E, Parés-Badell O, Martínez X, Carreras JJ, Villalobos F, Yeomans A, Morton K, Urchueguía Fornes A, Solórzano M, Roy D, Correcher-Martinez E, Bissacco CA, Aurelius T, Di Mauro G, Clothier H, Griffin J, Jiang Y, Kwong JC, Sturkenboom M.Vaccine. 2026 Mar 9;78:128397. doi: 10.1016/j.vaccine.2026.128397. Online ahead of print.PMID: 41806493

Immunogenicity of Three-session Intradermal Rabies Post-exposure Prophylaxis in Indian Children and Adolescents.

Agarwal A, Rana S, Mathur SB, Manchanda V, Agarwal K, Singh M.Pediatr Infect Dis J. 2026 Mar 1;45(3):280-283. doi: 10.1097/INF.0000000000005004. Epub 2025 Sep 17.PMID: 40966763

Methods for 2025 HELPinKids&Adults and Clinical Practice Guideline for Reducing Distress during Vaccination.
Taddio A, Shah V, McMurtry CM, Lang E, MacDonald NE, Constantin K, Uleryk E; HELPinKids&Adults Team.Clin J Pain. 2026 Mar 12. doi: 10.1097/AJP.0000000000001371. Online ahead of print.PMID: 41814946

Factors Associated with Human Papillomavirus Vaccination Intention Among Young Men in Japan: A Cross-Sectional Study.
Ando H, Shen J, Morishige KI, Watanabe H.J Community Health. 2026 Mar 7. doi: 10.1007/s10900-026-01564-z. Online ahead of print.PMID: 41793608

Chitosan nanoparticle based deltagE IBRV **Vaccine**: A Novel DIVA compatible strategy for enhanced immunity in guinea pigs.
Pawaskar NK, Kumar A, Saini M, Gupta PK.Int J Pharm. 2026 Mar 10;692:126626. doi: 10.1016/j.ijpharm.2026.126626. Epub 2026 Jan 30.PMID: 41621499

A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.
Bever KM, Huff AL, Danilova L, Wetzel M, Tandurella JA, Durham JN, Wang T, Lee JW, Coyne EM, Montagne JM, Mitchell JT, Hernandez AG, Shin SM, Anders RA, Wang H, Fertig EJ, Jaffee EM, Le DT, Ho WJ.Cancer Immunol Res. 2026 Mar 4;14(3):411-422. doi: 10.1158/2326-6066.CIR-25-0545.PMID: 41524570 **Free PMC article.** Clinical Trial.

COVID-19 Vaccination and Impact on Morbidity Among Nursing Home Residents, October 2024-January 2025: An Ecological Analysis.
Khan FL, Boucher J, Wiemken TL, Cook AD, Bergroth T, Yehoshua A, Zasowski EJ, Lopez SMC, Puzniak LA.J Am Med Dir Assoc. 2026 Mar;27(3):106029. doi: 10.1016/j.jamda.2025.106029. Epub 2026 Jan 6.PMID: 41389841 **Free article.**

Increasing the Rates of Postpartum Measles, Rubella, and Varicella Vaccination in Nonimmune Mothers: An Electronic Medical Record-Based Quality Improvement Intervention.
Park J, Kwon DY, Sue R, Bahl K, Wang A, Gamboa S, Linker AS, Aoun R, Abraham C.Am J Perinatol. 2026 Mar;43(4):519-526. doi: 10.1055/a-2651-6147. Epub 2025 Jul 9.PMID: 40633814

Managing Fever and Vaccination Risks in Dravet Syndrome: From Pathophysiology to Clinical Practice.
Ferretti A, Bianchi M, Costa M, Di Nardo G, Mennini M, Perilli L, Perulli M, Riva A, Striano P, Parisi P.J Child Neurol. 2026 Mar 4:8830738261420285. doi: 10.1177/08830738261420285. Online ahead of print.PMID: 41778674

Unexpected Applications of AlphaFold in Molecular Sciences.
Jiang J, Wang G, Li D, Hayes N, Jones B, Shi Y, Qiu H, Zhang B, Zhou T, Wei GW.Annu Rev Biochem. 2026 Mar 9. doi: 10.1146/annurev-biochem-051424-071952. Online ahead of print.PMID: 41801768 Review.

Statistical Methods for Multi-jurisdictional Australian **Vaccine** Safety Investigations of Rare Adverse Events.
Morgan HJ, Bloomfield L, Clothier HJ, Ngeh S, Cadby G, Carcione D, Boyd JH, Kattan GS, Buttery JP, Effler P.Drug Saf. 2026 Mar;49(3):353-365. doi: 10.1007/s40264-025-01615-9. Epub 2025 Oct 1.PMID: 41032228 **Free PMC article.**

Stable expression of Interleukin-18 in a live-attenuated PRRSV backbone confers safe and potent immune protection in pigs.
Guo Z, Li J, Luo M, Shuai W, Zhou Y, Jiang Y, Li L, Tong W, Tong G, Zeng Y, Wang J, Gao F.Int J Biol Macromol. 2026 Mar 3:151172. doi: 10.1016/j.ijbiomac.2026.151172. Online ahead of print.PMID: 41786181

Immunogenicity of SARS-CoV-2 **vaccine** prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
Dislers A, Nilova O, Jansons J, Skrastina D, Bogans J, Petrovskis I, Spunde K, Stepanovs R, Kazaks A, Zajakina A, Sominskaya I.J Gen Virol. 2026 Mar;107(3):002240. doi: 10.1099/jgv.0.002240.PMID: 41785011 **Free PMC article.**

Protein Vesicles as Emerging Platforms for Drug Delivery, Vaccines, and Immunotherapy.
Tasnim N, Jang Y.Annu Rev Chem Biomol Eng. 2026 Mar 6. doi: 10.1146/annurev-chembioeng-100724-084456. Online ahead of print.PMID: 41791407 Review.

Ensuring the Public Health Impact of Malaria Vaccination in High-Transmission Settings.
Bell GJ, Emch ME, Moormann AM, Bailey JA.Am J Trop Med Hyg. 2026 Jan 15;114(3):410-412. doi: 10.4269/ajtmh.25-0613. Print 2026 Mar 4.PMID: 41666430

In the shadow of HIV: Fear, rumor, and stigma among young women living with HIV in COVID-19 pandemic in Western Kenya.
Yusuf MF, Onyango-Ouma W, Prince RJ, Geissler PW.Med Anthropol Q. 2026 Mar;40(1):e70026. doi: 10.1111/maq.70026. Epub 2025 Oct 22.PMID: 41124378

Endemicity of a Yellow Fever Virus Strain Revealed by Entomological Surveillance in Southeastern Senegal.
Gaye A, Ndione MHD, Ndiaye EH, Dieng M, Gaye M, Doukanda SFM, Sankhe S, Fall G, Weaver SC, Diagne MM, Diallo M.Am J Trop Med Hyg. 2025 Dec 16;114(3):536-539. doi: 10.4269/ajtmh.25-0430. Print 2026 Mar 4.PMID: 41666455

Post-infectious Basal Ganglia Encephalitis Caused by Mumps: A Case Series.
Kamate M, Pawar G, Hattiholi V.J Child Neurol. 2026 Mar 10:8830738261422782. doi: 10.1177/08830738261422782. Online ahead of print.PMID: 41804778

Epitope-spanning antigenic variation reprograms immunodominance and broadens immunity in sequential influenza vaccination.
Wan XF, Guan M, Balamalaliyage P, Chen H, Prasai K, Alcala A, Driver J, Olivier AK, Gu W, Frymire C, Madrid DMC, Gao C, Wang C, Li T, Tunterak W, Yang Q, Ramesh A, Ali M, Smith D, Li L, Sant AJ, Hang J, Xie H, Zhou M, Tao YJ.Nat Commun. 2026 Mar 2. doi: 10.1038/s41467-026-70202-y. Online ahead of print.PMID: 41771913 **Free article.**

Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions.
Jamwal S, Calhoun C, Mohanty S, Montgomery RR, Krishnamurti L, Shaw AC, Yildirim I.Immunology. 2026 Mar;177(3):445-456. doi: 10.1111/imm.70080. Epub 2025 Dec 12.PMID: 41387179 **Free PMC article.** Review.

Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort.
Neo YN, Martinez-Alvarez L, Davagnanam I, Girafa G, Bremner F, Braithwaite T, Khaleeli Z, Nowak V, Toosy AT, Petzold A; International Consortium on Optic Neuritis (ICON).Graefes Arch Clin Exp Ophthalmol. 2026 Mar;264(3):851-862. doi: 10.1007/s00417-025-06805-w. Epub 2025 Nov 29.PMID: 41318886 **Free PMC article.**

Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation.
Atabey T, Derking R, Newby ML, Bouhuijs JH, Snitselaar JL, Vink M, Aldon Y, Allen JD, Crispin M, Sanders RW.J Virol. 2026 Mar 4:e0148125. doi: 10.1128/jvi.01481-25. Online ahead of print.PMID: 41778789 **Free article.**

Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
Moser ITK, Dobrescu AI, Sommer I, Goeschl S, Sharifan A, Ledinger D, Klerings I, Gartlehner G.Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05536. Online ahead of print.PMID: 41771131 Review.

Adult dengue vaccination in a low transmission setting: A modelling study in Singapore.
Senapati A, Thein TL, Leo YS, Clapham HE.PLoS Negl Trop Dis. 2026 Mar 2;20(3):e0014062. doi: 10.1371/journal.pntd.0014062. eCollection 2026 Mar.PMID: 41770744 **Free PMC article.**

Cytotoxic and immunomodulatory activity of CD151-LEL-based peptides in breast cancer and THP-1 cells.

Vempati RK, Malla R.Hum Immunol. 2026 Mar;87(3):111676. doi: 10.1016/j.humimm.2026.111676. Epub 2026 Feb 1.PMID: 41628581

Persistent measles immunization gaps in LMICs: Insights from the 2024 revision of the WHO/UNICEF estimates of National Immunization Coverage.
Mwale M.Vaccine. 2026 Mar 7;75:128298. doi: 10.1016/j.vaccine.2026.128298. Epub 2026 Jan 31.PMID: 41621116

Incidence and bacterial etiology of acute otitis media in children in the pneumococcal conjugate **vaccine** era: A systematic literature review and meta-analysis.
Bhuiyan MU, Hernandez-Suarez G, Pilishvili T, Mayer B, Abbing-Karahagopian V.Vaccine. 2026 Mar 7;75:128270. doi: 10.1016/j.vaccine.2026.128270. Epub 2026 Jan 29.PMID: 41616651 **Free article.** Review.

Adapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission.
Spencer JC, Burger EA, Portnoy A, Campos NG, Regan MC, Sy S, Kim JJ.Med Decis Making. 2026 Mar 6:272989X261425681. doi: 10.1177/0272989X261425681. Online ahead of print.PMID: 41792911 **Free PMC article.**

Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.
Jarrard D, Eickhoff J, Kyriakopoulos CE, Jeon D, Tonelli TP, Johnson L, Huang W, McNeel DG.J Immunother Cancer. 2026 Mar 4;14(3):e013790. doi: 10.1136/jitc-2025-013790.PMID: 41781018 **Free PMC article.** Clinical Trial.

Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox.
Wang W, Gao Q, Li Y, Guo H, Zheng J, Fu Y, Liao Y.J Nanobiotechnology. 2026 Mar 8. doi: 10.1186/s12951-025-03876-z. Online ahead of print.PMID: 41796317 **Free article.** Review.

Demographic and genetic factors shape the epitope specificity of the human antibody repertoire against viruses.
Olin A, Pou C, Jaquaniello A, Crook J, Tan Z, Roux M, Dubois F, Charbit B, Liu D, Donnadieu F, Garcia L, Lambert C, Bloch E, Clave E, Araujo IL, Toubert A, Rotival M, Simon-Lorière E, White M, Brodin P, Duffy D, Quintana-Murci L, Patin E; Milieu Intérieur Consortium.Nat Immunol. 2026 Mar;27(3):600-612. doi: 10.1038/s41590-026-02432-7. Epub 2026 Feb 16.PMID: 41699059 **Free PMC article.**

Complete and partial forms of X-linked MCTS1 deficiency in patients with mycobacterial disease.
Zhou Q, Bagarić I, Komma F, Prakash C, Abolhassani H, Chavoshzadeh Z, Tsao L, Vatovec T, Soudée C, Rosain J, Minter DJ, Lu C, Al-Sukaiti N, Wu B, Sun J, Zhang Q, Casanova JL, Pan-Hammarström Q, Chan AY, Al-Farsi T, Wang X, Bustamante J, Bohlen J.J Hum Immun. 2026 Jan

30;2(2):e20250073. doi: 10.70962/jhi.20250073. eCollection 2026 Mar 2.PMID: 41623352 **Free PMC article.**

The promises and challenges of neoantigen cancer vaccines.
Ott PA.Nat Biotechnol. 2026 Mar 10. doi: 10.1038/s41587-026-03018-2. Online ahead of print.PMID: 41807825 Review.

Antibody-mediated feedback modulates interclonal competition in the germinal center.
Barbulescu A, Bilanovic J, Langelaar T, Teetz AK, Urnavicius L, Hobbs A, Shen JJ, Abrahamse NH, de Carvalho RVH, Mesin L, Ferreira CL, Bortolatto J, Victora GD.Immunity. 2026 Mar 10;59(3):734-745.e5. doi: 10.1016/j.immuni.2026.01.008. Epub 2026 Feb 24.PMID: 41742422 **Free article.**

Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses.
Moriyama S, di Iulio J, Zatta F, Hauser K, Asanuma H, Muñoz HE, Errico JM, Adachi Y, Dang HV, Czudnochowski N, Sasaki E, Chen A, Chen YP, Kotaki R, Peter A, Vetti E, Onodera T, Cyrus Maher M, Rosen LE, Shirakura M, Snell G, Hasegawa H, Takahashi Y, Corti D, Pizzuto MS.Nat Commun. 2026 Mar 2. doi: 10.1038/s41467-026-70036-8. Online ahead of print.PMID: 41771877 **Free article.**

Large language models for bioinformatics.
Ruan W, Lyu Y, Zhang J, Cai J, Shu P, Ge Y, Lu Y, Gao S, Wang Y, Wang P, Zhao L, Wang T, Liu Y, Fang L, Liu Z, Liu Z, Li Y, Wu Z, Chen J, Jiang H, Pan Y, Yang Z, Chen J, Liang S, Zhang W, Ma T, Dou Y, Zhang J, Gong X, Gan Q, Zou Y, Chen Z, Qian Y, Yu S, Lu J, Song K, Wang X, Sikora A, Li G, Li X, Li Q, Wang Y, Zhang L, Abate Y, He L, Zhong W, Liu R, Huang C, Liu W, Shen Y, Ma P, Zhu H, Yan Y, Zhu D, Liu T.Quant Biol. 2025 Sep 28;14(1):e70014. doi: 10.1002/qub2.70014. eCollection 2026 Mar.PMID: 41676319 **Free PMC article.** Review.

Early Measles Vaccination in Infants less than 12 Months: Global Practices, Immunity Outcomes, and Implications for Disease Prevention.
AlSaihati A, Chaudhary M, Olarte L.J Pediatric Infect Dis Soc. 2026 Mar 12:piag018. doi: 10.1093/jpids/piag018. Online ahead of print.PMID: 41818477

Pre-existing influenza antibodies, younger age, and increased CD4 T_{E+EM} predict influenza vaccination responses in transplant recipients.
Rollenhagen C, Parvathinathan G, Stedman MR, Chalasani G, Birdwell KA, Sanders ML, Ramkumar M, Higdon LE, Ye N, Santos JJS, Hensley SE, Maltzman JS.Hum Immunol. 2026 Mar 10;87(5):111721. doi: 10.1016/j.humimm.2026.111721. Online ahead of print.PMID: 41812549

A human cerebral organoid model of West Nile virus encephalitis shows innate immunocompetency.
Steffen JF, Widerspick L, Jansen S, Tappe D.Nat Commun. 2026 Mar 7;17(1):2318. doi: 10.1038/s41467-026-70281-x.PMID: 41794851 **Free PMC article.**

What's Hot in HIV in 2025-A Basic and Translational Science Review from IDWeek 2025.

Teixeira AR, Caskey M.J Infect Dis. 2026 Mar 3:jiag135. doi: 10.1093/infdis/jiag135. Online ahead of print.PMID: 41774769

The effect of school-based educational session on knowledge, attitudes, and beliefs of cervical cancer among adolescents in mixed day high schools in Embu County: a quasi-experimental study.
Kivuti-Bitok LW, Mugo CW, Mituki D, Marete C, Ngune I, Wells J.BMC Public Health. 2026 Mar 11. doi: 10.1186/s12889-026-26675-z. Online ahead of print.PMID: 41814231

Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study.
Luo X, Liu H, Kuang H, Xie Y, Zhang R, Zhu Y, Ning B.Virus Res. 2026 Mar;365:199700. doi: 10.1016/j.virusres.2026.199700. Epub 2026 Feb 4.PMID: 41643751 **Free PMC article.**

Advances in Staphylococcus aureus extracellular vesicles: navigating challenges, embracing prospects.
Fu C, Li Z, Sun Y, Lin S, Yang X, Li X.Lett Appl Microbiol. 2026 Mar 6;79(3):ovag009. doi: 10.1093/lambio/ovag009.PMID: 41728926 Review.

Plant-produced monoclonal antibodies recognize the native circumsporozoite protein on *Plasmodium falciparum* sporozoites.
Thiganta K, Rattanapisit K, Suwanchaikasem P, Roobsoong W, Bulaon CJI, Phoolcharoen W.Biotechnol Rep (Amst). 2025 Dec 30;49:e00944. doi: 10.1016/j.btre.2025.e00944. eCollection 2026 Mar.PMID: 41550789 **Free PMC article.**

Mitochondrial Electron Transport Chain Modulation Orchestrates Divergent TLR3 and TLR7 Responses.
Sheridan ME, Ahmed D, Al Daraawi M, Kovac N, Cassol E.J Leukoc Biol. 2026 Mar 11:qiag034. doi: 10.1093/jleuko/qiag034. Online ahead of print.PMID: 41811758

The X Factor in Immunity: Sex Differences Shaped by the X Chromosome.
Radovanovic KB, Wynalda M, Anguera MC.Immunol Rev. 2026 Mar;338(1):e70107. doi: 10.1111/imr.70107.PMID: 41574968 **Free PMC article.** Review.

Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy.
Li B, Liu G, Zhu Y, Chen L, Zhang N, Zhu X, Sun Y, Liu X, Liu W, Ma Y, Tian X, Yang Y, Zhu M.Cell Host Microbe. 2026 Mar 6:S1931-3128(26)00078-8. doi: 10.1016/j.chom.2026.02.010. Online ahead of print.PMID: 41794037

Local antibody feedback enforces a checkpoint on affinity maturation in the germinal center and promotes epitope spreading.
Yan Y, Wang X, Xie Z, Bader DLV, Lim RH, Ma KM, Cottrell CA, Steichen JM, Xu L, Villavicencio PM, Akauliya M, Koo JH, Shen JM, Vernich A, Kalyuzhniy O, Allen JD, Albowaidey AA, Alicea A, Chen B, Georgeson E, Ellis-Pugh JR, Alavi N, Esposito A, Naili H, Phelps N, Kelley B, Kubitz M, Phan QA,

Liguori A, Prum T, Tingle R, Lu D, Eskandarzadeh S, Liu X, Warner JE, Weldon SR, Himansu S, Crispin M, Nair U, Liu S, Schief WR, Batista FD.Immunity. 2026 Mar 10;59(3):746-767.e9. doi: 10.1016/j.immuni.2026.01.011. Epub 2026 Feb 13.PMID: 41690309 **Free article.**

First description of Siberian sturgeon herpesvirus-induced mortality in Russian sturgeon (Acipenser gueldenstaedtii) and in Siberian sturgeon (Acipenser baerii) in Hungary: An emerging pathogen in aquaculture.
Hoitsy M, Mitró G, Gál J, Sós E, Bali K, Sós-Koroknai V, Ziszisz Á, Tóth T, Abonyi F, Doszpoly A.Acta Vet Hung. 2025 Nov 25;74(1):14-18. doi: 10.1556/004.2025.01226. Print 2026 Mar 4.PMID: 41288612

Nanovaccines in cancer immunoprevention and immunotherapy: Current insights and future directions.
Uti DE, Alum EU, Ugwu OP.Cancer Treat Res Commun. 2026 Mar 5;47:101166. doi: 10.1016/j.ctarc.2026.101166. Online ahead of print.PMID: 41802376 Review.

Conserved CD4⁺ T cell staphylococcal and streptococcal epitopes enable broad-acting vaccines in mice.
Braverman J, Monk IR, Turner AM, Braun A, Zhang H, Chung S, Jones CM, Zareie P, La Gruta NL, Rimmer J, Carter GP, Howden BP, Wang N, Purcell AW, Stinear TP, Wakim LM.Nat Microbiol. 2026 Mar;11(3):731-746. doi: 10.1038/s41564-026-02265-y. Epub 2026 Feb 19.PMID: 41714815

Risk Communications and Community Engagement for COVID-19 **Vaccine** Uptake Among Indigenous Peoples in the Americas: The Experience in Colombia.
González Abril K, Sarmiento JCA, Escamilla T.Health Commun. 2026 Mar;41(3):426-434. doi: 10.1080/10410236.2024.2446971. Epub 2026 Feb 12.PMID: 41674492

Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.
Relano-Rodriguez I, Du J, Lin ZJ, Kerwin M, Tarquis-Medina M, Urbano E, Cui J, Watkins M, Lavine CL, Zhao P, Habib R, Agostino C, Ghosh S, Park J, Boroughs C, Walsh AA, Melo MB, Shukla N, Shaw GM, Hahn BH, Irvine DJ, Wells L, Weiner DB, Seaman MS, Kulp DW, Veazey RS, Pallesen J, Escolano A.Nat Immunol. 2026 Mar;27(3):586-599. doi: 10.1038/s41590-025-02408-z. Epub 2026 Feb 3.PMID: 41634485 **Free PMC article.**

UL24 deletion attenuates Marek's disease virus replication and pathogenicity.
Kang Y, Yang X, Wang R, Zhu W, Yao L, Lv L, Du Y, Zhuang G, Sun A.Vet Microbiol. 2026 Mar;314:110903. doi: 10.1016/j.vetmic.2026.110903. Epub 2026 Jan 22.PMID: 41610489

Poly(A) variants supporting robust transmission stability in bacteria and high protein expression in animals for mRNA *in vitro* transcription.

Chen H, Qin W, Bao H, Chen X, Ye X, Wang Y, Liu L, Zhang Y, Sun Y, Zhang T, Dong Y, Cen S, Zhang W.Mol Ther Nucleic Acids. 2025 Dec 22;37(1):102809. doi: 10.1016/j.omtn.2025.102809. eCollection 2026 Mar 12.PMID: 41552384 **Free PMC article.**

Insights into host responses, viral evolution, and implications for vaccines and therapeutics for Mpox.
Garnier N, Schinazi RF, Titanji BK.Curr Opin HIV AIDS. 2026 Mar 1;21(2):110-117. doi: 10.1097/COH.0000000000001009. Epub 2026 Jan 5.PMID: 41492168 Review.

Physicochemical properties and immunological effects of macrophage membrane-coated PLGA nanoparticles loaded with Hericium erinaceus polysaccharides.
Qin T, Hong A, Lin Y, Zheng Z, Fan G, Chen C, Ren Z.Colloids Surf B Biointerfaces. 2026 Mar;259:115366. doi: 10.1016/j.colsurfb.2025.115366. Epub 2025 Dec 11.PMID: 41389608

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection.
Yan H, Li Y, Liu C, Guo H, Liu Y, Wang H, Ge X, Zhang Z, Ju B.Microbiol Spectr. 2026 Mar 11:e0263825. doi: 10.1128/spectrum.02638-25. Online ahead of print.PMID: 41810956 **Free article.**

Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.
Ortiz-Prado E, Prieto-Marin JG, Izquierdo-Condoy JS, Vasconez-Gonzalez J, Villamil-Parra WA, Viscor G, Niño-Méndez ÓA, Correa-Bautista JE, Rusiñol M, Cevallos-Robalino D, Navarro JC, Villalobos-Madriz JA.Lancet Reg Health Am. 2026 Mar 4;56:101431. doi: 10.1016/j.lana.2026.101431. eCollection 2026 Apr.PMID: 41809389 **Free PMC article.** Review.

Excipients: New opportunities for complex challenges USP's approaches to addressing complex challenges related to excipients.
Sheehan C, Liu J, Zhang P, Wang H, Chang A.Eur J Pharm Biopharm. 2026 Mar 7:115045. doi: 10.1016/j.ejpb.2026.115045. Online ahead of print.PMID: 41802499 Review.

Structural and binding studies of the mycobacterial heat shock protein reveal a silent state and offer insights into dendritic cell activation.
Barra G, Sala M, Scala MC, Campiglia P, Kim HJ, Ruggiero A, Berisio R.Int J Biol Macromol. 2026 Mar 5;353:151218. doi: 10.1016/j.ijbiomac.2026.151218. Online ahead of print.PMID: 41794242

[Prevention of infectious diseases : The role of infectious disease specialists].
Vehreschild M, de With K, Kramme E, Lehmann C, Schelling J, Schenkel-Häger C, Fätkenheuer G.Inn Med (Heidelb). 2026 Mar 5. doi: 10.1007/s00108-026-02071-y. Online ahead of print.PMID: 41784780 Review. German.

Analyzing the impact of gender-specific vaccination strategies and behavioral dynamics on HPV transmission.
Jahan N, Hossain MS, Ariful Kabir KM.Sci Rep. 2026 Mar 4. doi: 10.1038/s41598-026-40661-w. Online ahead of print.PMID: 41781446 **Free article.**

Synthesis of Carbohydrate Derivatives in multicomponent reactions: Approaches and applications.
Andrade IMG, Lima Filho EO, Desmarais MOL, Valadão CLF, Forezi LDSM, da Silva FC.Carbohydr Res. 2026 Mar;561:109809. doi: 10.1016/j.carres.2025.109809. Epub 2025 Dec 29.PMID: 41477934 Review.

Reducing Vaccination Pain in Infants: A Randomized Controlled Trial on the Effects of ShotBlocker and Manual Pressure.
Kışlalı Taş Ş, Sari D, Taşkıran N.Clin Pediatr (Phila). 2026 Mar;65(3):317-325. doi: 10.1177/00099228251387875. Epub 2025 Oct 29.PMID: 41159533 Clinical Trial.

A Case for Anti-IgE Vaccination.
Engeroff P, Gharailoo Z, Vogel M, Bachmann MF.Allergy. 2026 Mar 11. doi: 10.1111/all.70287. Online ahead of print.PMID: 41814126 Review.

Harnessing genomics for identifying disease-resistant eels: Advances, applications, and sustainable aquaculture.
Liu M, Zhou K, Liu Z, Wei S, Ribas L, Cao Q.Comp Biochem Physiol Part D Genomics Proteomics. 2026 Mar;57:101695. doi: 10.1016/j.cbd.2025.101695. Epub 2025 Nov 19.PMID: 41297417 Review.

Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies.
Depierreux DM, Ruiz F, Lilly M, Guenthoer J, Chohan V, Overbaugh J.PLoS Pathog. 2026 Mar 12;22(3):e1014026. doi: 10.1371/journal.ppat.1014026. Online ahead of print.PMID: 41818265

Production of Recombinant Neuraminidase NA Protein of Influenza A/H5N2 Virus and Its Application for the Detection of Virus-Specific IgG to Influenza A Viruses.
Gupalova TV, Bormotova EA, Leontieva GF, Kramskaya TA, Desheva YA, Suvorov AN.Bull Exp Biol Med. 2026 Mar 11. doi: 10.1007/s10517-026-06614-z. Online ahead of print.PMID: 41811411

Computational modelling of the equine arteritis virus GP5/M Dimer: Implications for immune evasion and virulence.
Veit M, Matczuk AK.PLoS One. 2026 Mar 10;21(3):e0344287. doi: 10.1371/journal.pone.0344287. eCollection 2026.PMID: 41805756 **Free PMC article.**

[Measles immunity in the Swedish population].
Hagstam P, Englund H.Lakartidningen. 2026 Mar 6;123:25144.PMID: 41787919 **Free article.** Review. Swedish.

Ten years of Zika in Brazil: achievements, challenges and perspectives.
Yuji Sasazaki F, Tudella GCN, de Oliveira-Filho EF, Lopes TRR, Carmo RF, Flores EF, Silva Júnior JVJ.Virol J. 2026 Mar 2;23(1):57. doi: 10.1186/s12985-026-03093-6.PMID: 41772670 **Free PMC article.** Review.

Evolution of H5N1 Cross-Species Transmission: Adaptive Mutations Driving Avian-to-Human Infection.
Man W, Du L, Liu Y, Pang Z, Zhu H, Hong B, Xu Z, Fan H.Adv Genet (Hoboken). 2026 Jan 11;7(1):e00051. doi: 10.1002/ggn2.202500051. eCollection 2026 Mar.PMID: 41531488 **Free PMC article.**

HPV vaccination is associated with lower risk of cancers among females.
Hung YM, Lin TT, Wang SI, Wu PJ, Chang R, Wei JC.Am J Med. 2026 Mar;139(3):311-320.e12. doi: 10.1016/j.amjmed.2025.10.016. Epub 2025 Oct 24.PMID: 41138956

Vaccination recommendations and adherence in Inflammatory Bowel Disease: a physician-patient discordance study.
Ferreiro-Iglesias R, Hernández-Camba A, Valdivia A, Rodríguez-Lago I, Zabana Y, Acosta MB; GETECCU Youth Group and ACCU Spain.Gastroenterol Hepatol. 2026 Mar 2:502714. doi: 10.1016/j.gastrohep.2026.502714. Online ahead of print.PMID: 41780635 English, Spanish.

First isolation of nontoxigenic tox gene-bearing Corynebacterium ulcerans from a diphtheria case in Minas Gerais, Brazil.
Couto Calazans Silva A, de Oliveira Sant'Anna L, Nunes Soares PC, do Carmo Sant'Anna Cardoso T, Nunes Ramos J, Mattos-Guaraldi AL, Sanches Dos Santos L.Braz J Microbiol. 2026 Mar 2;57(1):66. doi: 10.1007/s42770-026-01878-z.PMID: 41770434 **Free PMC article.**

Sex Differences in the Impact of Obesity on Immunity.
Vijayakumar S, Pantha S, Budha Magar S, Dhakal S.Immunol Rev. 2026 Mar;338(1):e70101. doi: 10.1111/imr.70101.PMID: 41575180 **Free PMC article.** Review.

Expansion of cluster 3 Tembusu virus in Guangdong geese with hepatitis-splenomegaly syndrome and evidence of recombination.
Yang CC, Tan WH, Zou RJ, Liang Y, Zhang XL, Shao JW.Comp Immunol Microbiol Infect Dis. 2026 Mar;126:102439. doi: 10.1016/j.cimid.2026.102439. Epub 2026 Jan 15.PMID: 41544371

Chapare Virus: A Re-Emerging Zoonotic Arenavirus With Limited Preparedness.
Sharmin S, Raj A, Zawad MA, Jahan A, Ahmed Z, Khair Fatema MU.Rev Med Virol. 2026 Mar;36(2):e70111. doi: 10.1002/rmv.70111.PMID: 41640223 Review.

Epidemiological investigation and public health response to a diphtheria outbreak in Jalalabad Union, Sylhet, December 2023.
Hassan MM, Rahman S, Islam MF, Sultana S, Habib MA, Hassan MR, Qayum MO, Jony MHK, Habib ZH, Alam AN, Rahman M, Shirin T.IJID Reg. 2025 Nov 16;18:100805. doi: 10.1016/j.ijregi.2025.100805. eCollection 2026 Mar.PMID: 41487598 **Free PMC article.**

Structure and functional role of the SLHs-CBM54 tandem in bacterial multimodular glycoside hydrolases.
Berezina OV, Selimzyanova AI, Gordeev KV, Schwarz WH, Lunina NA.Enzyme Microb Technol. 2026 Mar;194:110787. doi: 10.1016/j.enzmictec.2025.110787. Epub 2025 Nov 21.PMID: 41289733 Review.

Engineering of cell line assembled enteric organoid for enterovirus infection.
Moghe AS, Nandi SS, Bhonde RR, Kamyab SS, Sawant SA, Karandikar MN.Arch Virol. 2026 Mar 10;171(4):118. doi: 10.1007/s00705-026-06541-4.PMID: 41805869

Decoding the Glycan Shield: Immune Recognition and Response to the HIV-1 Envelope Trimer.
Nawaz Z, Adams T, Demirturk ME, Avci FY.J Biol Chem. 2026 Mar 6:111350. doi: 10.1016/j.jbc.2026.111350. Online ahead of print.PMID: 41796803 **Free article.** Review.

Managing Infodemics in Africa: The Role of the Africa Infodemic Response Alliance (AIRA) in Advancing Theory and Practice During the COVID-19 Pandemic.
Anoko JN, Kobie AG, Ho E, Rahman MM, Nyawade S, Sowo L, Abdulrahman DI, Cordero JP, Kirigia D, Bailo DA, Nanyunja M, Braka F, Chamla D, Gueye AS, Moeti M.Health Commun. 2026 Mar;41(3):455-461. doi: 10.1080/10410236.2025.2556969. Epub 2026 Feb 12.PMID: 41674494

Rotavirus induces mucosal B-cell responses through the TLR3/TRIF and MAVS pathways.
Zhang RR, Yang YY, Wang M, Yang WR, Azeem RM, Niu FX, Yang YX, Hu MJ, Shi CW, Yang GL, Huang HB, Wang JZ, Jiang YL, Cao X, Wang N, Zeng Y, Yang WT, Wang CF.Vet Microbiol. 2026 Mar;314:110910. doi: 10.1016/j.vetmic.2026.110910. Epub 2026 Jan 30.PMID: 41621168

Engineering bright and genetically stable fluorescent Streptococcus suis strains for functional in vitro and in vivo applications.
Saralegui L, García C, Jurado P, Bosch C, van Setten M, Wessel V, Bermúdez R, Marín C, Arenas J.Vet Microbiol. 2026 Mar 2;316:110964. doi: 10.1016/j.vetmic.2026.110964. Online ahead of print.PMID: 41793869 **Free article.**

Use of the test-negative design to estimate the protective effect of a scalar immune measure: A simulation analysis.
Zhang Z, Boyer CB, Lipsitch M.Am J Epidemiol. 2026 Mar 4:kwag036. doi: 10.1093/aje/kwag036. Online ahead of print.PMID: 41778892

Bacteriophage Therapy: Current Strategies and Future Perspectives.
Zhou Z, Fu H, Li M, Han Z, Wu Z, Fan H, Shen N, Zheng J.MedComm (2020). 2026 Mar 1;7(3):e70645. doi: 10.1002/mco2.70645. eCollection 2026 Mar.PMID: 41777249 **Free PMC article.** Review.

Brucella-infected macrophage-derived microparticles enhance the host anti-Brucella acquired immune response.

Zhang Y, Yuan J, Wu A, Wang Z, Ni R, Yan K, Liang X, He T, Gu M, Meng C, Li H, Zhang C, Sheng J, Ma Z, Xu M, Zhang Y, Zhumanov KT, Zhang J, Yi J, Wang Y.Vet Microbiol. 2026 Mar;314:110930. doi: 10.1016/j.vetmic.2026.110930. Epub 2026 Feb 6.PMID: 41666696

Monoclonal antibodies for Mpox: protective targets and therapeutic potential.
Guardado-Calvo P, Freund NT, Coelho CH.Curr Opin HIV AIDS. 2026 Mar 1;21(2):118-124. doi: 10.1097/COH.0000000000001014. Epub 2026 Jan 16.PMID: 41543221 Review.

Progress and potential of ferritin nanocages for cancer drug delivery.
Giacobbo V, Gorgoglione F, Sevieri M, Bignami B, Tagliolini I, Corsi F, Mazzucchelli S.Expert Opin Drug Deliv. 2026 Mar;23(3):467-480. doi: 10.1080/17425247.2025.2584632. Epub 2025 Nov 11.PMID: 41213168 **Free article.** Review.

Tuberculosis and inflammatory bowel disease.
Madero L, Bastón I, Brunet-Mas E, Calafat M; Grupo Joven de GETECCU.Gastroenterol Hepatol. 2026 Mar;49(3):502587. doi: 10.1016/j.gastrohep.2025.502587. Epub 2025 Oct 14.PMID: 41101460 Review. English, Spanish.

Mpox and the Ethics of Outbreak Management: Lessons for Future Public Health Crises.
Obasa AE, Botes M, Kleinsmidt A, Staunton C.Dev World Bioeth. 2026 Mar;26(1):43-49. doi: 10.1111/dewb.70001. Epub 2025 Jul 18.PMID: 40679088

Adenovirus type 5 vector-based COVID-19 **vaccine** does not increase the likelihood of HIV infection.
Ruiz-Palacios GM, Cahn PE, Halperin SA, Wang R, Wang L, Perez C, Figueroa MI, Yan M, Li R, Ye L, Huang H, Barreto L, Gou J, Zhu T.Vaccine. 2026 Mar 4;78:128378. doi: 10.1016/j.vaccine.2026.128378. Online ahead of print.PMID: 41785679

Immunosuppressive Tumor Microenvironment and Therapeutic Landscape of Diffuse Intrinsic Pontine Glioma.
Zhou S, Matosevic S.Med Res Rev. 2026 Mar 9. doi: 10.1002/med.70037. Online ahead of print.PMID: 41804105 Review.

Bispecific antibodies in solid tumors: An Italian Association of Medical Oncology (AIOM) multidisciplinary perspective on immunology and vaccination.
Lasagna A, Del Re M, Danesi R, Andreoni M, Tessitore D, Di Maio M, Silvestris N, Pedrazzoli P.Crit Rev Oncol Hematol. 2026 Mar 6;221:105253. doi: 10.1016/j.critrevonc.2026.105253. Online ahead of print.PMID: 41796915 Review.

Host-specificity assessment of feline alphaherpesvirus-1 derived immunocontraceptive candidates in non-feline models.
Cottingham E, Krekeler N, Johnstone T, Hartley C, Devlin J.Virol J. 2026 Mar 4;23(1):64. doi: 10.1186/s12985-025-03036-7.PMID: 41782150 **Free PMC article.**

Chiral Polyproline Enables Functional Stealth for Simultaneous Long Circulation and Endoplasmic Reticulum-Targeted Antigen Presentation.
Hu M, He Y, Wu L, Su W, Zhang W, Yu X, Guo M, Li Y, Lu H, Chen C, Cai R.ACS Nano. 2026 Mar 10;20(9):7908-7927. doi: 10.1021/acsnano.5c21970. Epub 2026 Feb 21.PMID: 41721792

Rare anatomical localizations of hydatid cysts (2020-2025): Narrative review of presentation, imaging, and management.
Zülfikaroğlu B, Akgül Ö, Dinç T.Turk J Surg. 2026 Mar 5;42(1):13-25. doi: 10.47717/turkjsurg.2026.2025-9-22. Epub 2026 Feb 20.PMID: 41717794 **Free PMC article.**

Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma.
Liu S, Zhang L, Wu W, Chen MY, Qian F.Mol Ther Nucleic Acids. 2025 Dec 12;37(1):102803. doi: 10.1016/j.omtn.2025.102803. eCollection 2026 Mar 12.PMID: 41541271 **Free PMC article.**

Clinical and molecular characterization of a fulminant meningococcemia case in an adult caused by Neisseria meningitidis serogroup Y clonal complex 23 strain in China.
Liang Y, Xu L, Liu S, Liang Z, Lin B, Ye J, Nie S.Diagn Microbiol Infect Dis. 2026 Mar;114(3):117242. doi: 10.1016/j.diagmicrobio.2025.117242. Epub 2025 Dec 24.PMID: 41483663

Designing a recombinant coat protein to reduce tobacco mosaic virus infection in plants.
Sheibani N, Arab SS, Kamalvand M.J Biomol Struct Dyn. 2026 Mar;44(4):1749-1755. doi: 10.1080/07391102.2024.2430456. Epub 2024 Nov 26.PMID: 39589026

T-cell-mediated immunity in mastitis: pathogen-driven cytokine networks and implications for applied microbiology.
Li B, Ming R, Yuan H, Zhang H, Zhang T.J Appl Microbiol. 2026 Mar 5:lxag067. doi: 10.1093/jambio/lxag067. Online ahead of print.PMID: 41784511

Impact of immunization strategies, public health and social measures on the incidence of varicella among children aged 0-14 years in Quzhou City.
Fang Q, Yang H, Wang S, Gong X, Zheng C, Yin Z.Hum Vaccin Immunother. 2026 Dec 31;22(1):2639804. doi: 10.1080/21645515.2026.2639804. Epub 2026 Mar 3.PMID: 41773514 **Free PMC article.**

Structural Basis of MERS-CoV Receptor Interactions and Antibody Neutralisations.
Gavor E, Choong YK, Singh S, Sivaraman H, Yin ES, Sivaraman J.Rev Med Virol. 2026 Mar;36(2):e70113. doi: 10.1002/rmv.70113.PMID: 41761653 **Free PMC article.** Review.

Proteomic Adaptations of *Escherichia coli* in Urinary Tract Infection Patients.
Nartey LK, Weke K, Yuen V, Kibsey P, Chen MX, Goodlett DR.J Proteome Res. 2026 Mar 6;25(3):1714-1723. doi: 10.1021/acs.jproteome.5c01165. Epub 2026 Feb 16.PMID: 41698857

SARS-CoV-2 mRNA vaccines: unresolved mechanisms of myocardial damage.
Glossmann HH.Arch Toxicol. 2026 Mar;100(3):1177-1180. doi: 10.1007/s00204-025-04252-4. Epub 2025 Dec 8.PMID: 41361115 Review.

Do we know about respiratory syncytial virus in Türkiye?
Başkol Elik D, Vatansever G, Taşbakan SE, Ateş S, Pullukçu H, Taşbakan M, Köksal İ.Expert Rev Respir Med. 2026 Mar;20(3):337-344. doi: 10.1080/17476348.2025.2569125. Epub 2025 Oct 4.PMID: 41038803

IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination.
Zhang W, Allen EK, Li S, Tarasova I, Farrukee R, Kedzierski L, Gilbertson B, McQuilten HA, Habel JR, Allen LF, Rockman S, Londrigan SL, Kent SJ, Wheatley AK, Trubiano JA, Kotsimbos TC, Cheng AC, Schroeder J, Crawford JC, Thomas PG, Kedzierska K, Nguyen THO.EMBO Mol Med. 2026 Mar 9. doi: 10.1038/s44321-026-00395-8. Online ahead of print.PMID: 41803327 **Free article.**

Rapid growth and thematic shifts in mRNA therapeutics research catalyzed by the COVID-19 pandemic.
Annadurai P.Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar 7. doi: 10.1007/s00210-026-05173-4. Online ahead of print.PMID: 41792451

Signatures of native-like glycosylation in RNA replicon-derived HIV-1 immunogens.
Chawla H, Willcox JT, Hayes GM, Silva M, Lee WH, Ozorowski G, Butler J, Mckay PF, Shattock RJ, Ward AB, Irvine DJ, Crispin M.RSC Chem Biol. 2026 Jan 12;7(3):400-413. doi: 10.1039/d5cb00165j. eCollection 2026 Mar 11.PMID: 41623524 **Free PMC article.**

Exosome-Based Strategies in Hepatocellular Carcinoma: Mechanisms, Immunotherapy, and Clinical Challenges.
Farah H, Kadhim-Abosaoda M, Mohaisen-Mousa H, Jyothi R, Priyadarshini-Nayak P, Janney-J B, Singh G, Singh-Chauhan A, Kumar-Mishra M.J Gastroenterol Hepatol. 2026 Mar;41(3):863-879. doi: 10.1111/jgh.70245. Epub 2026 Feb 2.PMID: 41623268 Review.

Diarrhea, Rotavirus, and the Nursing Research Gap: A Bibliometric Analysis of Global Research and Implications for Public Health Nursing.
Aydin MA, Adiyaman A, Kasimoğlu N, Gürol A.Public Health Nurs. 2026 Mar-Apr;43(2):445-459. doi: 10.1111/phn.70065. Epub 2026 Jan 9.PMID: 41510902 Review.

Natural syndemic infection between African swine fever virus (ASFV) and porcine reproductive and respiratory syndrome virus (PRRSV) leads to shifting of ASFV tissue tropism to lungs with exacerbated presentation of the disease.
Balakrishna CB, Rajkhowa TK, Jayappa K, Risatti GR.Infect Genet Evol. 2026 Mar;138:105872. doi: 10.1016/j.meegid.2025.105872. Epub 2025 Dec 30.PMID: 41478517 **Free article.**

A metabolic alarmin from keratinocytes potentiates systemic humoral immunity.
Ji Z, Gao J, Zhang S, Li J, Wu H, Yao J, Ma X, Xin Y, Zhu Y, Zhao M, Zhao Z, Shen K, Wu T, Qian X, Wang J, An H, Li Y, Sun W, Zhao Q, Zhou X, Gao R, Duan Q, Li C, Geng X, Yang M, Xiao R, Liu J, Wang W, Wang J, Fu Y, Zhang JR, Chen X, Tong P, Cheng G, Qi H, Wu L, Zeng W, Xi Q, Zhang L, Lai Y, Yang W, Zhang Y, Lu Q, Liu W.Nature. 2026 Mar 4. doi: 10.1038/s41586-026-10167-6. Online ahead of print.PMID: 41781621

Genetic polymorphism and natural selection of apical membrane antigen-1 in Plasmodium malariae isolated from Vietnam.
Nguyễn ĐTD, Lê HG, Võ TC, Nguyễn TH, Kang JM, Nguyễn KO, Trinh NTM, Van Khanh C, Hanh NTL, Van TTH, Trung NK, Cho M, Son TT, Quang HH, Na BK.BMC Infect Dis. 2026 Mar 3;26(1):476. doi: 10.1186/s12879-026-12935-1.PMID: 41776459 **Free PMC article.**

Effect of Probiotic and Synbiotic Supplementation on Growth Performance, Serum Parameters and Gut Histomorphometry in Broiler Chickens Challenged With Eimeria.
Chhetri S, Singh DK, Tiwari BB, Neupane S, Shah BR, Subedi D.Vet Med Sci. 2026 Mar;12(2):e70842. doi: 10.1002/vms3.70842.PMID: 41653099 **Free PMC article.**

Effect of Low Glucose on mRNA Delivery Efficiency via Lipid Nanoparticles and Its Underlying Mechanisms.
Hu Z, Shi L, Lin X, Zhang Q, Zhang Y, You F, Chen J, Wang H, Ye Y, Chen J, Deng W, Deng G.Mol Pharm. 2026 Mar 2;23(3):2050-2063. doi: 10.1021/acs.molpharmaceut.5c01780. Epub 2026 Feb 2.PMID: 41627893

Epidemiology and characteristics of bacterial meningitis of children with cerebrospinal fluid leakage or cochlear implant.
Levy C, Bizot E, Milcent K, Birgy A, Béchet S, Varon E, Cohen R.J Pediatric Infect Dis Soc. 2026 Mar 9:piag015. doi: 10.1093/jpids/piag015. Online ahead of print.PMID: 41800559

Prevalence and distribution of HPV types in Australian patients with oropharyngeal cancer over time.
Yaksich L, Hartel G, Panizza BJ, Whiteman DC, Antonsson A.Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70432. Online ahead of print.PMID: 41795209

Mpox Outbreak in the East Africa Region: Current Status, Containment Measures, Challenges, and Future Direction.
Sindayiheba R, Gahamanyi N, Ndayisenga J, Ntagwabira E, Nsengiyumva E, Kabalisa E, Misbah G, Mukagatare I, Mutesa L, Muvunyi CM.Public Health Chall. 2026 Feb 9;5(1):e70194. doi: 10.1002/puh2.70194. eCollection 2026 Mar.PMID: 41675254 **Free PMC article.** Review.

Distinct mechanisms of ER stress-mediated autophagy induction by high- and low-virulence pseudorabies virus strains.
Lv Y, Huang X, Lu Z, Feng X, Ouyang K, Chen Y, Wei Z, Huang W, Qin Y.Vet Microbiol. 2026 Mar;314:110914. doi: 10.1016/j.vetmic.2026.110914. Epub 2026 Jan 30.PMID: 41621166

Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.
Kenealy T, Aguirre-Duarte N, Roxburgh RH, Royle G, Mitchelson B, Ingram J, Williams N, Petousis-Harris H.Vaccine. 2026 Mar 7;75:128275. doi: 10.1016/j.vaccine.2026.128275. Epub 2026 Jan 31.PMID: 41621119 **Free article.**

The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints.
Stuart R, Theopold N, Miall N, Kobayashi E, Vernam S, Taskin T, Dull PM.Vaccine. 2026 Mar 7;75:128187. doi: 10.1016/j.vaccine.2025.128187. Epub 2026 Jan 22.PMID: 41576708

Extracellular vesicles from microalgae Pavlova in non-heated condition potently enhance innate immune response as a novel cell-derived immunostimulatory adjuvant.
Morishita M, Yamada K, Taira T, Nakahara K, Waku T, Minato K, Ogawara KI.J Pharm Sci. 2026 Mar;115(3):104158. doi: 10.1016/j.xphs.2026.104158. Epub 2026 Jan 10.PMID: 41525821

Comparative analysis of SUMO and his-tag fusion for soluble expression of the SARS-CoV-2 omicron RBD in E. coli.
Zargan S, Mesdaghinia S, Jalili H, Dabirmanesh B, Khajeh K.Protein Expr Purif. 2026 Mar;239:106869. doi: 10.1016/j.pep.2025.106869. Epub 2025 Dec 9.PMID: 41380356

Awareness of HPV-related cancers and the HPV vaccination programme in Scotland: a cross-sectional study of gender, deprivation and knowledge gaps.
Nguyen-Thanh H, Marshall L, Wilson H, Stewart K, Kavanagh K, Sorensen A.J Public Health (Oxf). 2026 Mar 6;48(1):239-248. doi: 10.1093/pubmed/fdaf136.PMID: 41189120

Parents' perceived safety, usability, and acceptability of vaccination through microarray patches: A preliminary multi-national cross-sectional survey.
Berger MN, Mathieu E, Davies C, Shaban RZ, Bag S, Skinner SR.Hum Vaccin Immunother. 2026 Dec;22(1):2642457. doi: 10.1080/21645515.2026.2642457. Epub 2026 Mar 10.PMID: 41805238 **Free PMC article.**

Spatial and social determinants of the 1857 yellow fever epidemic in Lisbon.
Bates IH, Li SL, Parag KV, Gaythorpe KAM, Abecasis AB, Smallman-Raynor M, Faria NR.PLoS Negl Trop Dis. 2026 Mar 9;20(3):e0014059. doi: 10.1371/journal.pntd.0014059. Online ahead of print.PMID: 41801989 **Free article.**

Documentation Gaps in Animal Bite Reexposure Cases: Economic and Public Health Implications in a Tertiary Anti-Rabies Clinic in North India.
Singh AD, Oberoi S, Kaler N, Singh H, Kaur J.Am J Trop Med Hyg. 2026 Mar 5:tpmd250773. doi: 10.4269/ajtmh.25-0773. Online ahead of print.PMID: 41785477

Lipid metabolism drives dietary effects on T cell ferroptosis and immunity.
Wang N, Chen Z, Yao Y, Sun C, Wei W, Sun L, Zhang H, Li F, Butcher D, Sun SR, Gong J, Jiang YC, Qi Y, Huang J, Nettelfield S, Liu R, Zheng X, Li C, Fu Y, Geng H, Zhao L, Sun H, Yang Y, Ge Y, Pazhouhandeh M, Barlow CK, Jeppe KJ, Yunis J, Zhu C, Wei Y, Liang X, Bridle K, Frazer DM, Tey SK, Li Y, Yang Z, Shu M, Liu Z, Crawford D, Yu D.Nature. 2026 Mar 4. doi: 10.1038/s41586-026-10193-4. Online ahead of print.PMID: 41781622

Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination.
De Chiara A, Nele V, Angelillo A, Campani V, Campanile A, Froechlich G, Scognamiglio A, Pellino E, Greco A, Chinello C, Pagani L, Eugster R, Luciani P, Corbo C, Nicosia A, Sasso E, De Rosa G.Mol Ther Nucleic Acids. 2026 Jan 30;37(1):102851. doi: 10.1016/j.omtn.2026.102851. eCollection 2026 Mar 12.PMID: 41736889 **Free PMC article.**

Novel anti-NS1 human single domain antibody from dengue infected NS1 positive patients.
Bhikhabhai OM, Kumar H.Protein Expr Purif. 2026 Mar;239:106875. doi: 10.1016/j.pep.2025.106875. Epub 2025 Dec 26.PMID: 41456644

Development of anti-CD4-1/CD8β monoclonal antibodies and spatiotemporal immune profiling of response to live attenuated IHNV in rainbow trout (Oncorhynchus mykiss).
Li S, Ma Y, Ao R, Zhao D, Guan X, Xu G, Lv X, Liu M.Fish Shellfish Immunol. 2026 Mar 6;173:111257. doi: 10.1016/j.fsi.2026.111257. Online ahead of print.PMID: 41796695

Recombinant immunogen rBm7462 expressed in a transgenic plant (Arabidopsis thaliana) as a new approach for Rhipicephalus microplus **vaccine**.
Peconick AP, Kalks KHM, Tafur-Gómez GA, Alves BH, Arruda LM, de Barros M, Patareli S, Ferraz JC, Santos AA, Vargas Viloria MI, Patarroyo JH.Vaccine. 2026 Mar 5;78:128422. doi: 10.1016/j.vaccine.2026.128422. Online ahead of print.PMID: 41793800

Engineering lipid-coated silica nanoparticles as versatile adjuvant delivery platform for the TLR4 agonist MPLA.
Schreiber AG, Konrad J, Liebl R, Beitzinger B, Krutina J, Madej G, Lindén M, Ziegler C, Breunig M.Int J Pharm. 2026 Mar 10;692:126629. doi: 10.1016/j.ijpharm.2026.126629. Epub 2026 Feb 5.PMID: 41653941

Dietary nano-chromium picolinate enhances interferon-gamma expression in heat-stressed broilers vaccinated against Newcastle disease.
Hajializadeh F, Talebi A, Jozani RJ.Res Vet Sci. 2026 Mar;200:106044. doi: 10.1016/j.rvsc.2025.106044. Epub 2025 Dec 26.PMID: 41468791

Identification and computational analysis of conserved YXXΦ motifs in the pan-serotypes of dengue virus NS5 protein and their implications in host-virus interactions.

Khalil A, Noor F, Tahir Ul Qamar M, Liaqat S, Nahid N, Haque A, Ashfaq UA.J Biomol Struct Dyn. 2026 Mar;44(4):2204-2217. doi: 10.1080/07391102.2025.2475224. Epub 2025 Mar 11.PMID: 40070139

Inhibitory effect of three components derived from Salvia miltiorrhiza against human cytomegalovirus.
Wang S, Zhou X, Lin Z, Su H, Wu X, Chang Y, Fu Y, Zhu T, Sun C, Zhang J, Li L, Lin P, Mao G.Virol J. 2026 Mar 2. doi: 10.1186/s12985-026-03107-3. Online ahead of print.PMID: 41772635 **Free article.**

Human immune response to primary cryptosporidiosis parallels murine infection models.
Van Fossen D, Rodriguez HJ, Naz F, Perriello C, Gilchrist CA, Taylor JJ, Petri WA Jr, Brown AC.Infect Immun. 2026 Mar 10;94(3):e0070125. doi: 10.1128/iai.00701-25. Epub 2026 Feb 4.PMID: 41636514 **Free PMC article.**

Adult and maternal pertussis vaccination in China: intention, preferences, and pricing implications from a discrete choice experiment.
Wu B, Cheng T, Zhang Y, Kezhong A, Hou Z, Ying X, Fu C.Vaccine. 2026 Mar 7;75:128243. doi: 10.1016/j.vaccine.2026.128243. Epub 2026 Jan 19.PMID: 41558206

Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis.
Ali MA, Sheikh H, Reza MS, Paul TR, Noor T, Kumar N, Bhat MA, Mollah MNH.PLoS One. 2026 Mar 11;21(3):e0337970. doi: 10.1371/journal.pone.0337970. eCollection 2026.PMID: 41811936 **Free PMC article.**

Machine learning framework for early detection of polio outbreaks from acute flaccid paralysis surveillance data.
Gemechu H, Biru G, Gebremeskel E, Teshome F, Nemomssa HD, Dese K, Wakjira E, Tefera M, Alayu M, Ayana G, Kong J.Virology. 2026 Mar 5;619:110863. doi: 10.1016/j.virol.2026.110863. Online ahead of print.PMID: 41806444

Senescent Cancer cell-derived vaccines: Current Progress, immunological challenges, and translational perspectives.
Song Y, Li R, Guo H.Vaccine. 2026 Mar 7;79:128430. doi: 10.1016/j.vaccine.2026.128430. Online ahead of print.PMID: 41797079 Review.

Duration of immunity following infection with moderately virulent ASFV.
Friedrichs V, Deutschmann P, Wernike K, Carrau T, Beer M, Blome S, Schäfer A.PLoS Pathog. 2026 Mar 3;22(3):e1014018. doi: 10.1371/journal.ppat.1014018. eCollection 2026 Mar.PMID: 41774768 **Free PMC article.**

Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants.

Tsung S, Zeng YB, Shah K, Asch SM, Salomon JA, Owens DK, Chen K.Pediatrics. 2026 Mar 1;157(3):e2025071558. doi: 10.1542/peds.2025-071558.PMID: 41713490

The effect of BCG vaccination on systemic inflammation in neonates.
Koeken VACM, Nissen TN, Birk NM, Boahen CK, van Crevel R, Kumar V, Li Y, Aaby P, Benn CS, Netea MG.Vaccine. 2026 Mar 7;75:128241. doi: 10.1016/j.vaccine.2026.128241. Epub 2026 Jan 26.PMID: 41592435 **Free article.** Clinical Trial.

Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities.
Corneillie L, Mézière L, Montpellier C, Drouet B, Aliouat-Denis CM, Cocquerel L.Antiviral Res. 2026 Mar;247:106353. doi: 10.1016/j.antiviral.2026.106353. Epub 2026 Jan 20.PMID: 41571028 **Free article.** Review.

Serotype-specific incidence and comparative **vaccine** coverage of invasive pneumococcal disease among adults 65 years of age in European countries from 2011 to 2023.
Floros L, Johnson KD, Tsoumani E.Vaccine. 2026 Mar 7;75:128181. doi: 10.1016/j.vaccine.2025.128181. Epub 2026 Jan 20.PMID: 41564841 **Free article.** Review.

Ethical challenges around mandatory vaccination among nurses: A systematic review of qualitative and quantitative evidence.
Kung PJ, Chen CM, Lin EC, Shu BC, Tew Y, He J, Fang CJ, Reynolds NR, Ornstein KA.Int J Nurs Stud. 2026 Mar;175:105313. doi: 10.1016/j.ijnurstu.2025.105313. Epub 2025 Dec 10.PMID: 41494304 Review.

Evidence on mpox clade Ia and clade Ib: A rapid research needs appraisal.
Spasenoska D, Araya N, de Swart M, Henschke N, Harriss E, Tam G, Patrick-Nwosu A, Moetlediwa M, Ndlovu M, Ntamo Y, Probyn K, Steinke S, Ashley L, Cheng V, Villanueva G, Harris T, Ndwandwe D, Turtle L, Carville S, Norton A, Sigfrid L.Int J Infect Dis. 2026 Mar;164:108348. doi: 10.1016/j.ijid.2025.108348. Epub 2025 Dec 27.PMID: 41461353 **Free article.**

Knockout of key receptors (PDGFRA and NRP2) in the guinea pig model blocks direct and endocytic pathways of CMV cell entry.
Qin Y, Choi KY, El-Hamdi N, McGregor A.J Gen Virol. 2026 Mar;107(3):002236. doi: 10.1099/jgv.0.002236.PMID: 41805587 **Free PMC article.**

A novel fluopyram-abamectin trunk-injection formulation: enhanced translocation and efficacy against pine wilt disease.
Yang C, Li D, Li Y, Liu Z, Zhang W, Wen X, Wang X, Feng Y, Yin W, Liu Y, Sang Y, Zhang X.Pest Manag Sci. 2026 Mar 2. doi: 10.1002/ps.70695. Online ahead of print.PMID: 41771763

EIF4H and YBX1 are essential host factors for hepatitis E virus replication and pathogenesis.

Ju X, Dong L, Liu T, Zhang F, Sun X, Schwoerer MP, Ren W, Gong M, Ploss A, Qin W, Wu X, Wang L, Ding Q.Proc Natl Acad Sci U S A. 2026 Mar 10;123(10):e2529289123. doi: 10.1073/pnas.2529289123. Epub 2026 Mar 4.PMID: 41779781

Hepatitis C virus elimination: So close, so far?
Pawlotsky JM.Antiviral Res. 2026 Mar;247:106360. doi: 10.1016/j.antiviral.2026.106360. Epub 2026 Feb 3.PMID: 41644064 Review.

Longitudinal Plasma Proteome of Pfizer/BNT162b2 Pre- and Postbooster Vaccinated Healthy Individuals Reveals Distinct Protein Profiles upon SARS-CoV-2 Spike Protein Stimulation.
Raheed T, Therachiyil L, Inchakalody V, Peerapen P, Younis SM, Ahmad F, Jochebeth A, Al-Suwaidi AK, Zaqout A, Akbar S, Prabhu KS, Al-Yaqoub A, Abukhattab M, Sasi S, Koolikkad F, Uddin S, Dermime S, Al-Khal A, Al-Maslamani M, Thongboonkerd V, Ahmad A, Ansari AW.J Proteome Res. 2026 Mar 6;25(3):1571-1583. doi: 10.1021/acs.jproteome.5c00962. Epub 2026 Feb 3.PMID: 41631862

Antibody responses to SARS-CoV-2 **vaccine** in nursing home residents support a Bi-annual update schedule.
Paxitzis AN, Oyebanji OA, Olagunju OJ, Keresztesy D, Payne M, Ragavapuram V, Sundheimer N, See E, Wilk D, Cao Y, Abul Y, Nugent C, Dickerson E, Wallace T, Holland L, Nanda A, Pfeifer WM, Balazs AB, King CL, Gravenstein S, Canaday DH, Wilson BM, Bosch J.Vaccine. 2026 Mar 7;75:128240. doi: 10.1016/j.vaccine.2026.128240. Epub 2026 Jan 24.PMID: 41581480 **Free article.**

Germline Homozygous RAG1 Missense Variant Associated With Epstein-Barr Virus Negative Childhood Burkitt Lymphoma: A Case Report.
Mammadova N, Yildirim A, Gokce N, Ozcan A, Karakukcu M, Dundar M.J Pediatr Hematol Oncol. 2026 Mar 1;48(2):e97-e101. doi: 10.1097/MPH.0000000000003159. Epub 2026 Jan 14.PMID: 41538412

Streptococcus agalactiae 1a capsule (cpsE) and hemolysin (cylE) deletion mutants display attenuated virulence in Nile tilapia (Oreochromis niloticus).
Fyrand K, Xu C, Zegeye ED, Kjos M, Evensen Ø.Fish Shellfish Immunol. 2026 Mar;170:111097. doi: 10.1016/j.fsi.2026.111097. Epub 2026 Jan 7.PMID: 41512938

Human papillomavirus vaccination and herpes simplex virus infection: A cross-sectional analysis of young women in the United States.
Hu J, Han H, Zhu J, Shan Y.Int J STD AIDS. 2026 Mar;37(4):403-409. doi: 10.1177/09564624251406411. Epub 2025 Dec 7.PMID: 41353593 **Free PMC article.**

The Neisseria gonorrhoeae cytochrome c_2-bacterial peroxidase electron-transfer complex is competent in hydrogen peroxide reduction.
Bragança PMS, Barreiro DS, Carepo MSP, Pauleta SR.J Inorg Biochem. 2026 Mar;276:113164. doi: 10.1016/j.jinorgbio.2025.113164. Epub 2025 Nov 25.PMID: 41317563 **Free article.**

Incidence of Herpes Zoster Infection (Shingles) Among Adults Living With and Without HIV in British Columbia, Canada: A Population-Based Study.
Lima VD, Hussain SS, Yan J, Copp E, Hull M, Budu M, Duailibe F, Trigg J, Leung V, Phillips P, Guillemi S, Hogg RS, Montaner JSG.J Infect Dis. 2026 Mar 10:jiag118. doi: 10.1093/infdis/jiag118. Online ahead of print.PMID: 41805836

Immunity in Harmony: Utilizing Overlapping Epitopes for Tuberculosis and COVID-19 Protection.
Pasricha K, Prajapati S, Lamba T, Malik JA, Khan MA, Nanda S, Zafar MA, Tripathi NM, Bandyopadhyay A, Agrewala JN.Protein Pept Lett. 2026 Mar 5. doi: 10.2174/0109298665417756251207111117. Online ahead of print.PMID: 41786686

Determinants of incomplete childhood immunisation among children aged 12-23 months in Koore Zone, Southern Ethiopia: a community-based case-control study.
Melese A, Wondirad M, Melke A, Tamiso A, Yoseph A.BMJ Paediatr Open. 2026 Mar 3;10(1):e004245. doi: 10.1136/bmjpo-2025-004245.PMID: 41775407 **Free PMC article.**

Risk of mortality among older adults hospitalized for COVID-19 with and without vaccination in Mexico.
Alanis-Ocádiz A, Gasca-López LE, Martínez-Bautista H, Muñoz-Villegas P, Quiñones-Villalobos C, Urrutia-Alanis P, Cuéllar-Roque F, Villagrana-Gutiérrez GL, Padilla-López J.Rev Med Inst Mex Seguro Soc. 2026 Mar 3;64(2):e6823. doi: 10.5281/zenodo.17537398.PMID: 41774840 **Free article.**

Extracellular vesicles of *Emergomyces africanus* modulate host immune responses and reflect metabolic adaptations to nutrient availability.
Honorato L, Sabino ALRdN, Artunduaga Bonilla JJ, Mendoza SR, Kornetz J, Dos Reis FCG, Albergoni ER, Alves V, Frases S, Guimarães AJ, Zamith-Miranda D, Sidoli S, Nosanchuk JD, Rodrigues ML, Nimrichter L.Infect Immun. 2026 Mar 10;94(3):e0063225. doi: 10.1128/iai.00632-25. Epub 2026 Feb 17.PMID: 41700888 **Free PMC article.**

From dye exclusion to high-throughput screening: A review of cell viability assays and their applications.
Naveen KV, Tyagi A, Ibrahium OMH, Fischer REAW, Ostafe R.Biotechnol Adv. 2026 Mar-Apr;87:108764. doi: 10.1016/j.biotechadv.2025.108764. Epub 2025 Nov 21.PMID: 41276195 Review.

HPV-positive head and neck squamous cell carcinoma: From molecular pathogenesis to therapeutic frontiers.
Li Y, Zhou S.Int J Biol Markers. 2026 Mar 7:3936155261428136. doi: 10.1177/03936155261428136. Online ahead of print.PMID: 41793138 **Free article.** Review.

IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients.

Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, Falck-Ytter Y, Baden L.Clin Infect Dis. 2026 Mar 2:ciag117. doi: 10.1093/cid/ciag117. Online ahead of print.PMID: 41766598

Progress Towards Elimination: Hepatitis B and C Among Children and Young Adults in Rural Mongolia.
Dashdorj ED, Sereenendorj K, Ochirsum B, Bat-Ulzii P, Renchindorj B, Dashdorj AN, Budeebazar M, Enkhbat M, Ochirbat E, Lkhagva-Ochir O, Enkhbat A, Bat S, Yagaanbuyant D, Terrault N, Onom NDD, Bungert AS, Dashdorj NB.J Viral Hepat. 2026 Mar;33(3):e70145. doi: 10.1111/jvh.70145.PMID: 41623214

Leveraging machine learning for accurate forecasting of pulmonary tuberculosis epidemics in a coastal city in China.
Yang J, Pan J, Chen J, Xu Y, Zhang X.Trop Med Health. 2026 Mar 8. doi: 10.1186/s41182-026-00934-6. Online ahead of print.PMID: 41794777

Advancing Vaccination Strategies for Older Adults: Insights of the Adult Immunization Board Meeting.
Del Riccio M, Maggi S, Wieczorowska-Tobis K, Newell K, Czech M, Botelho-Nevers E, Michel JP, Hummers E, Duque S, Lundgren J, Barrat J, Tan L, Wysocki J, Boccalini S, Bechini A, Jindal S, Hendrickx G, Van Damme P, Bonanni P, Pattyn J.Drugs Aging. 2026 Mar 6. doi: 10.1007/s40266-026-01284-y. Online ahead of print.PMID: 41792534 Review.

[Health disparities and legislative determinants in Latin America: Multivariate comparative analysis of life expectancy, infant mortality, and immunization in Chile, Colombia, and Honduras (2011-2019)].
Estupiñan Ruiz CA, Correa-Arrieta C, Hincapié-Carvajal JA.Aten Primaria. 2026 Mar;58(3):103428. doi: 10.1016/j.aprim.2025.103428. Epub 2026 Jan 14.PMID: 41539142 **Free PMC article.** Spanish.

Electrochemical immunosensor for sensitive detection of Crimean-Congo hemorrhagic fever virus based on a flexible electrode of carbon nanofibers modified with copper (II) phosphate nanoflowers.
Rahmati Z, Raoof JB.Biosens Bioelectron. 2026 Mar 1;295:118291. doi: 10.1016/j.bios.2025.118291. Epub 2025 Dec 3.PMID: 41365106

Pharmacy access and shingles vaccinations in the US: a propensity score matching analysis.
Wittenauer R, Shah PD, Bacci JL, Mooney SJ, Stergachis A.Vaccine. 2026 Mar 7;75:128256. doi: 10.1016/j.vaccine.2026.128256. Epub 2026 Jan 30.PMID: 41619356

Polarization and health-related behaviors and outcomes during the COVID-19 pandemic: a systematic review.
Ipekci AM, Filsinger M, Buitrago-Garcia D, Kobler Betancourt CI, Liwanag HJ, Frahsa A, Low N.SSM Popul Health. 2025 Dec 4;33:101891. doi: 10.1016/j.ssmph.2025.101891. eCollection 2026 Mar.PMID: 41492540 **Free PMC article.**

Gavi's Zero-Dose Learning Hubs: Enhanced Approach for Evidence Generation and Use from Local to Global.

Reynolds HW, Corrêa GC, Vollmer N, Broekhuysen E, Saville E, Hogan D, Johnson HL.Health Policy Plan. 2026 Mar 10:czag028. doi: 10.1093/heapol/czag028. Online ahead of print.PMID: 41805772

Radiosensitizing in situ cancer vaccines combined with immune checkpoint blockade to overcome resistance to radioimmunotherapy.
Wang X, Hirose M.Biomater Adv. 2026 Mar;180:214565. doi: 10.1016/j.bioadv.2025.214565. Epub 2025 Oct 19.PMID: 41135444

Protective effect of adult vaccination on the development of dementias: A systematic review.
Mariscal-Lopez E, Agredano-Sanchez M, Lopez-Gigosos RM, Mariscal A, Fariñas-Guerrero F, Gutierrez-Bedmar M, Guts-Chornoknyzha M.Neurologia (Engl Ed). 2026 Mar;41(2):501939. doi: 10.1016/j.nrleng.2026.501939.PMID: 41765607 **Free article.** Review.

A systematic review of dengue controlled human infection studies: safety, viral kinetics and immunology.
Chhabra S, Chia PY, Leo YS, Young BE.PLoS Negl Trop Dis. 2026 Mar 12;20(3):e0014086. doi: 10.1371/journal.pntd.0014086. Online ahead of print.PMID: 41818269

Improving and sustaining adolescent access to primary care in a socioeconomically vulnerable urban community in Brazil: outcomes of a quality improvement initiative.
Timbó de Paiva Neto F, Marques RG, Saad LDC, Palacio DDC, Borella AC, Arcos AR, Miranda RM, da Silva AM, Rodrigues MDS, Vernal S.BMJ Paediatr Open. 2026 Mar 3;10(1):e004330. doi: 10.1136/bmjpo-2025-004330.PMID: 41775408 **Free PMC article.**

Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy.
Yang F, Lu Y, Lang X, Sun L, Zou H, Zhou Z, Guo Y, Guo Y, Wang X, Han M.Mol Pharm. 2026 Mar 2;23(3):1969-1984. doi: 10.1021/acs.molpharmaceut.5c01664. Epub 2026 Feb 19.PMID: 41711552

Seroepidemiological Observational Study in Total and Neutralizing Antibodies to SARS-CoV-2 Among Primary Care Patients in Crete, Greece.
Pournara Z, Kissandraki E, Koursioti S, Linardakis M, Symvoulakis EK, Anastasaki M, Lionis CD, Sourvinos G.In Vivo. 2026 Mar-Apr;40(2):1207-1219. doi: 10.21873/invivo.14276.PMID: 41760294 **Free PMC article.**

Molecular Detection and Genetic Diversity of Measles and Parainfluenza Viruses Circulating in Humans in Bangladesh: A Cross-Sectional Study.
Choudhury SD, Khan MA, Amin E, Abedin J, Munro S, Kaczmarek M, Forwood JK, Shirin T, Flora MS, Epstein JH, Islam A.Health Sci Rep. 2026 Feb 25;9(3):e71832. doi: 10.1002/hsr2.71832. eCollection 2026 Mar.PMID: 41757344 **Free PMC article.**

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.

Anderson SA, Smith ER, Wan Z, Amend KL, Secora A, Djibo DA, Kazemi K, Song J, Parlett LE, Seeger JD, Selvam N, McMahill-Walraven CN, Hu M, Chillarige Y, Forshee RA.Vaccine. 2026 Mar 7;75:128225. doi: 10.1016/j.vaccine.2026.128225. Epub 2026 Feb 4.PMID: 41643233

Incidence of Guillain-Barré Syndrome in Chile: A Population-Based Study Between 2013 and 2022.
Galiá-Llaña R, Ronda-Rojas D, Del Solar-Benavides A, Otto-Yáñez M, Torres-Castro R, Vera-Uribe R, Fregonezi G, Rivera-Lillo G.J Peripher Nerv Syst. 2026 Mar;31(1):e70103. doi: 10.1111/jns.70103.PMID: 41578680

Combined transcriptome and function analyses of peripheral blood white cells highlight the disease-resistant mechanism of CD79a/CD79b in Chinese tongue sole (Cynoglossus semilaevis).
Tian M, Liu J, Guo R, Li H, Chen S, Wang L.Fish Shellfish Immunol. 2026 Mar;170:111116. doi: 10.1016/j.fsi.2026.111116. Epub 2026 Jan 8.PMID: 41519212

Measles, mumps, rubella, and varicella seroprevalence in health care workers: A cross-sectional study from Tan Tock Seng Hospital and the National Centre for Infectious Diseases, Singapore.
Yuen PJX, Lim DW, Chavatte JM, Thein TL, Loh PL, Tan CCY, Tang HL, Lim DRX, Au AJH, Mohamed Ashar MZ, Gao Q, Lin RTP, Toh MPHS, Sadarangani SP.Int J Infect Dis. 2026 Mar;164:108364. doi: 10.1016/j.ijid.2025.108364. Epub 2026 Jan 3.PMID: 41490770 **Free article.**

Genotypic characterization and epidemiology of genital Chlamydia trachomatis among women: A hospital-based study in Hangzhou, China.
Zhou Q, Dong S, Sun Y, Shi X, Shi X, Xu B.Int J Infect Dis. 2026 Mar;164:108356. doi: 10.1016/j.ijid.2025.108356. Epub 2025 Dec 30.PMID: 41478337 **Free article.**

Pregnancy exposure to individual phthalate concentrations and their mixtures in relation to pediatric serum antibody response.
Feiler MO, Salerno M, Quataert SA, Tellez-Rojo MM, Lamadrid-Figueroa H, Estrada G, Wright RO, Jusko TA, Colicino E.Eur J Epidemiol. 2026 Mar 12. doi: 10.1007/s10654-026-01387-1. Online ahead of print.PMID: 41817940

Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines.
Kim JG, Xu J, Lee D, Song J, Lee S, Hong MH, Zhu J, Zhu A, Patwari K, Shim EH, Shin JE, Park OH, Rho J, Ko KC, Lee EG, Kang OY, Won EJ, Kim BH, Jang JP, Jang JH, Kim DJ, Hwang JH, Mitchell MJ, Cha-Molstad H.ACS Nano. 2026 Mar 3;20(8):7022-7045. doi: 10.1021/acsnano.5c19036. Epub 2026 Feb 15.PMID: 41691524

Assessment of the Impact of a One Health Approach-Based Training on Poultry Rearing and Farm Biosecurity Management in Bangladesh.
Islam M, Silva-Fletcher A, Haque ME, Mahmud R, Tomley F, Hoque MA.Vet Med Sci. 2026 Mar;12(2):e70843. doi: 10.1002/vms3.70843.PMID: 41653103 **Free PMC article.**

Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.
Sevilla JP, Burnes D, Bloom DE.Infect Dis Ther. 2026 Mar;15(3):651-682. doi: 10.1007/s40121-026-01299-3. Epub 2026 Jan 20.PMID: 41559505 **Free PMC article.** Review.

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies.
Martino EA, Caserta S, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.Eur J Haematol. 2026 Mar;116(3):204-214. doi: 10.1111/ejh.70065. Epub 2025 Nov 25.PMID: 41292288 **Free PMC article.** Review.

Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis **vaccine** candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Wagner L, Obersriebnig M, Hochreiter R, Kadlecek V, Larcher-Senn J, Hegele L, Maguire JD, Murphy T, Derhaschnig U, Bézay N, Jaramillo JC, Eder-Lingelbach S, Messier M.Lancet Infect Dis. 2026 Mar;26(3):314-328. doi: 10.1016/S1473-3099(25)00541-9. Epub 2025 Nov 7.PMID: 41213278 Clinical Trial.

Design and evaluation of novel pyrimidine-based nucleoside analogs as antivirals: Identification of MCH-1623 as a potent broad-Spectrum antiviral candidate.
Yan X, Sun H, Mo C, Ma L, Hu C, Zhong Z, Su Y, Yin L, Zhang J, Chen J, Liu Y, Han X, Liu Y, Xu J, Cen S, Chen Y, He X.Bioorg Chem. 2026 Mar;170:109472. doi: 10.1016/j.bioorg.2026.109472. Epub 2026 Jan 7.PMID: 41512356

Rotavirus-specific IgA and IgG Patterns During the First Two Years of Life in the PREVAIL Birth Cohort.
Baker JM, Mijatovic-Rustempasic S, Casey-Moore MC, White B, Mattison CP, Burke RM, Conrey SC, Morrow AL, Payne DC, Gautam R, Parashar UD, Tate JE, Staat MA, McNeal MM.J Infect Dis. 2026 Mar 3:jiag141. doi: 10.1093/infdis/jiag141. Online ahead of print.PMID: 41774770

"Three of a kind?" Unmasking the clinical burden of human metapneumovirus and parainfluenza virus compared to respiratory syncytial virus in hospitalized adults: A pre-COVID-19 multicenter cohort study.
Davido B, Mamona C, Gault E, Annane D, Beaune S, Dumoulin J, de Truchis P, Saleh-Mghir A, Lemarié B, Loubet P.Int J Infect Dis. 2026 Mar;164:108353. doi: 10.1016/j.ijid.2025.108353. Epub 2025 Dec 26.PMID: 41456769 **Free article.**

Public Health Impact and Cost-Effectiveness of Routine and Catch-Up Human Papillomavirus Vaccination in Girls and Women in Selected Regions of China: A Model-Based Study.
Fu X, Zhang Q, Wagner AL, Yao Y, Xia Y, Wang F, Lu Y.Pharmacoeconomics. 2026 Mar;44(3):343-357. doi: 10.1007/s40273-025-01584-y. Epub 2026 Jan 27.PMID: 41591634

Serological protection against influenza and cardiovascular events in cardiac ICU patients during seasonal epidemics.
Galar A, Sanz-Muñoz I, Eiros JM, Alonso R, Catalán P, Cobos A, Juárez M, Sousa-Casasnovas I, Valerio M, Antunez-Muiños P, Barbeito-Castiñeiras G, Blanco-Alonso S, Folgueira MD, García-Acuña JM, Lalueza A, Lázaro F, Lopez-de-Sa E, Martín L, Muñez-Rubio E, Portero F, Ramos-Martínez A, Romero-Gómez MP, Rosillo S, Fernández-Avilés F, Martínez-Sellés M, Bouza E, Munoz P.Int J Infect Dis. 2026 Mar;164:108406. doi: 10.1016/j.ijid.2026.108406. Epub 2026 Jan 20.PMID: 41570890 **Free article.**

Interrupted time-series analysis of nationwide surveillance in Thai adult pneumococcal diseases over 14 years: evidence to inform policy in resource-limited countries.
Ngamprasertchai T, Kerdsin A, Ruenroengbun N, Srisompong J, Dhitinanmuang W, Kajeekul R, Laohasakprasit K, Chavapradit N, Wongkamhla T, Charoenpong L, Rattanaumpawan P, Lawpoolsri S, Turner P.Expert Rev Vaccines. 2026 Mar 12:2645382. doi: 10.1080/14760584.2026.2645382. Online ahead of print.PMID: 41816940

Current global estimates, risk factors, and knowledge gaps for Hepatitis E virus (HEV): A scoping review.
Ahmed MK, Maroofi H, Blunt M, Labrique A, Kirkwood C, Vannice K, Talaat KR, Lynch J, Kmush BL.PLoS Negl Trop Dis. 2026 Mar 11;20(3):e0013980. doi: 10.1371/journal.pntd.0013980. eCollection 2026 Mar.PMID: 41811926 **Free PMC article.**

Genomic and patient epidemiology of *Streptococcus dysgalactiae* subspecies *equisimilis* in Houston, Texas.
Pouga L, Beres SB, Olsen RJ, Long SW, Graviss EA, Musser JM.Microbiol Spectr. 2026 Mar 6:e0368325. doi: 10.1128/spectrum.03683-25. Online ahead of print.PMID: 41789911 **Free article.**

Impact of demographic factors and HIV status on Hepatitis B vaccination adherence and completion rate among high-risk populations in Lagos State, Nigeria.
Shoyemi E, Aghedo OG, Obi C, Uwaoma CPK, Azeez OS, Oyeniyi O.PLoS One. 2026 Mar 4;21(3):e0321434. doi: 10.1371/journal.pone.0321434. eCollection 2026.PMID: 41779730 **Free PMC article.**

Herpes zoster vaccination and the risk reduction of ophthalmic diseases: A nationwide emulated target trial in South Korea.
Lee S, Lee K, Yeo D, Jo H, Park J, Woo S, Branda F, Rahmati M, Lee J, Choi JH, Kim S, Yang JM, Lee H, Yon DK.Vaccine. 2026 Mar 2;78:128400. doi: 10.1016/j.vaccine.2026.128400. Online ahead of print.PMID: 41775120

Effectiveness of the influenza and Tdap vaccination educational module (InTroDuce-Programme) on knowledge and intention for antenatal vaccination: A cluster randomised controlled trial protocol among pregnant women in Malaysian primary care clinics.

Lau HC, Sekawi Z, Ching SM, Abu Bakar N, Dapari R, Mohamed Alias SR, Talib NH, Dzulkifli IH, Md Alwi N, Abdul Hamid H, Mat Din H.PLoS One. 2026 Mar 12;21(3):e0344651. doi: 10.1371/journal.pone.0344651. eCollection 2026.PMID: 41818225

Guanylate-binding proteins balance iNOS/Arg-1 in myeloid cells during *L. major* infection and promote host defense to infection.
Fry L, Adhvaryu H, Roys H, Bowlin A, Venugopal G, Bird JT, Washam C, Yamamoto M, Coers J, Byrum S, Voth D, Weinkopff T.mBio. 2026 Mar 10:e0282525. doi: 10.1128/mbio.02825-25. Online ahead of print.PMID: 41805192 **Free article.**

RALP1 is essential for schizont maturation and erythrocyte invasion in Plasmodium falciparum.
Wu J, Zhang Z, Pang J, Yang W, Ngim C, Li P, Ye J, Tian B, Cheng X, Wang F, Zhang Q, Shang X.Parasit Vectors. 2026 Mar 6. doi: 10.1186/s13071-026-07329-w. Online ahead of print.PMID: 41792842 **Free article.**

Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era.
Shigayeva A, Coleman BL, Golden AR, Martin I, Zhanel G, Adam H, Gold WL, Kandel C, Katz KC, Krajden S, Lovinsky R, Muller MP, Ostrowska K, Rau N, Ricciuto D, Richardson D, Vermeiren C, Faheem A, Farooqi L, Green K, Hassan K, Lefebvre M, Li AX, Malik N, Nayani S, Pejkovska M, Plevneshi A, Sultana A, Vikulova T, Zhong Z, McGeer A; Toronto Invasive Bacterial Diseases Network.Vaccine. 2026 Mar 4;78:128351. doi: 10.1016/j.vaccine.2026.128351. Online ahead of print.PMID: 41785682 **Free article.**

Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023.
Gao S, Xie T, Cai M, Su M, Zhao T, Zhang X, Zhang S, Wang M, Xu Q, Cheng Y, Cui F, Liu F.Hum Vaccin Immunother. 2026 Dec;22(1):2611652. doi: 10.1080/21645515.2025.2611652. Epub 2026 Mar 3.PMID: 41773582 **Free PMC article.**

Geographic disparities and determinants of DTP3 vaccination coverage among children aged 0-59 months in Somalia: a multilevel analysis.
Omar MA, Mohamud MA, Mouse AI, Muse AH.Confl Health. 2026 Mar 1. doi: 10.1186/s13031-026-00777-2. Online ahead of print.PMID: 41765923 **Free article.**

Absenteeism related to respiratory infections among healthcare personnel in hospitals in Greece from 2020-2021 to 2024-2025.
Maltezou HC, Giannouchos TV, Gamaletsou MN, Koukou DM, Lemonakis N, Sourri F, Peskelidou E, Botsa E, Lourida A, Hatzigeorgiou D, Panagopoulos P, Sipsas NV.Vaccine. 2026 Mar 7;75:128264. doi: 10.1016/j.vaccine.2026.128264. Epub 2026 Jan 22.PMID: 41576702

Dysfunction of circulating follicular helper T cells in people living with HIV who are HBV small surface protein antibody (HBsAb)-negative despite HBV vaccination.

Sedohara A, Kanno Y, Arai K, Arizono K, Koga M, Nakahara F, Saito M, Adachi E, Yotsuyanagi H.BMC Infect Dis. 2026 Mar 11. doi: 10.1186/s12879-026-13027-w. Online ahead of print.PMID: 41814210

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.
Miao S, Sun Y, Qu Y, Zhu L, Zhong Z, Meng F.Acta Biomater. 2026 Mar;212:624-636. doi: 10.1016/j.actbio.2025.12.045. Epub 2025 Dec 24.PMID: 41453423

Zinc oxide nanoparticles from drug delivery to immunomodulation: progress and challenges.
Conte M, Vighetto V, Cauda V.Expert Opin Drug Deliv. 2026 Mar 9:1-13. doi: 10.1080/17425247.2026.2638409. Online ahead of print.PMID: 41739446

Tunable wrinkled topographies direct dendritic cell maturation and immune phenotypes.
Chavda A, Zhou X, Tokmedash MA, Moon JJ, Min J.Acta Biomater. 2026 Mar;212:428-443. doi: 10.1016/j.actbio.2025.12.050. Epub 2025 Dec 30.PMID: 41478520 **Free article.**

Unveiling the genitourinary phenotype of long COVID: a systematic review and meta-analysis.
Peñaherrera-Vásquez D, Reina A, Merlo F, Fajardo-Loaiza T, Zambrano-Sánchez G, Rivadeneira J, Fuenmayor-González L.Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05073-9. Online ahead of print.PMID: 41796425 Review.

Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis.
Eldesouki MH, Ibrahim A, Alkasabrah O, Youssef MY, Mohamed E, Alsakarneh S, Farraye FA, Hashash JG.Dig Dis Sci. 2026 Mar 6. doi: 10.1007/s10620-026-09773-1. Online ahead of print.PMID: 41790400

Demographic and clinical correlates of discordant QuantiFERON TB Gold tuberculosis screening results in a low-incidence setting.
Sharma GK, Haq F, Totten AH, Marcos LA, Vorkas CK.Microbiol Spectr. 2026 Mar 3;14(3):e0282225. doi: 10.1128/spectrum.02822-25. Epub 2026 Feb 9.PMID: 41660848 **Free PMC article.**

Longitudinal serological response to SARS-CoV-2 among rohingya refugees in cox's bazar, Bangladesh: implications for pandemic preparedness in humanitarian settings.
Tanvir NA, Siddik AB, Mukta SA, Islam MS, Dey MMM, Khan SI, Islam Z, Bhuiyan ATMRH, Rahman MR, Qadri F, Picot VS.Confl Health. 2026 Mar 8. doi: 10.1186/s13031-026-00774-5. Online ahead of print.PMID: 41796384 **Free article.**

Maternal preparedness for uptake of newborn hepatitis B immunoprophylaxis at birth: Implications for preventing mother-to-child transmission in resource-limited settings.
Senoo-Dogbey VE, Iddrisu S, Wuaku DA, Ashaley MD.IJID Reg. 2026 Jan 17;18:100846. doi: 10.1016/j.ijregi.2026.100846. eCollection 2026 Mar.PMID: 41704805 **Free PMC article.**

Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness.
Ciapponi A, Ballivian J, Berrueta M, Sambade JM, Castellana N, Bardach A, Brizuela M, Caravario J, Comande D, Couto E, Mazzoni A, Parker E, Salva F, Stegelmann K, Xiong X, Stergachis A, Munoz FM, Buekens P.Drug Saf. 2026 Mar 6. doi: 10.1007/s40264-026-01657-7. Online ahead of print.PMID: 41792577

Misinformation and Profitability of Hepatitis B Virus Claims on Instagram: Formative Cross-Sectional Study.
Warner ZC, Turner CA, Alvarez R, Gallegos-Orozco JF, Green A, Warner EL.JMIR Form Res. 2026 Mar 2;10:e71584. doi: 10.2196/71584.PMID: 41769926 **Free article.**

A booster vaccination for Salmonella spp. minimally affects feeding behavior in beef × dairy calves fed with automated milk feeders.
Bone BJ, James RE, Cantor MC.J Dairy Sci. 2026 Mar;109(3):2933-2943. doi: 10.3168/jds.2025-27105. Epub 2026 Jan 15.PMID: 41547447 **Free article.**

Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
Faijue DD, Bouaddi O, Mackey K, Deal A, Cinar EN, Morais B, Bojang S, Al-Sharabi I, Seale H, Ssali A, Le Doare K, Hargreaves S.Vaccine. 2026 Mar 7;75:128249. doi: 10.1016/j.vaccine.2026.128249. Epub 2026 Jan 20.PMID: 41564840 **Free article.** Review.

Randomised, double-blind, parallel group, placebo-controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infants in the UK: BALLOON study - study protocol.
Kotecha SJ, Lowe J, Gillespie D, Perez-Alijas M, Aboklaish AF, Mahachi TL, Cumming OS, Harris D, Hubbard M, Thomas-Jones E, Jones T, Ladell K, Moore C, Humpreys I, Grigg J, Berrington J, Kotecha S.BMJ Open. 2026 Mar 9;16(3):e107929. doi: 10.1136/bmjopen-2025-107929.PMID: 41802797 **Free article.**

The impact of accumulating immune adaptation in circulating strains of HIV-1.
Al-Kaabi M, Castley A, Deshpande P, Chopra A, Nolan D, Mallal S, John M, Gaudieri S.HIV Med. 2026 Mar 8. doi: 10.1111/hiv.70215. Online ahead of print.PMID: 41795223

Quinolinic acid as trigger/biomarker of dysosmia/dysgeusia in patients with acute coronavirus disease 2019: A retrospective case-control study.
Tsukiji J, Koizume S, Takahashi T, Murakami S, Takahashi H, Mitsunaga S, Nakamura S, Narimatsu H, Miyagi Y.Brain Behav Immun Health. 2026 Jan 12;52:101175. doi: 10.1016/j.bbih.2026.101175. eCollection 2026 Mar.PMID: 41630806 **Free PMC article.**

Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis.
Jehle DVK, Sunesra R, Williams SM, Bilby NJ, Paul KK, Hill K.Ther Adv Pulm Crit Care Med. 2026 Mar 3;21:29768675251413432. doi: 10.1177/29768675251413432. eCollection 2026 Jan-Dec.PMID: 41788322

Patentes registradas en Patentscope

Estrategia de búqueda: *(Vaccine) AND DP:([1.03.2026 TO 12.03.2026]) as the publication date 39 records.*

1.WO/2026/050432ENGINEERED FLAVIVIRUS ANTIGENS AND USES THEREOF
WO - 05.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/043820Solicitante VACCINE COMPANY, INC.Inventor/a WEIDENBACHER, Payton Anders-Benner
The present disclosure provides modified flavivirus polypeptides useful as antigens and polynucleotides encoding the same, and related compositions, methods of making, and methods of using. Also provided herein are enveloped virus-like particles and cells comprising all or a portion of said modified flavivirus polypeptides. In particular, these modified flavivirus polypeptides are useful for eliciting an immune response against flavivirus infection.

2.20260061046COMBINATION VACCINE FOR PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS
US - 05.03.2026
Clasificación Internacional A61K 39/145Nº de solicitud 19382507Solicitante NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventor/a Masashi SHINGAI
Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

3.WO/2026/049474IMMUNOGENIC COMPOSITION COMPRISING MALONATE SEMIALDEHYDE DECARBOXYLASE (MSAD), AND VACCINE COMPOSITION FOR PREVENTING OR TREATING NONTUBERCULOUS MYCOBACTERIA INFECTION, COMPRISING SAME
WO - 05.03.2026
Clasificación Internacional A61K 39/04Nº de solicitud PCT/KR2025/012997Solicitante SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventor/a KIM, Bum-Joon
The present invention relates to an immunogenic composition comprising a malonate semialdehyde decarboxylase (MSAD) protein or a polynucleotide encoding same, and a vaccine composition and a pharmaceutical composition for preventing or treating nontuberculous mycobacteria infection, which

comprise same. The vaccine composition and the pharmaceutical composition, which comprise the MSAD protein or the polynucleotide encoding same, of the present invention, have excellent preventive and therapeutic efficacy against nontuberculous mycobacteria infection. In addition, the vaccine composition and the pharmaceutical composition, which comprise the MSAD protein or the polynucleotide encoding same, of the present invention, have a greater effect of preventing and treating nontuberculous mycobacteria infection when administered intranasally, and have a greater effect of preventing and treating nontuberculous mycobacteria infection when used in combination with an immune adjuvant.

4.WO/2026/055587VESICULAR STOMATITIS VIRUS MARBURG VIRUS VACCINE
WO - 12.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/045321Solicitante INTERNATIONAL AIDS VACCINE INITIATIVE, INC.Inventor/a PARKS, Christopher, L.
The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVAG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVAG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses. Vaccination may occur via intramuscular administration, oral administration, or intranasal administration.

5.WO/2026/049553COMPOSITION FOR ENHANCING VACCINE IMMUNE RESPONSE, COMPRISING INTESTINAL MICROORGANISMS AS ACTIVE INGREDIENTS
WO - 05.03.2026
Clasificación Internacional A61K 39/39Nº de solicitud PCT/KR2025/013268Solicitante KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventor/a SONG, Joon-young
The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

6.WO/2026/047307HSP110-ENRICHED AUTOLOGOUS CANCER VACCINE
WO - 05.03.2026
Clasificación Internacional A61K 39/00Nº de solicitud PCT/FR2025/050775Solicitante HASTIMInventor/a ROUQUET, Nicole
The invention relates to an autologous cancer vaccine and to the method for preparing same. The autologous vaccine according to the present invention is based on hydroxyapatite and/or tricalcium phosphate particles on which tumor proteins are adsorbed, these tumor proteins being enriched in HSP110.

7.WO/2026/046276MULTIVALENT INFLUENZA MRNA VACCINE
WO - 05.03.2026
Clasificación Internacional C12N 15/62Nº de solicitud PCT/CN2025/117472Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a DONG, Yijie
The present invention provides an isolated mRNA molecule, comprising the following elements in sequence from a 5' end to a 3' end: (1) a 5' cap; (2) a 5'UTR region; (3) an immunogenic fragment-coding region of influenza virus hemagglutinin (HA); (4) a 3'UTR region; and (5) a PolyA tail. The PolyA and coding region sequence of the mRNA molecule are both optimized, so that an mRNA influenza vaccine has controllable quality during production and exerts optimal immune response. Also provided are a composition and vaccine comprising the mRNA, and a method for using same to induce an immune response to an influenza virus in a subject.

8.WO/2026/045872NOVEL ADJUVANT POLYPEPTIDE SEQUENCE AND USE THEREOF
WO - 05.03.2026
Clasificación Internacional C07K 14/33Nº de solicitud PCT/CN2025/113132Solicitante RONGCAN (SHANGHAI) BIOTECH CO., LTDInventor/a ZHANG, Xueqing
The present invention relates to the field of vaccines, and in particular to a novel adjuvant polypeptide sequence and a use thereof. The adjuvant polypeptide sequence provided by the present invention comprises amino acid sequences of tetanus toxoid epitopes P2 and P16 and further comprises amino acid sequences of P30 and/or PX. The adjuvant polypeptide sequence aims to expand the coverage population of immune responses by increasing epitope diversity. In addition, the present invention uses an LNP (lipid nanoparticle) delivery system to introduce an mRNA encoding an adjuvant polypeptide and an initial antigen protein into a human body, thereby improving the immunostimulatory ability of the initial antigen. The adjuvant polypeptide sequence provided by the present invention and the initial antigen sequence are preferably fused, thereby simplifying the composition of mRNA in a nucleic acid vaccine and reducing the complexity of vaccine preparation.

9.WO/2026/054672PNEUMONIA VACCINE
WO - 12.03.2026
Clasificación Internacional C07K 14/255Nº de solicitud PCT/RU2025/050110Solicitante DUKHOVLINOV, Ilia VladimirovichInventor/a DUKHOVLINOV, Ilia Vladimirovich
The invention relates to the field of health care, and more particularly to the prevention of infections that cause pneumonia and other illnesses using an immunogenic protein containing fragments of the proteins FliC, PspA, OmpA and PE, connected by rigid linkers, wherein: - the FliC protein fragment contains SEQ ID NOs: 2 and 3 connected to one another by a flexible linker; - the PspA protein fragment contains SEQ ID NO: 4; the OmpA protein fragment contains SEQ ID NOs: 5-8 connected to one another by flexible linkers; - the PE fragment contains SEQ ID NO: 9. Also proposed are a host cell and a method for producing the protein. The immunogenic protein is suitable for use as a broad-spectrum polyvalent vaccine and exhibits a marked protective effect against Streptococcus pneumoniae, Haemophilus influenzae and Klebsiella pneumoniae, as well as providing for production efficiency and safety.

10.WO/2026/047168POLYPEPTIDE SUBDOMAIN MALARIA VACCINE
WO - 05.03.2026

Clasificación Internacional A61K 39/015Nº de solicitud PCT/EP2025/074592Solicitante STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMInventor/a JORE, Matthijs Miklas
The invention is in the field of vaccines, particularly in the field of polypeptide vaccines that target malaria. Malaria is caused by a parasite that is transmitted by mosquitoes. Transmission- blocking vaccines can prevent transmission from human to mosquito and thus can prevent spread of the disease. The invention provides polypeptides that show remarkable efficiency when used in a transmission-blocking vaccine strategy.

11.WO/2026/052881CHIKUNGUNYA VIRUS VACCINE MULTIDOSE FORMULATION AND USE THEREOF IN OUTBREAKS
WO - 12.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/075699Solicitante VALNEVA AUSTRIA GMBHInventor/a WALKE, Prasad
The present invention relates to a multidose lyophilized vaccine composition for the prevention or treatment of a chikungunya virus infection and/or a chikungunya virus associated clinical illness of any severity. Further provided are methods for manufacturing lyophilized multidose compositions comprising an attenuated chikungunya virus and kits comprising such compositions.

12.20260061047NEWCASTLE DISEASE VIRUS WITH IMPROVED HEAT RESISTANCE, AND NEWCASTLE DISEASE VIRUS VACCINE COMPRISING SAME
US - 05.03.2026
Clasificación Internacional A61K 39/17Nº de solicitud 19125251Solicitante BIOPOA, INC.Inventor/a Sun-Hee Cho
The present specification provides: a Newcastle disease virus with improved heat resistance; a Newcastle disease vaccine comprising the virus; a polypeptide comprising an L protein in the virus; a polynucleotide encoding same; and a recombinant vector comprising the polynucleotide.

13.WO/2026/045748USE OF TRNA IN PROMOTING PROTEIN-CODING ABILITY OF MRNA
WO - 05.03.2026
Clasificación Internacional C12N 15/113Nº de solicitud PCT/CN2025/109246Solicitante PEKING UNIVERSITYInventor/a XIA, Qing
The present invention relates to the use of tRNA in promoting the protein-coding ability of mRNA. The expression level of a target protein is improved by means of overexpressing tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. Further provided is a new tRNA+mRNA immunopotentiating vaccine. By means of introducing one or more tRNA molecules, the antigen protein encoding ability of an mRNA vaccine is enhanced, thereby eliciting stronger humoral and cellular immune responses in vivo. Further provided is a recombinant cell for producing an antibody. The recombinant cell overexpresses tRNA capable of increasing the expression level of the antibody, and the tRNA comprises a tRNA isodecoder family. Further provided is a recombinant cell for producing or packaging recombinant AAV, wherein the recombinant cell overexpresses tRNA capable of improving the AAV packaging efficiency.

14.WO/2026/046768MUCOSAL VACCINE ADJUVANT
WO - 05.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/073597Solicitante THE

PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLINInventor/a LAVELLE, Ed
This invention relates to a mucosal vaccine composition and to an adjuvant comprising highly deacetylated chitosan for use in a method of immunotherapy, wherein the adjuvant is administered by a mucosal administration.

15.WO/2026/045325A FUSION PROTEIN FOR THE PREVENTION OF STREPTOCOCCUS PNEUMONIAE INFECTION AND ITS APPLICATION
WO - 05.03.2026
Clasificación Internacional A61K 39/09Nº de solicitud PCT/CN2025/090122Solicitante NANJING CHENGSHI BIOMEDICAL TECHNOLOGY CO., LTD.Inventor/a HAN, Tiyun
The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

16.WO/2026/046991VACCINE
WO - 05.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/074270Solicitante NEC ONCOIMMUNITY ASInventor/a VARDAXIS, Alexandros Ioannis
The present invention relates to immunogenic protein sequences, and polynucleotides, compositions, and vaccine compositions thereof, which have been optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, and have the ability to confer a broad immunity against multiple Betacoronavirus subgenera, species, and viral variants.

17.WO/2026/050864VACCINES AND METHODS FOR THE TREATMENT OF NEISSERIA GONORRHOEAE INFECTIONS
WO - 12.03.2026
Clasificación Internacional A61K 39/095Nº de solicitud PCT/CA2025/051173Solicitante ENGINEERED ANTIGENS INC.Inventor/a FEGAN, Jamie E.
Disclosed are novel vaccine compositions comprising multiple N. gonorrhoeae TbpB proteins or immunogenically equivalent portions thereof. The vaccine compositions may be used to ameliorate or prevent pathogenic infections in humans, caused by N. gonorrhoeae. Related methods and uses are also disclosed.

18.WO/2026/047025PHOTOCONTROLLABLE CONJUGATE, PHARMACEUTICAL COMPOSITION

AND KIT COMPRISING THE SAME, AND USES THEREOF
WO - 05.03.2026
Clasificación Internacional A61K 41/00Nº de solicitud PCT/EP2025/074341Solicitante RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventor/a HARTMANN, Gunther
The present invention relates to a light-activatable photocaged conjugate, which, upon activation, is capable of inducing an immune response, wherein said conjugate comprises: (a) at least one double-stranded oligonucleotide, comprising: (i) a first strand of a ribonucleic acid having a length of at least eight nucleotides; and (ii) a second strand of a ribonucleic acid having a length of at least eight nucleotides and forming complementary base pairs with the first strand; and (b) at least one photoremovable protecting group (PPG); wherein the at least one PPG is coupled to a ribose at the 2'-O-position or a nucleobase of a nucleotide in the first or second strand of the at least one double-stranded oligonucleotide according to item (a). The present invention moreover provides a pharmaceutical composition, a drug delivery system, an adjuvant, a vaccine and kit for use in medicine, each of them comprising a conjugate according to the invention. The present invention also relates to said conjugate for use as a medicament, for use as a vaccine, for use as an adjuvant, for use in a method of treatment or prevention of a disease, for use in a method of infiltrating immune cells, preferably T cells, and for use in a method of turning cold into hot tumours.

19.WO/2026/055709MITOCHONDRIA-FACILITATED DELIVERY OF MRNA
WO - 12.03.2026
Clasificación Internacional A61K 35/12Nº de solicitud PCT/US2025/045647Solicitante WASHINGTON UNIVERSITYInventor/a CURIEL, David
Among the various aspects of the present disclosure is the provision of compositions and methods of a gene delivery system. The compositions include at least one therapeutic molecule and an isolated mitochondria, and optionally further complexed to a lipid nanoparticle. Methods of molecule delivery include the use of isolated mitochondria as a vector for the delivery of the therapeutic molecule. A method of treating a patient in need of a gene vaccine is also described, in which the mRNA of the administered composition encodes a vaccine antigen, including but not limited to at least a portion of a SARS-CoV-2 spike protein.

20.3293912CORONAVIRUS VACCINE COMPOSITION, METHOD THEREFOR AND USE THEREOF
CA - 01.03.2026
Clasificación Internacional A61K 38/00Nº de solicitud 3293912Solicitante SICHUAN CLOVER BIOPHARMACEUTICALS, INC.Inventor/a Peng LIANG

21.3292600VACCINE COMPOSITION AGAINST AFRICAN SWINE FEVER VIRUS
CA - 01.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud 3292600Solicitante CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventor/a Mario Pablo ESTRADA GARCIA

22.3287856METHOD FOR TREATING TUMORS USING COMBINATION OF ONCOLYTIC VIRUS VACCINE AND IMMUNE CELLS
CA - 01.03.2026
Clasificación Internacional A61K 35/766Nº de solicitud 3287856Solicitante JOINT BIOSCIENCES

(SH) LTD.Inventor/a Guoqing ZHOU

23.WO/2026/047192IONIZABLE LIPIDS
WO - 05.03.2026
Clasificación Internacional C07C 323/12Nº de solicitud PCT/EP2025/074647Solicitante ETHERNA IMMUNOTHERAPIES NVInventor/a DE KOKER, Stefaan
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipid disclosed herein.

24.WO/2026/050132DOMINANT NEGATIVE TOXOID ANTIGEN APPROACH FOR PROPHYLACTIC AND POST-INFECTION TREATMENT OF SWINE AGAINST AFRICAN SWINE FEVER VIRUS WITH DIFFERENTIATING INFECTED FROM VACCINATED ANIMALS (DIVA) CAPABILITY
WO - 05.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2025/043301Solicitante MALCOLM, ThomasInventor/a MALCOLM, Thomas
A composition including modified ASFV outer-membrane protein antigen mutants (termed dominant negative toxoid antigens) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. A method for the treatment and/or prevention of ASFV by administering a dominant negative toxoid antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and/or preventing ASFV. An ASFV vaccine composition including dominant negative toxoid antigens. A composition including dominant negative toxoid antigens in conjunction together and in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection. Methods and compositions allowing for differentiation of infected from vaccinated animals (DIVA).

25.3297782VIRAL-VECTOR RECOMBINANT VACCINE AGAINST PORCINE EPIDEMIC DIARRHEA
CA - 01.03.2026
Clasificación Internacional A61K 39/215Nº de solicitud 3297782Solicitante LABORATORIO AVI-MEX, S.A. DE C.V.Inventor/a Bernardo LOZANO-DUBERNARD

26.WO/2026/052882YELLOW FEVER VIRUS (YFV) COMPOSITIONS AND PRODUCTION THEREOF
WO - 12.03.2026
Clasificación Internacional C12N 7/02Nº de solicitud PCT/EP2025/075700Solicitante VALNEVA AUSTRIA GMBHInventor/a SCHLEGL, Robert
The present invention relates to a process for producing high yields of yellow fever virus (YFV) particles for vaccine manufacture. Also provided are liquid frozen or lyophilized YFV or chikungunya virus (CHIKV) formulations, and their use in the prevention of a yellow fever and chikungunya virus

infections. Further provided are combination liquid or lyophilized formulations of YFV and CHIKV, and their use in the prevention of yellow fever virus and chikungunya virus infections.

27.3297282VARICELLA-ZOSTER VIRUS (VZV) VACCINE
CA - 01.03.2026
Clasificación Internacional A61K 39/25Nº de solicitud 3297282Solicitante SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD.Inventor/a Linxian LI

28.3296649RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
CA - 01.03.2026
Clasificación Internacional A61K 39/12Nº de solicitud 3296649Solicitante SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD.Inventor/a Linxian LI

29.WO/2026/055516METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE
WO - 12.03.2026
Clasificación Internacional A61K 39/145Nº de solicitud PCT/US2025/045185Solicitante MOREHOUSE SCHOOL OF MEDICINEInventor/a GRAHAM, Barney S.
A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

30.3289084RECOMBINANT EXPRESSION VECTOR FOR PRODUCTION OF VIRUS-LIKE PARTICLE-BASED MULTIVALENT NOROVIRUS VACCINE AND MANUFACTURING METHOD THEREFOR
CA - 01.03.2026
Clasificación Internacional A61K 39/125Nº de solicitud 3289084Solicitante INTHERA INC.Inventor/a Deog Young CHOI

31.WO/2026/054725USE OF MIR-342 ENRICHED, TAMOXIFEN LOADED, MESENCHYMAL STEM CELL DERIVED EXOSOMES FOR OVERCOMING TAMOXIFEN RESISTANCE IN BREAST CANCER
WO - 12.03.2026
Clasificación Internacional A61K 31/7105Nº de solicitud PCT/TR2024/051057Solicitante BURSA ULUDAĞ ÜNİVERSİTESİInventor/a ÇEÇENER, Gülşah
The invention relates to a pharmaceutical composition comprising tamoxifen-loaded mesenchymal stem cell-derived exosomes enriched with miR-342 for use in the pharmaceutical and vaccine industry, in the treatment of cancer, in the treatment of breast cancer, in overcoming tamoxifen resistance in the treatment of estrogen receptor positive breast cancer using tamoxifen.

32.3295010RSV VACCINE COMPOSITION, METHOD AND USE THEREOF
CA - 01.03.2026
Clasificación Internacional A61K 39/155Nº de solicitud 3295010Solicitante SICHUAN CLOVER

BIOPHARMACEUTICALS, INC.Inventor/a Joshua LIANG

33.325774RSV VACCINE
IL - 01.03.2026
Clasificación Internacional A61K 39/00Nº de solicitud 325774Solicitante ASTRAZENECA ABInventor/a LALIBERTE, Jason Paul

34.3294011ADENOVIRAL VECTOR VACCINE, AND PREPARATION METHOD AND USE THEREOF
CA - 01.03.2026
Clasificación Internacional A61K 35/761Nº de solicitud 3294011Solicitante CANSINO BIOLOGICS INC.Inventor/a Juan SHAO

35.20260061045METHOD FOR PREVENTION AND TREATMENT OF VIRAL DISEASE
US - 05.03.2026
Clasificación Internacional A61K 39/145Nº de solicitud 19320827Solicitante MOREHOUSE SCHOOL OF MEDICINEInventor/a Barney S. GRAHAM
A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

36.3301211METHOD OF SELECTING NEOANTIGEN FOR DEVELOPMENT OF PERSONALIZED CANCER VACCINE
CA - 01.03.2026
Clasificación Internacional G16B 25/00Nº de solicitud 3301211Solicitante LG CHEM, LTD.Inventor/a Seihwan JEONG

37.WO/2026/050666PREFUSION-STABILIZED EBV GB PROTEINS
WO - 05.03.2026
Clasificación Internacional A61K 39/245Nº de solicitud PCT/US2025/044221Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a MCLELLAN, Jason
Provided herein are engineered EBV gB polypeptides. In some aspects, the engineered gB polypeptides exhibit enhanced conformational stability and/or immunogenicity/antigenicity of the prefusion conformation. Methods are also provided for use of the engineered gB polypeptides as diagnostics, in screening platforms, and/or in vaccine compositions.

38.WO/2026/050341IMMUNOGENIC COMPOSITIONS CONTAINING LIPOOLIGOSACCHARIDES AND METHODS OF USE THEREOF
WO - 05.03.2026
Clasificación Internacional A61K 39/385Nº de solicitud PCT/US2025/043665Solicitante STIRX INCInventor/a GILL, Davinder
Immunogenic and vaccine compositions containing a *Neisseria gonorrhoeae* lipooligosaccharide (LOS), or a fragment thereof, are provided. The LOS may be conjugated to a carrier such as a carrier

protein, virus-like particle (VLP), liposome, inorganic gold particle, dendrimer, outer membrane vesicle (OMV), generalized modules for membrane antigens (GMMA), and protein nanocages. Methods of protecting or treating a subject *from Neisseriagonorrhoeae* infection and methods of manufacturing the compositions are also provided.

39.20260063627METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE
US - 05.03.2026
Clasificación Internacional G01N 33/543Nº de solicitud 19065036Solicitante Gilead Sciences, Inc.Inventor/a Christian BRANDER
The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and/or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES